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The malaria parasite ingests between 80-100% of the host red blood cell’s iron in the form of 
haemoglobin, which is catabolised to amino acids and ferriprotoporphyrin (Fe(III)PPIX), that 
it subsequently detoxifies to form the biocrystal, haemozoin. Neutral lipids have been 
implicated as the biological molecules responsible for the nucleation of haemozoin in vivo, 
though their exact role is unclear. This thesis has investigated the interaction between these 
lipids and Fe(III)PPIX. By exploiting the fluorescence quenching ability of Fe(III)PPIX, Stern-
Volmer plots were generated to estimate the concentration of Fe(III)PPIX partitioned into 
Nile red stained neutral lipid droplets (NLBDs) over a pH range. The pH dependence was 
found to correlate with the charge of the Fe(III)PPIX molecule and the largest amount of 
Fe(III)PPIX partitioning was observed under the acidic pH conditions of the parasite digestive 
vacuole (pH 4.80), where haemozoin is formed. From the fluorescence maximum of Nile red, 
the relative polarity inside the lipid droplets was shown to lie between that of acetone and 
octanol with a Dimroth-Reichart ET(30) parameter of 45 kcal/mol. The lipophilicity of 
Fe(III)PPIX was validated by measuring the octanol-water partition coefficient,  log DOW, as 
1.8 for the ionised  form at pH 7.5 and a log P of 2.8 for the neutral form. 4-aminoquinoline 
drugs, chloroquine and amodiaquine, decreased the partitioning of Fe(III)PPIX into NLBDs at 
low pH owing to the consistently charged nature of the drug-Fe(III)PPIX complex. In contrast, 
the quinoline methanols, quinidine and quinine, strongly increased the observed lipophilicity 
of Fe(III)PPIX in a pH dependent manner. Quinidine was found to effect the largest increase 
on Fe(III)PPIX partitioning into NLBDs which was proposed to be due to a previously 
established inherent increased lipophilicity of the quinidine-Fe(III)PPIX complex.   
Neutral detergents have been used to mimic lipids to initiate β-haematin (synthetic 
haemozoin) formation in high-throughput screening. The speciation profile of Fe(III)PPIX in 
detergent solution was investigated using UV-vis spectroscopy and magnetic susceptibility 
measurements. The π-π dimer to μ-oxo dimer equilibrium constant, log K, was evaluated in 
different detergents so the percentage μ-oxo dimer could be predicted at any pH and 
Fe(III)PPIX concentration. The predominance of the π-π dimer species of Fe(III)PPIX in both 
neutral detergent monomeric and micellar solution at pH 4.80 was shown to correlate with 
the detergents ability to form β-haematin. Charged detergents, SDS and CTAB, that were 
found not to favor the π-π dimer, failed to promote β-haematin formation. 1H NMR and  
Stern-Volmer quenching experiments of a hydrophobic NR fluorescence signal inside neutral 
detergent micelles by Fe(III)PPIX revealed interaction with the hydrophobic fatty acid moiety 
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of the detergent suggesting that it is buried within the micelle. Despite neutral detergents 
ability to stabilise the π-π dimer in acidic solution, measurement of the association constants 
of quinoline antimalarials and Fe(III)PPIX in detergent showed no change from the pre-
established complexation between these drugs and the monomeric or μ-oxo dimer 
Fe(III)PPIX species in aqueous solution. Detergents were however, shown to decrease the 
surface tension of aqueous solution, facilitating the crystallisation process. 
To investigate how closely these neutral detergents mimic lipids in haemozoin formation, a 
comparison between the reported kinetic profile of β-haematin formation at a lipid-aqueous 
interface and that obtained in the neutral detergent, NP-40, was conducted. The kinetics of 
NP-40 mediated β-haematin formation were found to conform to the Avrami model with 
n=1, exhibiting a half-life of 19 min to form a maximum yield of 56% at a markedly slower 
rate than in the lipid. Chloroquine and quinidine were found to decrease the rate of β-
haematin formation in NP-40 in a reversible manner, to achieve a consistent yield of 52-55%.  
A crystal adsorption model based on the Langmuir isotherm was employed to explain the 
observed decrease in rate constant such that an adsorption equilibrium constant (log Kads) 
for each drug was determined from the kinetic data. Quinidine was found to adsorb more 
strongly than chloroquine, in contrast to the previously reported findings in the lipid system, 
where a combination of drug adsorption and precipitation of a drug-Fe(III)PPIX complex was 
proposed to explain the decrease in yield at high drug concentration. In the absence of any 
evidence of precipitation of a drug-Fe(III)PPIX complex in NP-40 solution, the reversible 
adsorption of drug to the fastest growing face of the β-haematin crystal was proposed to be 
solely responsible for the observed decrease in rate constant. An independent measurement 
of this adsorption was provided by UV-vis spectroscopy of these drugs with preformed β-
haematin, confirming that quinidine strongly adsorbs onto β-haematin in NP-40 solution. 
This work provides the first description of the aggregation state of Fe(III)PPIX and the first 
detailed kinetic investigation of β-haematin inhibition by antimalarials in neutral detergent 
solution. The ability of neutral detergents to promote β-haematin formation has been 
attractive for providing a fast cheap means of assaying haemozoin inhibition activity; 
however, a crucial finding is that there remain fundamental differences between the 
detergent system and the biological lipid environment that prevails inside the parasite 
digestive vacuole. When interpreting results from detergent-mediated high throughput 
screening assays cognisance of these differences is needed.  
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Glossary of Terms, Abbreviations and Definitions 
Iron species 
βH, ( β-haematin) – synthetic haemozoin. Also called haematin anhydride, referring to the 
propionate linked dimer of reciprocal haematin molecules that are hydrogen bonded to 
adjacent dimers. 
Fe(III)PPIX – Ferriprotoporphyrin IX referred to as ferrihaem, haem or haematin, where the 
axial ligand is either –OH/ H2O 
haem – prosthetic group composed of Fe (iron) and porphyrin ring. In this thesis, monomeric 
form of haem is Fe(III)PPIX, also referred to as ferrihaem 
haematin –  ferrihaem with and a fifth axial ligand, in this case –OH/H2O, porcine source. 
haemin – ferrihaem with Cl- axial ligand  
Hb – Haemoglobin 
Hz (haemozoin) – malaria pigment produced by blood-feeding parasites, microcrystalline 
form of reciprocal Fe(III)PPIX dimers linked by hydrogen bonds. 
PPIX, protoporphyrin IX – a porphyrin consisting of a tetrapyrrole containing methyl, vinyl 
and propionic acid side chains  
π-π dimer – co-facial association dimer of Fe(III)PPIX molecules  
μ-oxo dimer –   covalent dimer of Fe(III)PPIX with bridging oxide ligand. 
μ-propionato dimer – ‘haematin anyhydride’ dimer with the propionate of one Fe(III)PPIX 
molecule coordinated to the Fe3+ metal centre of an opposite faced Fe(III)PPIX molecule 
which in turn is coordinated via its propionate group to that Fe3+ centre. 
Lipid solutions 
Ace:MeOH – acetone: methanol solution, 1:9 volume/ volume, lipid solvent 
MSG – rac- 1- monostearoylglycerol  
MPG – rac- 1-monopalmitoylglycerol  
DOG – rac-1,3-dioleoylglycerol  
DLG – rac-1,3-dilinoleoylglycerol  
DPG – rac-1,3-dipalmitoylglycerol  
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NLB – Neutral Lipid Blend, biologically relevant mixture of acylglycerols (MSG: MPG: DOG: 
DLG: DPG) in mole ratio 4:2:1:1:1. 
NLD/s – Neutral lipid droplet/s 
SNLDs – synthetic neutral lipid droplets 
SNLBDs – synthetic neutral lipid blend droplets 
detergents 
CHAPS – 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate  
SDS – Sodium dodecyl sulfate  
CTAB – hexadecyl-trimethyl-ammonium bromide  
NP-40 – octylphenoxypolyethoxyethanol, Nonident P40  
Tween 20 – Polyoxyethylene (20) sorbitan monolaurate  
CMC – Critical micellar concentration, stable detergent aggregates in solution with defined 
properties  
buffers 
MES – (2-(N-morpholino)ethanesulfonic acid; buffer range pH 5.5 - 6.7) 
HEPES – (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid; buffer range pH 6.6 – 8.0) 
CHES – (2-(Cyclohexylamino)ethanesulfonic acid; buffer range pH 8.5 – 10.00) 
parasite terminology  
DV – Digestive/ food vacuole of parasite 
Pf – Plasmodium falciparum, malaria parasite of the genus Plasmodium 
Pv – Plasmodium vivax, species of the genus, Plasmodium (malaria parasite)  
trophs – trophozoites, metabolically active developmental stage of parasite life-cycle  
VAR – Vacuolar accumulation ratio of drug concentrations inside and outside digestive 
vacuole (log DpH5.2 / log DpH7.4) 
Antimalarial drugs 
AQ – Amodiaquine, 4-[(7-chloroquinolin-4-yl)amino]-2-[(diethylamino)methyl]phenol  
ART – Artemisinin  
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CQ – Chloroquine, (RS)-N'-(7-chloroquinolin-4-yl)-N,N-diethyl-pentane-1,4-diamine 
DHA – Dihydroartemisinin 
eQD – 9-Epiquinidine, (8R,9R)-6'-Methoxycinchonan-9-ol, quinidine enantiomer 
eQN – 9-Epiquinine, (8S,9S)-6'-Methoxycinchonan-9-ol, quinine enantiomer 
Hf – Halofantrine 
IC50 – 50% inhibitory concentration 
MF – Mefloquine 
PYR – Pyrimethamine  
QD – (8R,9S)-Quinidine, (1S)-[(2R,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-
methoxyquinolin-4-yl)methanol  
QN – (8S,9R)-Quinine, (1R)-[(2S,4S,5R)-5-ethenyl-1-azabicyclo[2.2.2]octan-2-yl]-(6-
methoxyquinolin-4-yl)methanol  
SP – Sulphadoxine  
General  
% – Percentage 
Ace – Acetone 
AFM – Atomic force microscopy 
CBSO – citric acid buffer saturated octanol 
CSD – Cambridge Structural Database 
cryo-TEM – cryogenic transmission electron microscopy 
cryo-XT – cryogenic soft X-ray tomography 
DMF – N, N-dimethylformamide,(CH3)2NCHO, solvent, 99.8% assay grade, Sigma Aldrich®  
Em – Emission 
ES – Excited state 
Ex – Excitation 
F – Fluorophore in its ground state 
F* – Excited state fluorophore 
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FQ – Ground state fluorophore-quencher complex 
F*Q – Excited state fluorophore complexed with quencher 
Fl. Int. – Fluorescence intensity, measured in arbitrary units (arb. units) based on PMT 
(photo-multiplier tube) voltage setting 
GS – Ground state 
HDP – haem detoxification protein 
HOMO – Highest occupied molecular orbital 
HPLC – High performance liquid chromatography 
HRP II, III – Histidine-rich proteins II and III 
IFE – Inner Filter Effect 
IR – Infrared 
kq – Bimolecular quenching constant, obtained for Stern Volmer collisonal quenching 
Kp – partition constant between two non-miscible phases 
KSV – Stern-Volmer quenching constant, product of kq.𝜏 
LCAO – Linear combination of atomic orbitals 
log DOW – logarithm of distribution coeffiecient in octanol and aqueous solution 
log POW – logarithm of partition coefficient of unionised form between octanol and aqueous 
solution 
LUMO – Lowest unoccupied molecular orbital 
Maldi-Tof – Matrix-assisted laser desorption ionisation time of flight mass spectrometry 
max – Maximum  
MD – Molecular dynamics (in silico simulation techniques) 
MeOH – Methanol 
min – Minimum 
𝑴𝑳 – Angular momentum quantum number 
MO – Molecular orbital 
NMR – Nuclear magnetic Resonance 
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NR – Nile red fluorescent dye, (9-diethylamino-5H-benzo[α]phenoxazine-5-one) 
Oct – Octanol 
pD – pH of a deuterated sample 
PIFE – Primary Inner Filter Effect 
pKa – log of an ionisation constant usually acid dissociation  
Q – Quencher 
SAMs – Self-assembled functionalized alkanethiol monolayers  
SIFE – Secondary Inner Filter Effect 
SV – Stern- Volmer (fluorescence quenching) 
𝝉 – Fluorescence lifetime of a fluorophore 
Tm  – gel-to-fluid transition temperature of lipids 
TICT – Twisted intramolecular charge transfer 
TLC – Thin Layer Chromatography 
μ – Average magnetic moment  
UV-vis – Ultraviolet/visible  
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Chapter 1: Introduction and Literature Review 
(1.1) The global burden of malaria 
Arguably, the most devastating infectious disease in history, malaria is thought to be 
responsible for exacting the largest toll on human and economic resources around the world 
since it was first recorded in 1600.1 In fact, the true burden of this disease will never be 
properly quantified as infection may occur asymptomatically and often cases are not 
reported in rural settings. Today, malaria is incident in ninety-seven countries encompassing 
six WHO geographical regions, placing an estimated 3.2 billion people at risk of infection 
(Fig.1.1).2 The bulk of this infection occurs in developing regions, particularly Africa, where 
approximately 90% of all malaria fatalities occurred in 2013.2  This prevalence in mainly Sub-




Figure 1.1. Global percentage of population risk for malaria infection shown by blue shading, the 
grey areas represent regions of no risk as reported by world malaria report 2013. Map created using 




Malaria features as number six of the Millennium Development Goals, which aimed to halt 
the spread and lower the incidence of this disease by 2015. To achieve this aim, great strides 
have been made by the eradication campaign in distribution and use of bed nets, increased 
global funding for existing treatments and the development of novel drugs, successfully 
reporting that the number of deaths decreased by forty-seven percent worldwide in 2013.2 
Malaria control follows an integrated strategy of “universal coverage”, applying the 
prevention and treatment techniques that are central to the “Roll back Malaria” initiative.3 
However, despite these efforts, malaria incidence is still endemic and the complications of 
treating children under the age of five, pregnant women and patients with HIV and other 
infectious diseases like tuberculosis and Ebola, severely hamper any progress toward 
relieving the burden of this disease, especially on the African continent.5 Added to this, 
resistance to current antimalarial therapies, poses a great challenge to achieving malaria 
eradication.6 In the fight against this global issue, an understanding and study of the agent of 
this disease has made a substantial impact toward eliminating malaria.  
(1.2) The malaria parasite 
Malaria is transmitted through the saliva of the infected female Anopheles mosquito, 
carrying a protozoan parasite of the genus, Plasmodium. Five species have been reported to 
affect humans; P. malariae, P.ovale and P. knowlesi occur with low incidence and fatality 
rates. While, P. vivax (Pv) and P. falciparum (Pf) are the most prevalent, with the latter being 
responsible for the majority of malaria associated deaths.1,7 The life cycle of the malaria 
parasite consists of two distinct parts, each occurring in the mosquito vector and human 
host, offering a complicated sequence of parasite stages that have proven difficult to target 
at once, this is illustrated in Fig. 1.2.8 The cycle begins as a mosquito (primary host) feeds on 
infected blood from a secondary human host, ingesting parasite gametocytes that travel to 
the midgut of a carrier mosquito.9 Thereafter undergoing sexual reproduction to form male 
and female gametes that fuse and undergo several stages of maturation to form complete 
oocysts that rupture releasing sporozoites into the salivary glands in a process called the 
sporogonic cycle. The unaffected mosquito vector then transmits the infection to another 
human host where the parasites are circulated in the bloodstream until they reach the liver 
to infect a hepatocyte commencing the liver stage of their life-cycle.10 At this stage, the liver 
schizonts can either lie dormant (in P.malariae and P. vivax) in a period associated with 
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asymptomatic malaria or after 4-5 days of growth and multiplication, the schizont can burst 
to release merozoites that invade the red blood cells (RBCs) to begin the metabolically 
active, blood stage.  
 
 
Figure 1.2 The life cycle of the malaria parasite encompassing the mosquito stage to human 
transmission followed by the human liver and blood cell stages with illustrated corresponding time 
periods. Reproduced and edited from Delves et al., (2012) in open access journal, Plos one.8 
 
The blood stage of the malaria parasite’s life cycle consists of asexual reproduction of the 
merozoites and involves ingestion of the host’s erythrocyte haemoglobin (Hb) as a source of 
amino acids. The development starts with formation of a ring that grows rapidly to develop 
the pre-digestive food compartments that fuse to form the digestive vacuole (DV) in the 
trophozoite (troph) , eventually maturing into a schizont again, before rupturing to release 
an increased number of merozoites to continue the blood stage infecting a new RBC.11 The 
released parasites and debris stimulate host production of pro-inflammatory cytokines, 
interleukins I and 6 (IL-1, IL-6) and tumor necrosis factor α (TNF-α) in an innate immune 
4 
 
response triggering the onset of the pathogenic symptoms of the disease.12,13 This release of 
a new batch of merozoites every 48 h is responsible for the fevers, chills, nausea and body-
aches that are symptomatic of P. falciparum and P.vivax infection.1 Several merozoites 
continue to mature into gametocytes in the blood stream ensuring the passage into another 
mosquito vector upon feeding to complete the entire life-cycle. Several parasites evade 
human immune responses by entering host cells, amongst them, the malaria parasite is 
among the most successful, as the bulk of its life-cycle is spent in the human RBC.14 It is 
during this erythrocyte stage that the parasite is most virulent, ingesting and degrading 
between 60-80% of the host’s RBC Hb. This process occurs from the ring to the troph stage 
inside the acidic DV, in a mechanism that is thought to provide a food source from the 
breakdown of the protein, globin, into amino acids as well as to make space for the growing 
parasite.15–17 
(1.3) Haemoglobin degradation pathway 
The ingestion, catabolism and fate of Hb in the malaria parasite is referred to as the Hb 
degradation pathway and is the primary target of past and present antimalarial drugs.18 
Illustrated by the schematic in figure 1.3, the various processes to achieve the final product 
are discussed throughout section 1.3. 
(1.3.1) Haemoglobin catabolism 
Briefly, the pathway is initiated by invagination of the parasitic plasma membrane to form 
transport vesicles (TV) that transfer Hb from the host RBC to the interior of the DV of the 
parasite. Process (A) of Fig.1.3 then commences, Hb is quickly cleaved proteolytically into 
iron (II) protoporphyrin IX (Fe(II)PPIX) or ‘haem’ and globin, the protein component which is  
broken down by a series of aspartic (plasmepsins I, II, IV and histoaspartic protease) and 
cystic proteases (falcipains 1, 2 and 3) as well as being digested into smaller fragments by 
the zinc metalloprotease (falcilysin) and dipeptidylaminopeptidase (PfDPAP1).19–22 The 
resultant peptides are transported out of the DV where they undergo further cleavage to 
afford the amino acids that serve as a nutrient source for parasite protein synthesis 
elsewhere in the cell.23,24 The four Fe(II)PPIX units that are released upon Hb degradation are 
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rapidly auto-oxidised by to the ferric form of iron protoporphyrin IX, Fe(III)PPIX or what is 
called, haematin (Fig. 1.4).25 
 
 
Figure 1.3. Schematic representation of the Hb degradation pathway in an infected RBC. Process (A) 
is the proteolytic digestion of Hb to peptides (that are further broken down outside the DV) and 
Fe(II)PPIX which is oxidised to yield, (B) Fe(III)PPIX.  Free Fe(III)PPIX is converted to a unit of 
reciprocal cyclic dimers (C) in a unknown mechanism that involves the formation of an Fe-
carboxylate linkage  between Fe(III)PPIX molecules, which are further hydrogen bonded to each 
other to form a Hz crystal (D). The crystal morphology is illustrated with each face annotated. Hb 
image from RCSB PDB (www.rcsb.org) PDB ID 1GZX, reprinted from Paoli et al.26–29 
 
Fe(III)PPIX (product B in Fig. 1.3) is a five co-ordinate protoporphyrin molecule consisting of a 
tetrapyrrole macrocycle with two vinyl and four methyl as well as two propionic acid group 
side chains attached to a Fe(III) metal centre and an axial ligand, that is pH dependent being 
either hydroxide (-OH) or water (H2O).
30 The pH of this acidic digestive compartment has 
been measured and reported to vary between pH 4.5 - 5.5 from fluorescence probe 
experiments, however, Haywood et al. have recently reported an estimate of pH 4.8 -5.2 in 
early trophs.31,32 The accumulation of Fe(III)PPIX or Fe(III)PPIX-drug adducts in the parasite 
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DV has been correlated with the development of oxidative reactive species which have been 
shown to cause the lipid peroxidation that is thought to be responsible for parasite death.33–
35 It is capable of disrupting parasite homeostasis by competitively binding key enzymes such 
as those involved in Hb degradation or catalysing the formation of small peptide fragments 
from proteins.36,37 It has also been shown free Fe(III)PPIX has a role in parasite metabolism 
where addition of free Fe(III)PPIX was observed to cause an initial decrease in the activity of 
PfGAPDH (regulatory enzyme in glycolytic pathway).38 PfGAPDH is implicated in other 
essential parasite processes for example nuclear RNA transport, DNA replication and 
membrane fusion, rendering the parasite vulnerable to a build-up of free Fe(III)PPIX.39 
 
More destructive, is the oxidative stress effects upon the release of free Fe(III) which is 
capable of interaction with parasite glutathione (GSH) causing lipid peroxidation through 
what is believed to be an intercalation mechanism due to its lipophilic nature.34,36 To 
circumvent this, the parasite employs a Fe(III)PPIX detoxification mechanism that sequesters 
the potentially harmful Fe(III)PPIX as an inert bio-crystal called haemozoin (Hz) (process C 
and product D in Fig. 1.3).40 By contrast, in mammals, Fe(III)PPIX is catabolised by the 
microsomal heme oxygenase enzyme, a key point of difference that makes this haem 
detoxification a unique parasite specific drug target.41 The drugs used to target this pathway 
and inhibit Hz formation will be discussed later on. 
 
Figure 1.4 Structure of Fe(III)PPIX with the porphyrin scaffold and propionate side chains highlighted. 




(1.3.2.1) Evolution of the understanding of haemozoin  
The process of Hz formation is not well understood. Since its first discovery in the eighteenth 
century, prior to identification of the disease, the exact mechanism of formation of these 
crystals appearing as a black pigment (malaria pigment) remains to be elucidated. From the 
nineteenth century until 1911, it was thought that this discolouration, found in the liver and 
brain of malaria victims, was the skin pigment, melanin, however, Carbone and Brown 
independently proved that the substance was in fact composed of  haem or Fe(III)PPIX (Fig. 
1.4).42,43 A time-line of each discovery that contributed to the current understanding of Hz is 
summarised in Fig. 1.5. For many years, the exact nature of this pigment was misunderstood 
encumbering investigations into its chemical structure, however, in 1991, Slater and 
colleagues found that a synthetic form of a microcrystalline Fe(III)PPIX called β-haematin 
(βH) was identical in nature and composition to isolated P. falciparum Hz.42 This confirmed a 
study from a few years before by Fitch and Kanjananggulpan which had shown Hz from 
malaria parasites to be composed only of Fe(III)PPIX.30  
Using UV-visible (UV-vis) absorbance and infrared (IR) spectroscopy and X-ray techniques, 
including extended x-ray absorption fine structure (EXAFS) spectroscopy and powder 
diffraction, the authors were able to demonstrate unequivocally that their synthetic 
haematin derivative, β-haematin (βH) was chemically the same as the biological extracts. 
They proposed that βH was formed by the formation of a Fe–O bond between the oxygen of 
a propionate group of one Fe(III)PPIX to the Fe(III) centre of an adjacent Fe(III)PPIX molecule 
allowing polymerisation to form the crystal.44 By comparison of IR spectra of the Fe(III)PPIX 
starting material and those of Hz and βH, the diagnostic stretching frequencies of the 
coordinated C=O and the C–O bonds were first identified. The belief that this insoluble form 
of Fe(III)PPIX was an anhydride polymer was widely held during this time and propagated 
until the structure was elucidated.  
(1.3.2.2) Structure and crystal morphology of synthetic haemozoin, β-haematin 
In 1997 Bohle and colleagues, obtained the X-ray powder diffraction (PXRD) pattern of both 
Hz isolated from late troph extracts and βH.45 They correctly identified the centrosymmetric 
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space group corresponding to the triclinic unit cell P-1, leading to a proposed structure 
composed of antiparallel polymer chains. However, in 2000, the same group elucidated the 
structure of βH by Rietveld refinement, dispelling the polymer theory and showing that the 
asymmetric unit was composed of reciprocal cyclic dimers of Fe(III)PPIX in which the 




Figure 1.5 A timeline of the impactful discoveries in the history of haemozoin (Hz) investigations. The 
background picture depicts a TEM of Hz crystals seen in the DV of an infected RBC was reproduced 
with permission from figure 2, in  S. Kapishnikov et al., PNAS, (2012) ©The National Academy of 
Sciences, USA.46 
 
The dimers were hydrogen bonded to each other via the other propionic acid group of each 
porphyrin to form the crystal structure pictured in Fig. 1.6. Subsequently, since, this first 
report of the crystal structure, many studies have been conducted toward understanding the 
mechanism of its formation both in vitro and in vivo, all contributing to the bulk of available 
knowledge on this pigment today. Spectroscopic studies have shown that Hz triclinic crystals  
are entirely composed of five-coordinate Fe(III)PPIX of high-spin state, S = 5/2,  and is 




                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
Figure 1.6 Molecular structure of Hz or βH. The Fe(III)PPIX dimeric unit with Fe–O bond between the 
Fe(III) centre of one Fe(III)PPIX molecule coordinated to the O–C=O (propionate) group of another 
Fe(III)PPIX molecule in a reciprocal fashion, this dimer is hydrogen bonded to another dimer via an 
O---OH interaction of the second propionic acid group to form the crystal packing observed for βH.50 
 
Exploiting the published structure of βH, Buller et al. investigated the theoretical growth 
form of the crystal and its isostructural natural counterpart, Hz.28 The Hartman-Perdok 
theory that the slowest growing faces are expressed in the crystal morphology which is 
dependent on the layer energy released when a new layer is formed, E1 and the inverse of 
the energies of attachment per molecule when a new layer is deposited onto the crystal 
surface, Eatt, was employed to explain the observed crystal face expression.
51 Computed 
values for Eatt and E1 allowed for the proposed needle-like crystal morphology along the c-
axis with dominant (100) and (010) faces expressed as well as the less developed (011) and 
minor 001 faces. The authors compared this theoretical morphology to isolated Hz crystals 
from different species which matched their model closely; this is illustrated in Fig. 1.7. The 
(001) face which is not expressed as a major face in the crystal habit was proposed to be the 





Figure 1.7 (a-b) Theoretical βH crystal morphology viewed along the a and c axis with the miller 
indices of the expressed faces indicated. (c-e) Superimposed images of theoretical morphology with 
SEM micrographs of Hz crystals isolated from P. falciparum and other blood-feeding organisms, S. 
mansoni and H. columbiae, respectively, indicating similar crystal habit. Image reproduced with 
permission from Buller et al., (2002), ©American Chemical Society.28 
 
(1.3.2.3) Stereoisomers of β-haematin 
It was later proposed that four stereoisomers of βH are theoretically possible in solution, 
based on the enantio-facial symmetry of Fe(III)PPIX that results in four different possible 
occupational arrangements of the vinyl groups on the periphery of the porphyrin ring. 52 The 
authors claimed that the original structure was reported to only contain the designated 
centrosymmetric isomer, cd1̅1. 
27,52 Another centrosymmetric isomer, cd1̅2 and two chiral 
structures, cd2(+) and cd2(-) were proposed to exist (Fig. 1.8). Initially, only the 
centrosymmetric units were thought to be incorporated into the growing βH crystal in large 
amounts, forming two distinct major and minor phases, as the presence of the chiral 
structures were shown to retard crystal growth in a capping mechanism that was suggested 
to account for the microcrystalline size of βH crystals.  Later studies by the same group, 
using powder X-ray diffraction (PXRD) techniques and computational density functional 
theory (DFT) modelling,  showed the powder diffraction data was consistent with two 
occupancy models, the major phase consisted of a mixture of the achiral isomer, cd1̅1 and 
the chiral isomer,  cd2(+) with a 50:50 occupancy.53 A minor phase  consisting of cd1̅1 with 
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small amounts of each chiral isomer was also proposed and it was suggested that the crystal 
consisted of all four phases, cd1̅1, cd2(+) cd1̅2, and cd2(-) with occupancies of 58:17:17:8.
53  
The initial proposal was met with a degree of skeptism from Bohle et al., where the authors 
re-examined the PXRD patterns of other βH data sets in an attempt to resolve the presence 
of three extra Bragg reflections noted by Strassø et al. 52,54  The authors stated that although 
the observed vinyl disorder  is consistent with the presence of the chiral isomers, the 
available PXRD data alone is insufficient to distinguish a biphasic model from a situation 
where the interference of these isomers is tolerated and merely manifests as vinyl 




Figure 1.8: Molecular structure of (a) Fe(III)PPIX to indicate the α, positions of the vinyl groups with 
all the possible positions in a βH dimer are shown in (b). (c) The four stereoisomers of βH, differing in 
the vinyl group positions, as indicated, are categorised according to their symmetry, the two 
centrosymmetric cyclic dimers, cd1̅1, and cd1̅2 and the chiral dimers, cd2(+) and cd2(-) with 





(1.3.2.4) Single crystal X-ray diffraction of β-haematin 
Despite there being several reports of its synthesis using a variety of reproducible methods 
and the structure having been reported from solving the PXRD pattern in 2000, the 
formation of a robust βH crystals large enough for a single crystal X-ray diffraction collection 
has proved elusive.27 In an attempt to further understand βH formation and crystal 
composition, Klonis et al. reported a reanalysis of the crystal structure data for βH and 
compared it with synchrotron PXRD data of Hz crystals isolated from P.falciparum.55 
Although analysed differently, the original structure of βH was confirmed with Hz and found 
to be similar in structure, albeit with a greater amount of disorder in the Fe(III)–O bond. This 
was rationalised by the resultant homogeneity of the synthesised βH compared with the 
natural product, Hz and an earlier observation of Walczak and co-workers where they used 
EXAFS to examine the iron environment in βH and Hz, showing that differences in the Fe(III)–
O bond length in Hz compared to βH results in a variable occupancy of the axial oxygen 
atom.56 Klonis et al. also controversially proposed that crystal nucleation is initiated by 
formation of non-covalent π-π type dimers of Fe(III)PPIX that align (with their axial ligands 
directed outward) in columns via P-type anti-parallel polymer interactions, which are 
stabilised by and coordinated to adjacent columns via interaction with the μ-propionato 
dimer (μ-Pr).56 This was in contrast with the prevailing theory that the βH crystal was formed 
from cyclic μ-propionato dimers linked via π-π interactions and hydrogen bonds.57  The 
structures of these proposed units and this suggested mode of crystal initiation are pictured 




Figure 1.9 The proposed model of Hz formation from the μ-propionato (μ-Pr) and π- π dimers of 
Fe(III)PPIX via P-type interactions. The π- π dimer columns are proposed to extend into 2D sheets via 
μ-propionato linkages. Molecular structures of these dimers are provided to show their structure, 
with the axial ligands of the π- π dimer being either aqua or -OH in aqueous (aq) solution. Figure 
reproduced and adapted with permission from Klonis et al., (2010)© American Chemical Society.55 
 
Hz has been shown to be morphologically different but structurally and chemically identical 
to a pigment isolated from other blood-feeding organisms, Schistosoma mansoni and 
Rhodinus Prolixus.58  The structure of Hz isolated from these species using synchrotron 
radiation PXRD was shown to match that of the reported structure of βH with the 
characteristic Fe(III)PPIX dimers linked via reciprocal Fe-carboxylate bonds, identified. 
The structure of an Fe(III)mesoporphyrin IX compound, called mesohaematin anhydride 
which contained ethyl groups in the usual vinyl group positions of the protoporphyrin, was 
shown to be isostructural to βH, forming propionate linked cyclic dimers (μ-Pr dimers) which 
were hydrogen bonded to DMSO (dimethyl sulfoxide) solvent molecules instead of each 
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other as in the case of haematin anhydride.56,59  However, the similarity between this 
analogue and βH was found to be greater than that for Fe(III)PPIX and βH using EXAFS, 
leading the authors to conclude that the haematin anhydride consisted of μ-propionato 
dimers  and not haematin monomers.60  
Bohle and colleagues recently proposed that Ga(III)PPIX was a good model of Fe(III)PPIX due 
to their similarity in charge, coordination number preferences and ionic radii.61,62 They 
successfully obtained a single crystal structure of this Gallium analogue of βH, which was 
characterised by the propionate bridged dimeric Ga(III)PPIX units, however, these were 
linked through intradimer hydrogen bonding of free propionic acid groups and the central 
metal, Ga(III) in this case was found to be six co-ordinate, with a pyridine ligand bound trans 
to the coordinated propionate.62 Nevertheless, this single crystal structure provided several 
insights into the crystal state of such molecules providing information that is lost in PXRD 
refinement.  
Recently, a closer analogue was fortuitously obtained when the first single crystal structure 
of a βH DMSO solvate was reported.63 The single crystal was grown in the presence of free 
base chloroquine (CQ), which the authors rationalised to have acted like the base, 2,6-
lutidine, originally used to crystallise βH in the first report of its structure. 63,64 The repeating 
centrosymmetric unit matched that of a proposed μ-propionato dimer consisting of two 
pentacordinate iron (III) porphyrins shifted laterally in the plane so that the two porphyrins 
are orientated with the opposite faces aligned parallel to each other and linked via a 
reciprocal propionate oxygen-Fe bond (Fig. 1.10).55 The crystal data used to solve the 
structure of the repeating unit and the external crystal morphology also matched that of the 
reported structures for Hz and βH solved by PXRD, however, a difference in crystal packing 
was observed.27,55  The presence of three DMSO solvent molecules with one hydrogen 
bonded to the free propionate group of both Fe(III)PPIX molecules was suggested to confer a 





Figure 1.10 The μ-propionato dimer reported by Gildenhuys et al. as the symmetrical repeating unit 
of β-haematin grown as a DMSO solvate. The hydrogen bonds between the DMSO solvent and a free 
propionic acid group on both porphyrin rings are indicated by a dashed red line. Non-relevant 
solvent molecules and hydrogens were omitted for clarity with the ellipsoids drawn at 50% 
probability for each atom. Image was reprinted with permission  from Gildenhuys et al. (2013), © 
American Chemical Society 63 
 
(1.3.3) State of Fe(III)PPIX in solution 
In order to understand the process of crystal formation, several studies on the Fe(III)PPIX 
starting material have been performed.65–69 Fe(III)PPIX behaviour in solution has been 
studied in great detail, however, the presence of a variety of species and aggregation states 
have complicated the evolution of the understanding this molecule and its interactions.70–72 
Fe(III)PPIX has a vast and complicated speciation in different solutions.73  The existence of 
several different aggregation states reported in the earlier literature led to many contrasting 
accounts of this speciation in solution. 74–80 The  UV-vis changes in the absorbance spectrum 
upon dimerisation were often analysed and characterised as polymerisation, coupled to this, 
the low solubility of Fe(III)PPIX in aq solution at certain pH values, initially hampered 
investigation into its speciation at low pH.81,82 Two landmark studies by Brown and 
colleagues, suggested that Fe(III)PPIX existed as a dimeric species in alkaline pH solution 
characterised by  marked changes in the most intense band in the UV-vis spectrum, that 
were inconsistent with Beers’ law behaviour.76 The dimerisation of monomeric Fe(III)PPIX, 
M,  to form the dimer, D, was found to fit a simple linearised equilibrium describing the 
dimerisation constant, K, and number of protons exchanged in the process, n (Eqn. 1.1.1 - 







⇔  𝐷 + 𝑛[𝐻+] (1.1.1) 
 





 log 𝐾𝑜𝑏𝑠 = log 𝐾 + 𝑛[𝐻
+]  (1.1.3) 
 
Analysis of the extinction coefficients of each species allowed for the calculation of log Kobs 
and n, which was reported to be one for both the monomer and dimer species enabling the 
calculation of a pKa (dimer) as 7.5.
76 A structural model of this dimer was proposed through 
identification of a characteristic Fe-O-Fe stretching frequency at 900 cm-1 in the IR spectrum 
of a solid sample precipitated from DMSO in the presence of NaOH, which was shown to be 
a μ-oxo bridged Fe(III) dimer characterised by an oxide ligand coordinated to the Fe(III) 
centres of both Fe(III)PPIX molecules (Fig. 1.11). 83 The structure proposed was thought to 
consist of two antiferromagnetically coupled Fe(III) centres which deviated 0.5 Angstroms 
(Å) out of the porphyrin plane toward the oxide ligand, a Fe-O bond length of 1.8 Å and a Fe-
O-Fe bond angle that was found to be between 165-180°, based on previously reported 




Figure 1.11 Early molecular model of the μ-oxo dimer form of Fe(III)PPIX as proposed by Brown et al. 
The angles and bond lengths were subsequently supported by X-ray crystal structure of the dimethyl 
ester derivative, however, the sixth coordinated H2O or 
-OH ligand is not present in the structure.76,87 
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However, the published structure of μ-oxo-bis[(protoporphyrin IX dimethyl ester)iron(III)], a 
close analogue of Fe(III)PPIX, was subsequently shown to be five co-ordinate lacking the 
sixth water or hydroxide ligand proposed.87 A later study to probe the magnetic and 
spectroscopic properties of the Fe-O-Fe linkage by O’Keefe et al., confirmed the existence of 
these antiferromagnetically coupled μ-oxo dimers by temperature dependent magnetic 
susceptibility measurements, however, they were not found to form spontaneously in aq 
solution and instead required the presence of a weak organic base (10% pyridine) in 
solution.88 Despite this observation, and several reports of different types of aggregation 
states for Fe(III) and other metalloporphyrins in the literature, the belief that the μ-oxo 
dimer species was the predominant form of Fe(III)PPIX in solution persisted.74,89–93 It was not 
until recently, in 2007, that de Villiers et al. showed conclusively through UV-vis 
spectroscopy and magnetic susceptibility measurements, that the dominant species of 
Fe(III)PPIX in aq solution was in fact a non-covalently associated π-π dimer. 66 This species 
was characterised by two Fe(III) porphyrins linked through π-stacking with their axial ligands 
facing outward from each other (pictured in Fig. 1.9). 66 The key distinguishable differences 
between these two dimeric forms of Fe(III)PPIX were the magnetic coupling of the 
antiferromagnetic μ-oxo dimer species yielding a magnetic moment, μ, of about 2.0 μB and 
the diagnostic absorption bands present in the charge-transfer (CT) region of the UV-vis 
spectrum between 550-650 nm for the μ-oxo dimer  initially highlighted by O’Keefe and 
colleagues. 66,88 These were found to absent in the π-π dimer spectrum, with an observed μ 




Subsequently, a comprehensive study by Asher et al. characterised the solvent effects on 
Fe(III)PPIX speciation.72 The speciation of Fe(III)PPIX was investigated in mixed aqueous 
solutions (high and low salt) over a pH range and in the presence of a variety of aprotic (eg. 
DMSO) and protic (eg. methanol) solvents using UV-vis and 1H NMR spectroscopy, magnetic 
susceptibility and diffusion measurements. The authors showed that water and polar protic 
solvent solutions, as measured by their Dimroth-Reichardt hydrophobicity parameter, ET(30), 
> 48.4 kcal.mol-1, were found to induce the π-π dimer form of Fe(III)PPIX.72 On the other 
hand, at low to neutral pH, in aprotic solvent mixtures, the monomeric species of Fe(III)PPIX 
was prevalent. However, as the pH of the solution was increased, the μ-oxo dimer species 
was favoured in mixed aq aprotic solvents (water-miscible) of low polarity. An investigation 
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of the temperature dependence of this μ-oxo dimer equilibrium in 40% aq DMSO showed its 
formation to be endothermic, indicating that this process was entropy driven under the 
conditions tested. The entropically favoured formation of the μ-oxo dimer species was 
proposed to be a solvation effect around the axial -OH/H2O ligand under the pH conditions of 
interest. Aprotic solvents are only capable of acting as hydrogen bond acceptors and 
therefore at alkaline pH, offer reduced solvation potential around the -OH axial ligand, 
requiring an increase in the water concentration around this ligand, relative to the bulk 
solvent. This process presumably results in the observed entropy decrease, favouring the 
release of one H2O ad two H
+ ions to form the μ-oxo dimer species. Conversely, in polar 
protic solvent mixtures capable of acting as both hydrogen bond donors and acceptors  at 
high pH, can replace the solvating water molecules around the axial -OH ligand.  This concept 
was explored by the solvent system choices by Asher et al., where it was found that the 
degree of π-π dimer species domination in solution, was correlated to the polarity of the 
solvent medium.72  
This suggestion recently gained support from a molecular dynamics (MD) simulation study 
that provided evidence of these solvation shells around each species, showing that the 
monomeric and π-π dimer species displayed prominent solvation shells around their axial 
ligands, and although solvated, the oxide bridge of the μ-oxo dimer, represented a drastic 
reduction in solvation, considering it was shared between the two porphyrins.69 The 
formation of higher aggregates of π-stacked μ-oxo dimers in concentrated salt solutions was 
suggested to occur as a result of competition for the hydration sphere around the axial 
ligand, lowering the stability of the hydrophilic face of the porphyrin (ligated face) relative to 
the μ-oxo dimer. The polar protic environment would still however favour the observed 
formation of π-stacked aggregates.72 A summary of their findings and the different 
conditions required for each Fe(III)PPIX species is presented in Scheme 1.1. This capacity for 
varied Fe(III)PPIX speciation in solution is often overlooked in the literature and needs to be 








Scheme 1.1 Representations of predominant species of Fe(III)PPIX in aq, mixed-aq  and high 
concentration solvent or salt solutions under variable conditions as characterised by UV-vis 
spectroscopy , magnetic susceptibility and diffusion measurements.72 
 
(1.3.4) Theories of haemozoin formation in vivo 
To date the mechanism of Hz formation in vivo is yet unelucidated, however, several 
investigations into this process have been reported.29 Widely held theories include auto-
catalysis, spontaneous formation, enzyme-catalysed detoxification mechanisms, and 
facilitation by histidine-rich proteins or lipid mediated biocrystallisation and even a 
combination of these processes. While multiple reports have provided evidence for each of 
these mechanisms, their exact roles are unclear and further investigation is required. A few 




(1.3.4.1) Protein catalysed formation of haemozoin 
In biology, a wide variety of detoxification processes are catalysed by enzymes or specific 
protein systems, efficiently compartmentalising each step in a series of specific interactions 
that are capable of completing structural transformations.95 Theories of enzyme catalysed Hz 
formation were first postulated in 1991 by Slater and Cerami, who showed lysed troph 
extracts, containing what was believed to be the active enzyme, haem polymerase, were 
capable of converting Fe(III)PPIX into Hz.96 Studies were able to show “inhibition of this 
enzyme” upon addition of quinoline antimalarials.97,98 However, this notion was dispelled 
upon publication of a study conducted by Dorn et al. which showed that heating of extracts, 
addition of “polymerases” or additional product,  had no effect on the observed ability to 
mediate synthetic Hz formation and thus concluded that no such enzyme was present in the 
extracts. 99 The authors went on to propose that Hz formation may in fact be as a result of an 
auto-catalytic process based on their observations that an increased amount of product 
formed in the presence of either Hz or βH. 99 This theory however, offered no explanation as 
to how the initial nucleation step occurred.  
Later, Sullivan et al. proposed that histidine-rich proteins (HRP II and III) were involved in this 
process.100 This idea was perpetuated 101,102 until it was later shown that  these HRP proteins 
were not as efficient at producing Hz as initially thought and was found to be mainly located 
in the cytosol of the red blood cell rather than at the site of Hz formation, inside the DV. 103–
105 It was thus proposed that Hz formation is a coordinated two-step process involving lipids 
and PfHRP II.104 Finally, the involvement of these histidine-rich proteins in Hz formation was 
disproved when studies found that in mutated species which lack the genes for the 
formation of these proteins, Hz was still detected.106,107  The presence or absence of PfHRP II  
or III was also found to have no effect on βH crystal morphology.108 
The hypothesis of protein catalysed Hz formation was recently rekindled when another 
protein called, haem detoxification protein (HDP), was proposed by Jani et al. and shown to 
bind Fe(III)PPIX strongly (-log Kd = 7.1) at an average of  2.7 binding sites per protein 
molecule.109 Recombinant HDP was found to effect a 50% conversion to βH within 20 min, 
however, HDP was found to lack the N-terminal sequence required for protein transport 
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signalling in order for it to be shuttled from accumulation in the parasite cytoplasm to the 
site of Hz formation in the DV. 109–111   
The most recent proposal involving proteins implicated in haemoglobin degradation and Hz 
formation, was a 200 kDa protein assembly of falcipain 2/2′, plasmepsin II, plasmepsin IV, 
HAP, falcilysin and HDP, introduced by Chugh et al. in 2012.112 The authors proposed from in 
vitro co-immunoprecipitation and MALDI-TOF mass spectrometry results, that HDP and 
falcipain 2 interact strongly, in the form of a Hz formation complex (HFC), to directly 
associate with the growing Hz crystal. Interestingly, a recent study on identification of the 
proteins associated with and embedded within isolated Hz crystals from P.falciparum 
extracts in the Egan laboratory using proteomics techniques found no evidence of the 
proteins belonging to the proposed complex.113 On the other hand, lipoproteins were 
identified, with known functions in lipid transport and biosynthesis, as were neutral and 
phospholipids, which lent further credence to an alternative hypothesis that lipids and not 
proteins are the biomolecules responsible for Hz formation in vivo. Plasmodium parasites are 
incapable of de novo biosynthesis of cholesterol and fatty acids, however, to develop its 
membranes, a significant amount of host lipid appropriation occurs throughout 
development.114 The complete lipid profile of the malaria parasite through all its stages of 
development is yet unelucidated but those that have been identified, have been shown to 
play a role in Hz formation.115 
(1.3.4.2) Lipid mediated haemozoin formation 
The possible involvement of biomolecules other than enzymes or individual proteins in Hz 
formation was explored in 1995 when Bendrat et al. controversially suggested that lipids 
may be responsible for mediating Hz formation in vivo and were likely the source of the 
observed auto-catalytic behaviour of Hz extracts.116,117 Through high-performance liquid 
chromatography (HPLC) analysis the authors were able to identify methyl esters of oleic, 
palmitic and stearic acids associated with the parasite lysates active in Hz formation. In a 
reply to this work, Ridley et al. showed that acetonitrile extracts from troph infected and 
uninfected erythrocytes were capable of initiating in vitro βH formation, leading the authors 
to propose that it was the acidic pH of the parasite lysate that was responsible for the 
observed Hz specificity.99,117 Later work by Fitch et al. on chloroform extracts of P. berghei 
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infected erythrocyte lysates showed that at least 70% of the proposed “haem polymerase” 
activity could be attributed to the cholesterol, phospholipids and acylglycerols found by TLC 
analysis of the extracts.118 Fitch and co-workers suggested that the lipids act by solubilising 
Fe(III)PPIX to facilitate Hz formation. The authors showed that mono and 
dioleoyacylglycerols as well as the detergent sodium dodecyl sulphate (SDS) were capable of 
mediating βH formation in vitro.118 The phospholipids, phosphatidylinositol, 
phosphatidylserine, sphingomyelin and phosphatidylcholine were also found to initiate βH 
formation.119  In support of lipid involvement, Jackson et al. showed that the lipophilic 
fluorescent probe Nile Red (NR) stained neutral lipid droplets of about 100 nm in size 
composed of di and triacylgylcerols associated with the parasite DV of infected 
erythrocytes.120 Fluorescence and confocal microscopy images of lipid bodies stained with 
NR obtained from the various stages of Plasmodium infection, are shown in Fig. 1.12. Further 
imaging evidence was provided in a review by Coppens and Vielemeyer, where Hz crystals 
were shown to be enveloped by neutral lipid bodies inside the parasite DV, also shown in 
Fig. 1.12.121    
Tripathi and co-workers in 2002, and later, as mentioned, Pandey et al., had postulated that 
lipids were involved in the biocrystallisation of Hz from studies showing that linoleic acid and 
the addition of mono-1-rac-oleoyl glycerol were capable of initiating βH formation.122,123 In 
2007, in a landmark study by Tripathi, along with Pisciotta and other authors showed by 
subcellular fractionation of parasite extracted Hz through a concentrated sucrose solution 
with malachite green staining, that mono and diacylgylcerols as well as polar lipids were in 
close association with Hz within the parasite DV (Fig. 1.13).124 A unique blend of neutral 
mono and diacylgycerol lipids were proposed to be the main components of the lipids found 
associated with Hz in vivo. The neutral lipid blend (NLB) includes, rac-1-monostearoylglycerol 
(MSG), rac-1-monopalmitoylglycerol (MPG), rac-1,3-dioleoylglycerol lipid (DOG), rac-1,3-
dilinoleoylglycerol (DLG) and rac-1,3-dipalmitoylglycerol (DPG), identified to be present in 
the volume ratio 4:2:1:1:1 from TLC and electron-spray ionisation mass spectrometry lipid 
analysis on saponin-purified trophs. Lipid extracts from purified digestive vacuoles, whole 
trophs, uninfected erythrocytes, the neutral lipid blend and a series of lipid standards were 
tested for Fe(III)PPIX crystallisation ability in vitro at pH 4.80, 37 °C where it was shown that 
the monoacylglycerols were the most efficient at producing βH.124 The authors offered 
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several suggestions as to the role of these lipids in Hz formation, expanding on earlier 
theories initially proposed by Fitch et al.118 and Jackson et al.120 postulating that the neutral 
lipid bodies offer a non-aqueous environment that excludes water, allowing for facile 
transformation of Hz dimers from the π-π dimer form of Fe(III)PPIX by release of axial water 
ligands under the acidic conditions of the DV. 124  
 
 
Figure 1.12 Identification of lipid bodies (LB) associated with Hz in Pf. infected erythrocytes shown in 
panels A-B taken with brightfield (left) and fluorescence (right) microscopy images of NR labelled 
lipids in malaria parasite at the (a) ring, (b) young troph, (c-f) mature tropozoite to schizont stages of 
its life-cycle. NR staining of a parasite with young troph infection in brightfield and under 
fluorescence (green) shown in panel (C) (1). A comparison of the signal obtained with multiple troph 
infection of one erythrocyte is offered by panel (2). Panels (D) (3) and (4) compare the staining 
pattern obtained in an infected erythrocyte with an un-infected one (only the erythrocyte membrane 
is stained), respectively. Furthermore, the LBs identified within Plasmodium were shown to be 
associated with Hz within the DV of the malaria parasite as highlighted by the arrow in panel (E). 
Scale bars represent 5 and 2 μM in A & B. Images A-D reproduced with permission from Jackson et 
al. (2004) © John Wiley and Sons.120 Image E copied with permission from Coppens and Vielemeyer, 
(2005), ©Australian Society for Parasitology Inc, Published by Elsevier Ltd.121 
 
As mentioned, the malaria parasite is not the only blood-feeding organism to detoxify 
Fe(III)PPIX as Hz crystals. While it is unknown if their mechanism of formation is exactly the 
same due to the extracellular formation of Hz in these organisms compared to the 
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intracellular process by P. falciparum, the identification of Hz inside lipid droplets or 
membrane bound vesicles from the midgut of S. mansoni and R. prolixus offers considerable 
support to the theory that this process is a lipid-mediated one.58 
 
 
Figure 1.13 TEM images of (A and B) malachite green stained LBs in parasite infected erythrocytes, a 
scanning electron micrograph of Hz inside the parasite DV which is shown to be enveloped by lipids. 
Panels (C-G) show Hz after successive stages of wash, where images C-E depict lipid deposits around 
the crystals, while (F-G) show TEM images of delipidated Hz crystals. Scale bar represents 1 μm. (H) 
shows the yields of βH formed by extracted lipid and each acylglycerol lipid component as identified 
by TLC. (I) SDS-Page gel electrophoresis showing minimal protein content in the right lane compared 
to the whole troph (left lane). No evidence of HRP, PfCRT or cytosolic Pf-aldolase (ALD) was 
identified in saponin-purified trophs (T) or Hz (SPHz) by Western blot analysis.  The lipids found were 
identified by TLC against lipid standards (J) showing a dominance of acylglycerols in isolated T, 
enriched digestive vacuoles (eDV) and SPHz. Reprinted with permission from Pisciotta et al. (2007), 





(1.4) Studies on the mechanism of haemozoin formation 
Several in vitro studies between Fe(III)PPIX and these neutral lipids as well as with solvents 
and lipid-like molecules to form βH have been performed, the most relevant of which will be 
discussed over the following pages.  
(1.4.1) Conversion of Fe(III)PPIX to β-haematin, in vitro 
To shed light on the possible role of lipids in the process of Hz formation, An earlier study by 
Egan et al. investigated the formation of βH at model organic / aq interfaces based on 
insights obtained from MD simulations  showing that the π-π dimer Fe(III)PPIX species 
spontaneously arranges its conformation to that of a βH crystal unit precursor (μ-propionato 
dimer) in vacuo, suggesting that crystallisation is facilitated by the absence of competing 
water molecules for hydrogen bonding (Fig. 1.14).57 Simulations in aq solution did not result 
in the spontaneous formation of the μ-propionato dimer precursor since the propionate 
groups were observed to move away from the Fe(III) centers to interact with the bulk water 
molecules. This led the authors to conclude that the non-aq environment offered by lipids 






Figure 1.14 (A) Results of an MD simulation conducted on (i) Fe(III)PPIX π-π dimers in the absence (ii) 
and presence of water. (iii) In vacuum, the conversion to a structural βH precursor is spontaneous, 
but it is not formed in aq solution. (B) shows the proposed conversion step of this precursor to the 
μ-propionato dimer present in the βH crystal unit in the absence of water. Image reproduced with 
permission from Egan et al. (2006),© Elsevier.57 
 
Further studies by de Villiers et al. using grazing incidence synchrotron X-ray diffraction 
(GXID) and X-ray reflectivity techniques on a premixed solution of Fe(III)PPIX at the model 
lipid, 1-myristoyl-glycerol (MMG)/air interface showed the formation of βH crystals oriented 
with their {100} faces parallel to the water surface.125 This was interpreted by proposing a 
stereospecific interaction between the exposed OH groups of MMG clusters and Fe(III)PPIX 
molecules to nucleate orientated crystallisation (Fig. 1.15a), suggesting that it was evidence 
of the effect of the favorable stereochemical interactions between the surface polar lipid 
head groups and the exposed -CO2H group via the oxygen lone pair on the {100} face of 
Fe(III)PPIX.  By analogy, the orientation of βH crystals was investigated at the surface of self-
assembled functionalized alkalanethiol monolayers (SAMs) with either OH or CH3 groups or a 
mixture of the two. Comparable to the lipid, OH functionalized SAMs were found to induce 
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βH nucleation primarily at its {100} face, whereas the alkyl functionalized SAMs induced 
nucleation preferentially via the {010} face as well as the {100} face.125 The {010} face is 
shown to expose the porphyrin ring CH groups (vinyl and methyl moieties) and was 
proposed to be likely to enjoy favourable interactions with the CH3-functionalised SAMs.  
 In support of this theory, a recent publication showed that lipid droplets of the proposed 
neutral lipid blend nucleate βH at the {100} and {1̅00} faces.126 A comparison of these 
crystals with Hz isolated from parasite extracts and βH formed at the pentanol/ aq interface 
using transmission electron microscopy (TEM) appeared to indicate that the size distribution 
of the neutral lipid droplets (NLDs) which were found to be in contact with  the βH crystals 
formed, determined their sizes (Fig. 1.15 d). Crystals formed at the pentanol/aq interface 
appeared to be longer than those nucleated by NLDs,  possibly due to the flat surface of the 
interface, as opposed to the curved lipid surface. Furthermore, βH crystals were found to lie 
on the surface of NLDs rather than inside as previously proposed.127 The larger Hz crystals 
from Pf DV extracts, were suggested to have formed aligned to the parasite DV membrane 
rather than smaller NLDs inside the DV.126 This hypothesis was consistent with evidence that 
DV inner membrane phospholipids or neutral lipid rafts rather than NLDs are responsible for 







Figure 1.15 (a) An illustration of the stereochemical contacts between βH and MPG lipid surface 
showing the proposed model for templated crystal growth, the near match between the positions of 
the βH propionic acid groups (yellow) at the {100} face and every third glycerol OH group (red) of 
the lipid is highlighted in (b).  The packing arrangement of βH along the c axis with {100} and {010} 
faces, illustrated by arrows is shown in (c). The image in (d)  depicts the angle of contact between βH 
and the surface of the NLD (assuming a spherical NLD), as observed from (e) TEM (a-c) and EELS (d) 
of βH crystals associated with the surface of NLDs. Image (c) reproduced with permission from de 
Villiers et al., (2009),©American Chemical Society125 and Images (a, b, d&e) reproduced with 







(1.4.2) Location of and type of lipid involved in haemozoin formation 
A percentage of the literature on lipid mediated Hz formation is polarised, with a 
considerable number of studies indicating that the phospholipids that comprise the DV or 
transport vesicle (TV) membranes rather than the proposed neutral acylglycerol lipid 
droplets, are the site of Hz formation in vivo.46,119,128–131 Kapishnikov and co-workers have 
investigated this extensively using cryogenic soft X-ray tomography (cryo-XT)  and 3D 
electron microscopy to show Hz clearly visible inside the parasite DV, inside infected 
erythrocytes.46,128 The Hz crystals of early trophs were shown to be aligned side by side along 
the needle crystal c axis parallel to the inner leaflet of a somewhat flattened DV membrane 
as seen by 3D rendering of the serial surface view microscopy images (Fig. 1.16). This was 
suggested to be the site of nucleation of Hz crystals. Later stage trophs and schizonts, were 
found to have larger Hz crystals toward the center of a more spherical DV, with all crystals 
orientated toward their {100} faces. The Hz crystals were never observed to be on the 
surface of or surrounded by acylglycerol lipids in contrast to earlier studies, nor was any Hz 
detected in Hb transport lipid vesicles.129 The authors proposed that heterogeneous 
nucleation of Hz crystals occurs at the inner DV membrane, which after crystal growth and 
maturation, break away from the membrane presumably because of the observed change in 
DV membrane curvature. The inner leaflet of the DV membrane has been shown to be much 
more fluid than the outer leaflet due to the presence of phospholipids such as 
phosphatidylethanolamine, phosphatidylserine, and phosphatidylinositol and a high 
proportion of saturated fatty acids.114  
It was acknowledged that phospholipid head groups were unlikely to induce the observed 
orientated nucleation and an acylglycerol lipid film adsorbed to or a part of the inner leaflet 
of the DV membrane was proposed as the nucleating lipid. They also suggested that Hz 
crystals grew in the aq phase, despite the thinking that a hydrophobic environment is 
required for loss of the axial H2O ligand to form the precursor to βH, the μ-Propionato 
dimer.125,132  A later publication by the same authors illustrated the DV membrane thickness 
between 4-5 nm, of which, roughly 86% comprises a lipid bilayer approximately 4.2 nm thick, 
with the remainder taking the form of isolated double layer patches of 8 nm thickness. 130 
This thickness was proposed to arise from a mixture of phospholipids, cholesterol and 
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acylgylcerols, the latter of which, make up the inner lipid leaflet that is suggested to nucleate 
Hz formation. 
 
Figure 1.16 TEM and cryo-XT images of different stage parasites with Hz crystals highlighted by 
yellow arrows.  (1) Panel (a) depicts a TEM of an early stage troph with smaller crystals aligned along 
the inner DV membrane, (b-c) surface rendered in 3D, with orthogonal views to show the alignment 
of Hz crystals along the flattened DV membrane (2d) TEM images of a later schizont stage (e-f) the 
larger Hz crystals in the center of a spherical DV can be clearly seen. (3g-h) The alignment and 
orientation of the Hz crystals parallel to the DV membrane is shown. Images reproduced with 
permission from Kapishnikov et al. (2012),©National Academy of Sciences.46 
 
An early report published by Ginsberg and Demel demonstrated the ability of Fe(III)PPIX to 
intercalate into phospholipid monolayers effecting a measurable increase in the surface 
pressure.133 The authors showed that the degree of Fe(III)PPIX incorporation into the 
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phospholipid membrane was determined by the speciation of Fe(III)PPIX, either as a 
monomer or dimer in which the former exhibited a greater amount of intercalation. Other 
than size, no reasons for this preference were offered and very little literature has explored 
the speciation effect on lipid permeation any further. 
 In support of the DV membrane being the site of Hz nucleation, in vitro studies on the ability 
of phospholipids to nucleate βH formation have been published.119,131,134 These works found 
that selected phospholipids and were efficiently and rapidly able to catalyse the 
crystallisation of Fe(III)PPIX to βH. The ability of selected phospholipids to induce βH 
formation at 37 °C was found to be inversely correlated to their gel-to-fluid transition 
temperature (Tm), which the authors suggested was due to the required membrane fluidity 
for Fe(III)PPIX insertion into acyl chains of phospholipids.131 This was observed in differential 
scanning calorimetry studies of the proposed neutral lipid blend which was found to have 
unique melting properties compared to its saturated and unsaturated lipid components, 
which were found to have higher and lower Tm values, respectively.
135 The blend was 
proposed to possess greater fluidity with less orientated packing, than its individual 
components. To explain these observations and offer suggestions as to the possible role of 
either neutral lipids or the DV membrane in Hz formation, some understanding of crystal 
nucleation and growth together with the role of stereochemical interactions is required.  
 
(1.4.3) Crystal nucleation and growth in the context of lipid and solvent 
mediated β-Haematin formation 
 
The transformation of Fe(III)PPIX into Hz in vivo or βH in vitro is the conversion of an 
amorphous solid into a crystalline solid material. Classical nucleation theory describes the 
aggregation of dissolved molecules in a supersaturated solution into organised nuclei of 
radius, r. The free energy of the surface of this new phase is positive and proportional to the 
square of the radius of the nucleus, however, the energy driving aggregation to form the 
nucleus is negative and proportional to the volume of the nucleus or r3.136  Once the nucleus 
has grown past a critical threshold size, r*, in a metastable phase, the total free energy of 
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the system begins to decrease as continued growth stabilises the transformation of the 
metastable phase to the new thermodynamically stable phase.137 Crystallisation processes 
are said to follow Ostwalds rule of stages or step-rule where the process of transformation 
occurs first by nucleation of new crystal nuclei either spontaneously or by the introduction 
of a heterogeneous stimulus.138 The Avrami equation models the complicated processes of 
nucleation and growth in the solid to solid state transformation with the following 
assumptions; (1) Nucleation occurs randomly and homogeneously over the entire 
untransformed portion of the material, (2) The growth rate is independent of the extent of 
transformation and (3) the growth rate is uniform in all directions.139,140  It has been shown 
to provide an approximate description of the kinetics of crystallisation of Fe(III)PPIX.63,67,141 
The Avrami constant, n, describes both the seed-formation dynamics or type of nucleation 
and the dimensionality of growth of the crystal at a constant temperature.  n is usually an 
integer between 1-4, reflecting the nature of the nucleation , either instantaneous or 
sporadic and the shape of the particles formed, either in 1, 2 or 3-dimensions to give rods, 
discs or spherical crystals, respectively. The rate constant, z, is a function of the nucleation 
rate (N) of new particles and growth rate (G), dependent on the volume and thus densities 
of the reactant (𝜌𝑟) and product (𝜌𝑝) as described in equation (Eqn) 1.2.1. The overall 
transformation kinetics are given by Eqn. 1.2.2., where 𝑚0 is the initial mass of Fe(III)PPIX 
and  𝑚𝑅, is the mass of Fe(III)PPIX after the crystallisation reaction has occurred at time t. 
The kinetics of transformation typically follow a sigmoidal profile allowing for a period of 
slow initial and end transformation with rapid crystallisation in between.138 






    (1.2.2) 
 
Egan et al. reported the kinetics of βH formation from 4.5 M acetate buffer at 60 °C to be 
sigmoidal with n = 4, indicating an initial slow phase to allow for sporadic nucleation 
(continuous and random) and crystal growth in 3-dimensions to form spherical crystals 
which terminate upon full conversion of Fe(III)PPIX into βH.67 The rate constant was 
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reported to be dependent on temperature, stirring rate, acetate concentration and pH.  
Another solvent, benzoic acid, was also found to initiate βH formation at a much lower 
concentration than acetate solution.141 The kinetics of this process were similarly found to 
be sigmoidal and fitted the Avrami equation, with n = 4. The authors explained the increased 
activity of benzoic acid by observing the kinetics of βH formation in a series of substituted 
benzoic acids and monitoring the temperature dependence of the acetate and benzoic acid 
reactions. The activity of the benzoic acids was proposed to be as a result of their propensity 
to form hydrogen bonds in solution whereby the carboxylic acid groups were suggested to 
disrupt any hydrogen bonds between Fe(III)PPIX propionate groups and axial H2O ligands, a 
process required for facilitation of βH formation. The benzene group in benzoic acid was 
suggested to allow for further π-π interactions with Fe(III)PPIX to discourage the observed π-
stacking of Fe(III)PPIX in solution causing the increased activity observed compared to 
acetate solution.141 The kinetics of βH formation in phospholipid and neutral lipid solution 
have subsequently been investigated, offering biologically relevant rates of crystallisation to 
account for the estimated concentrations of free Fe(III)PPIX in the DV.16,57,142,143 Initial 
studies found that individual neutral lipids and the blend of neutral lipids induced rapid 
formation of βH under biomimetic conditions with half-lives ranging between 1 and 4 min 
(Fig. 1.17).57,127 Confocal microscopy was employed to show that βH formation occurs in 
close association with neutral lipids, however, the Avrami equation was not applied to these 
data. 143  
A recent comprehensive study on the kinetics of βH formation was reported at a model 
lipid/aq interface.63 The observed exponential kinetics were modelled using the Avrami 
equation, with a reported n = 1 and a rate constant of 0.19 ± 0.02 min-1 corresponding to 
instantaneous nucleation and growth to form linear crystals. The lipid was found to promote 
βH formation from a fixed number of preformed nuclei with crystal growth in 1-dimension 
which was reported to be consistent with the observed morphology of long needle-shaped 






Figure 1.17 Multiple in vitro studies of neutral lipid mediated βH formation. (a) The βH yields 
obtained with different lipids. Monoacylglycerides: MPG, MSG and MOG; diacylglycerides: DOG, 
DPG, DLG, triglycerides: TOG and TMG and cholesterol (CHL). (b) The time taken (min) to form 50% 
βH (t1/2) for each lipid with the smallest observed half-life obtained for MOG and DOG. (c) The 
Arrhenius behaviour for MSG at pH 4.8 constructed from rate constants with slope (activation 
energy) of 76 KJ.mol-1. (d) The effect of pH on the yield of βH obtained with MSG at 37 °C. Figures 
reproduced with permission from Hoang et al. (2009),©Royal Chemical Society.127 
 
The exact site of Hz formation in the malaria parasite DV is still unconfirmed and the specific 
type of lipid molecule responsible for its crystallisation may be neutral acyl glycerols or 
charged phospholipids as the discussed works have postulated. Regardless of the nature of 
the lipid associated with Hz formation, the chemical relevance of a lipid mediated 
biocrysatllisation of Fe(III)PPIX is also unknown, to further the understanding of these 
interactions, the neutral acylglycerol lipids identified from TLC samples on parasite DV 




(1.4.4) Lipid mimics and other inducers of β-Haematin formation  
Lipid solutions and interfaces are dynamic and often difficult to study due to particle flux 
from coalescence and viscosity effects that result in light scattering and poor 
reproducibility.145–147 Coupled to this issue, commercially available purified lipids are 
expensive compared to common organic solvents. To circumvent these complications, 
several studies on the conversion of Fe(III)PPIX to βH have been conducted in solvent 
systems that serve as lipid mimics. As mentioned, octanol, pentanol and other alcohols have 
been shown to effectively induce βH formation in the literature.57,148 This ability has been 
linked to their degree of hydrophobicity and inherent ability to solubilise Fe(III)PPIX in acidic 
solution.148 Huy et al. also proposed that the lower surface tension of these solutions serves 
to decrease the energy required for forming βH nuclei.149 This phenomenon has also been 
reported for the ability of polyethylene glycols (PEGS) to induce βH formation in acidic 
solution.150 
Recently, research on the formation of βH from citrate buffer-saturated octanol solutions 
(CBSO) have shown that Fe(III)PPIX is four orders of magnitude more soluble in this solution 
than in aqueous solution at pH 4.8.151 The surface morphology of crystals prepared from this 
octanol solution was compared with those grown in 0.1 M acetate solution, of which the 
latter was found to exhibit unusual macro- and mesoscopic features not observed for the 
former or Hz crystals. The authors concluded that the organic lipid environment is essential 
for βH crystal formation. Following this, the same researchers published a biomimetic 
method of growing large 50 μm βH crystals from CBSO solution upon which they very 
recently proposed, using in situ atomic force microscopy (AFM), that crystallisation follows a 
strictly classical mechanism where two-dimensional nucleation occurs from solute molecules 
followed by epitaxial growth.152,153  
Neutral mono and diacylglycerol lipids are amphiphilic molecules that are believed to act by 
templated nucleation through their exposed polar OH groups.125 Due to the difficulty of 
studying lipid systems and their high cost, several groups have explored the ability of 
amphiphilic detergents to mimic lipids in the βH formation process.118,154,155 Specifically two 
sets of researchers have shown that neutral detergents, Tween-20 and NP-40, are capable of 
effectively initiating βH formation in moderate to high yields over approximately four to six 
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hours.150,151  Detergents are structurally unique molecules as they enable both hydrophobic 
interactions through their hydrocarbon chain portion and hydrophilic interactions through 
some polar headgroup with other substances contributing to a host of physical and chemical 
properties in solution.156,157 Mostly employed for the solubilisation and crystallisation of 
membrane proteins, detergents are defined by their ability to self-assemble and interact 
with hydrophobic surfaces in a concentration-dependent manner.158  
Increasing concentrations of detergent molecules in solution are known to form noncovalent 
aggregated structures called micelles (Fig. 1.18).159 The spontaneous association of 
amphiphilic molecules into thermodynamically stable micellar aggregates in aq solution 
leads to a reduction of the energetically unfavourable contact between polar water and the 
non-polar hydrocarbon chain parts of the detergent, while still maintaining the favourable 
polar contacts with the hydrophilic bulk solution. This unique structure enables detergents 
to solubilise nonpolar or organic materials in the hydrophobic regions of the micelle which 
enables detergent properties that differ from pure detergent monomer solution. The 
concentration at which detergent monomers begin to form these aggregated structures is 
referred to as the Critical Micellar Concentration (CMC) and is dependent on buffer or salt 
concentrations in solution as well as the pH and temperature of the solution.160 
There are multiple techniques to determine the CMC of a particular detergent, one method 
in particular exploits the solvatochroism of the hydrophobic dye, Nile Red (9-diethylamino-
5H-benzo[α]phenoxazine-5-one).161,162 NR is an intensively fluorescent dye in hydrophobic 
solvents or environments. It has been shown to emit the maximum fluorescence intensity 
with increasing hydrophobicity and thus it is highly selective for lipid or micelle 
environments. 163,164 NR is classified as a twisted intramolecular charge transfer (TICT) 
fluorescent probe.165 Generally, this class of probe responds to photoexcitation by twisting 
toward an ideal perpendicular excited state. The rate of formation of this TICT excited state 
decreases with increasing polarity (measured as ET(30)) of the solvent environment, 
decreasing the fluorescence intensity of the emitted signal. Hence, this extrinsic dye is used 
as a sensitive biological marker of micropolarity.166 In hydrophobic environments, excited 
state-fluorophore molecules experience an intramolecular electron transfer from the 
dialkylamino donor moiety to an adjacent acceptor (aromatic system) by twisting about the 
bond between them such that they are perpendicular, forming a highly polar TICT state that 
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is accompanied by an increase in fluorescence intensity and decrease in emission 
wavelength.166 Determination of detergent CMC is possible by measuring the increase in NR 
fluorescence emission as the regions of hydrophobicity increase upon micellisation (Fig. 
1.18).161  
At concentrations well-below to the optimum detergent concentration at which micelles 
form in solution, several reports of interactions of detergent monomers to form premicellar 
aggregates have been made.167–171 The smaller metastable aggregates of detergent dimers, 
trimers and higher aggregates have also been shown to exhibit increased hydrophobic 
regions and to lower the surface tension of aq solution like their more concentrated 
counterparts.172 
 
Both the neutral detergents mentioned above were utilised at concentrations well below 
their reported CMCs in the βH formation experiments and while no mechanistic studies have 
been reported about the role of detergents in Fe(III)PPIX crystallisation, these neutral 
amphiphiles and all the lipophilic systems discussed, have successfully been utilised as lipid 
‘mimics’ in colorimetric assays to screen for potential βH inhibitors.155,173–176 The drugs that 
target the Hz formation pathway are historically the most successful antimalarials, however, 
their mechanisms of action are not fully understood.177  
 
Figure 1.18 A schematic representation of the hydrophobic dye, Nile red, encapsulated to interact 
with the non-polar hydrocarbon chain region inside a neutral TWEEN-20 detergent micelle with 




(1.5) Targeting haemozoin formation for drug treatment 
(1.5.1) Quinoline antimalarials 
Natural treatments have been used to treat malaria for over thousands of years, with the 
earliest stemming from the Qinghao plant (Artemisia annua) in China178,179 and later 
quinoline based antimalarials, isolated from Peruvian or Jesuit’s bark (later called Cinchona 
bark) in Peru, used as a natural fever remedy and spread to other parts of the world by the 
Jesuit priests.180 This powdered bark was utilised across the world until eventually the active 
alkaloid compounds, QN and Cinchonidine, were identified in 1820.181 Limited supply and 
widespread demand led to the attempted synthesis of quinine, however, this was not 
accomplished until 1944, by which time the Bayer synthetic antimalarial, Chloroquine (CQ), 
was already the front-line antimalarial drug.177,181 CQ was successfully used to treat infection 
until the emergence of chloroquine-resistant parasites initially in isolated regions and later, 
spreading throughout the world until its use was eventually phased out. The current 
treatment for uncomplicated P.falciparum malaria infection varies throughout each WHO 
region and includes artemisinin combination therapy (ACT) of two different drugs with 
varied modes of action, usually artemether and lumefantrine.8,182 Although the mechanism 
of action of artemisinin and its derivatives is highly controversial, it is known that the 
presence of the endoperoxide bridge is essential for their antimalarial activity183 and they 
are responsible for significant oxidative stress within the parasite184–186, however, this has 
not been shown to affect Hz formation despite earlier assertions to this.187 The structures of 
these drugs, other quinoline based antimalarials as well as selected non-quinoline drugs and 
are shown in Figure 1.19.  
Despite widespread resistance to CQ and its analogues, quinoline-based antimalarials 
represent a powerful class of antimalarials that remain attractive due to their cheap easy 
synthesis and the low toxicity and safety of use during pregnancy of some of the 
compounds. Thus a greater understanding their mode of action offers the potential to 
design better targeted antimalarials with increased efficacy.177 Many studies have reported 
these drugs to accumulate inside the parasite DV and act against the intraerythrocytic stage 






























Figure 1.19  The molecular structures of selected quinoline and related antimalarial drugs 
including the 4-aminoquinolines (green) and quinoline (purple) and aryl methanols (blue)  which 
comprise the Hz inhibitors, as well as important non-quinoline related antimalarials including the 
anti-folate pyrimethamine (orange) and the artemisinin derivatives (pink). 
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While the relative effect may vary between the different structural families within this class 
of antimalarials the most notable effects of quinoline drug treatment include swelling of the 
DV,190 inference with Hb ingestion,191,192 morphological deficiencies of Hz crystals,193–195 
slower parasite growth and eventual death so that the leading hypothesis on their 
mechanism of action is their ability to inhibit normal Hz formation.195,196 Other mechanisms 
of action have been proposed such as DNA intercalation197,198 or inhibition of enzymes and 
proteins involved in the Hb degradation pathway including vacuolar phospholipases199, Hb 
proteases200 and even glutathione in the cytosol.201 However, a recent study by Combrink et 
al. reported, by using a cell fractionation assay, that a dose-dependent increase in Fe(III)PPIX 
concentration was measurable upon CQ treatment which was found to correlate with a 
decrease in the parasite growth curve.195 In fact, the percentage free Fe(III)PPIX curve was 
found to cross the parasite survivial curve at approximately the IC50 of the drug as seen in 
Fig. 1.20. A key result was that single-dose treatment with drugs, artesunate and 
lumefantrine as well as other quinoline antimalarials, amodiaquine, mefloquine and quinine  
above their IC50 concentrations,  were all shown to correspond to an increase in percentage 
free Fe(III)PPIX and a decrease in the amount of Hz formed. This was shown not to be the 
case for drugs pyrimethamine and sulphadoxine (SP), known to be antifolates rather than 
targeting the Hz pathway. 
In support of this mechanism, in vitro studies have shown that these quinoline drugs are 
capable of inhibiting βH formation96,202 in ways that have been linked to their lipophilicity 
203–205, their pH trapping ability of passive diffusion of charged drugs into the acidic DV 206 
and their affinity for binding Fe(III)PPIX in solution.207 Very early on Macomber et al. noticed 
the accumulation of CQ in the parasite DV suggesting that this and the effect of CQ on the 
morphology of Hz was integral to its mechanism of action.194 Chou and co-workers first 
identified that CQ strongly binds Fe(III)PPIX from parasite lysates and subsequent research 
has explored the formation of drug-Fe(III)PPIX complexes in solution that are thought to 
prevent Fe(III)PPIX from being incorporated into the growing Hz crystal and increase the 







Figure 1.20 Decrease in Hz formation (a&d) and increase in Fe(III)PPIX (b&e) upon CQ (Dose-
dependent) and other antimalarial drug treatment of troph stage parasites. Panel (c) shows the 
correlation between this increase in Fe(III)PPIX and decreasing parasite survival where the curves 






(1.5.2) Interaction of quinoline antimalarials and Fe(III)PPIX in  solution 
Initial reports of studies with nitrogen-containing compounds such as pyridine and cyanide, 
which showed the ability to bind to and effect changes in the UV-vis spectrum of Fe(III)PPIX 
in solution led to further studies to measure the ability of quinoline antimalarials (all bearing 
N-donor atoms) to bind Fe(III)PPIX in solution.207,210 A variety of spectroscopic and other 
analytical techniques were employed by various groups from the reports by Chou and Fitch 
using equilibrium dialysis208 to Mössbauer characterisation of drug-Fe(III)PPIX complexes70 , 
and binding constant  values reported by Dorn et al. using isothermal titration calorimetry 
(ITC) at pH 6.5 and 37°C.211 This paper proposed that CQ interacts with μ-oxo dimer form of 
Fe(III)PPIX thereby decreasing the amount of monomeric Fe(III)PPIX available for 
crystallisation after an earlier report by Moreau et al. suggested CQ interacts with two 
Fe(III)PPIX  μ-oxo dimers in a sandwich type complex via a hydrophobic interaction upon 
analysis of 1H NMR shifts of CQ in the presence of Fe(III)PPIX.212 Subsequent ITC 
measurements by Vippagunta et al. investigated the thermodynamics of association 
between CQ and its analogues with Fe(III)PPIX reporting multiple CQ molecules to interact 
with Fe(III)PPIX to form a drug-Fe(III)PPIX complex.213,214  Bacchawat et al. expanded upon 
this thermodynamic study of the complexes of CQ and its analogues with Fe(III)PPIX by 
performing ITC measurements in detergent solution which apparently ensured monomeric 
Fe(III)PPIX interaction.215 The authors of these works, however, were unaware of the 
tendency of Fe(III)PPIX to form two different types of dimers in solution and the assumption 
that inclusion of triton-X-100 detergent would ensure monomeric Fe(III)PPIX without any 
spectroscopic confirmation of the fact is questionable.66 
Thus later studies measured the strength of association between Fe(III)PPIX and several 
antimalarials in aq DMSO solution so that a correlation between the log K of binding and in 
vitro antimalarial efficacy was made. Aqueous DMSO has been shown to induce the 
monomeric form of Fe(III)PPIX as described above (section 1.3.3) and therefore the authors 
were able to monitor changes in the intense Soret band at 405 nm upon association.216,217 
Though these studies were performed in completely different solvent systems and direct 
comparison is not strictly correct, the values reported by Egan et al. in a two separate 
reports and the results obtained by Dorn et al. using ITC for the most relevant quinoline 
drugs are presented in Table 1.1.211,218 
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Table 1.1 Association constants for selected quinoline antimalarial-Fe(III)PPIX complexes 
determined by UV-vis spectroscopy and ITC experiments. 
Drug:Fe(III)PPIX 
(1:1) association 
log K (25°C, 40% Aq DMSO, 
HEPES 20 mM, pH 7.5)a 
log K (aq buffer 250 mM,pH 6.5)b 
stoichiometry (drug:Fe(III)PPIX) 
Chloroquine (CQ) 5.52 ± 0.03 5.60 ± 0.19 (1:2) 
Amodiaquine (AQ) 5.39 ± 0.04 4.97 ± 0.14 (1:2) 
Quinidine (QD) 5.02 ± 0.03* ̶ 
Quinine (QN) 4.10 ± 0.02 4.32 ± 0.04 (1:2.5) 
Mefloquine (MF) 3.90 ± 0.08 4.1 ± 0.2 (1:1.5) 
Halofantrine (Hf)  5.29 ± 0.01* 4.66 ± 0.07 (1:1) 
a,*Reported by Egan et al. 218,219  blog K calculated from K values reported by Dorn et al.211 
 
The shortcomings of these studies were that low drug aqueous solubility meant that most 
binding studies were performed in mixed aq systems and at pH values greater than the pH of 
the parasite DV. The complicated aggregation of Fe(III)PPIX in solution also led to varied 
binding stoichiometries being proposed for the different drugs especially for QN and MF 
which were proposed by Dorn et al. to interact with an unusual number of Fe(III)PPIX 
molecules (Table 1.1). High field NMR spectroscopy was used to evaluate the formation of 
drug-Fe(III)PPIX complexes for several antimalarials in solution with the authors initially 
reporting that all the quinoline drugs interact with Fe(III)PPIX μ-oxo dimers.220,221 However, 
later studies by this group used magnetic susceptibility studies to show that QN and CQ 
differentially perturb the monomer- μ-oxo dimer equilibrium with the former favouring 
monomeric Fe(III)PPIX and the latter proposed to interact with the μ-oxo dimer form of 
Fe(III)PPIX in aq DMSO and also in cationic and neutral detergent micelles.222,223 Following on 
from this observation, Crespo et al. reported a detailed pH investigation of the binding 
constant of CQ and Fe(III)PPIX in aq methanol solution in which Fe(III)PPIX was reported to 
be a π-π dimer species, however CQ was found to bind Fe(III)PPIX in a 2:1 stoichiometry, 
with the authors suggesting that the drug was likely to interact with an unligated face of 
Fe(III)PPIX and was therefore not the π-π dimer but the μ-oxo dimer with which CQ was 
proposed to interact.68   
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A very recent comprehensive study using multiple spectroscopic techniques showed the 
complex that forms between Fe(III)PPIX and CQ in solution was a μ-oxo-dimer and 
determined by Job Plot that CQ binds Fe(III)PPIX with a 1:2 stoichiometry and an aq 
association constant, log Kobs of 6.5 ± 0.2.
224 
Several works have proposed that rather than interacting through π-π stacking exclusively, 
quinoline methanol antimalarials form covalent or coordination complexes with 
Fe(III)PPIX.225,226 Warhurst conducted a spectrophotometric study of the Fe(III)PPIX 
complexes formed with QN, QD and MF in benzene where he reported direct coordination 
of the Fe(III) metal centre in Fe(III)PPIX to the quinuclidine nitrogen (QD and QN) and the 
piperidine nitrogen (MF).225 It was later demonstrated using spectroscopic and magnetic 
studies by Behere and Goff that in non-aq media, an alkoxide-Fe(III) linkage between the 
hydroxyl of quinine and metal centre of Fe(III)PPIX exists to form a QN-Fe(III)PPIX 
coordination complex.226 Later in 2011, Alumasa et al. performed several NMR and binding 
studies on QN analogues with variation at key functionalities.227 After evaluation of their βH 
inhibition and anti-parasite activities, it was proposed that the QN-Fe(III)PPIX structure was 
formed upon alkoxide coordination and furthermore the formation of a salt-bridge between 
the quinuclidyl nitrogen and the QN hydroxy proton involved in coordination.   
 
(1.5.3) Fe(III)PPIX-quinoline antimalarial drug complexes 
While NMR spectroscopy, Mössbauer studies and various computational methods have been 
used to propose models for the structure of these antimalarial drug-Fe(III)PPIX complexes, 
the first crystal structure of an antimalarial-Fe(III)PPIX compound was published as recently 
as 2008, for the aryl-methanol drug, Hf (Fig. 1.21).228 Single crystal X-ray diffraction 
confirmed that monomeric Fe(III)PPIX interacted with Hf through alkoxide coordination of 
the deprotonated drug hydroxyl group to the Fe(III) centre of Fe(III)PPIX in addition to π- 
stacking of the phenanthrene ring over the porphyrin and formation of an intermolecular 
hydrogen bond between the protonated alkyl nitrogen of Hf and the propionate oxygen of a 
neighbouring Fe(III)PPIX, as predicted through earlier studies.226,229 The authors proposed 
that this mode of binding was likely for the structurally similar quinoline methanol drugs, QN 
and QD, which was confirmed recently when the crystal structures of their Fe(III)PPIX 
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complexes were published (Fig 1.21).230 Both quinoline methanol drugs, QN and QD, were 
found to complex Fe(III)PPIX through formation of an alkoxide bond to the Fe(III) centre via 
their benzylic alcohol functional group as well as π-stacking between the porphyrin and 
aromatic ring systems and finally the formation of an intramolecular hydrogen bond 
between the protonated amine of the quinuclidine ring and the propionate oxygen of 
Fe(III)PPIX. Previously performed molecular modelling calculations on the strain energy 
required to form this intramolecular hydrogen bond showed that the ease in which it was 
formed correlated with the observed biological activity of these drugs and their inactive 
enantiomers, epiquinine (eQN) and epiquinidine (eQD).228 It was suggested that QD, the 
most active of the quinolone methanol drugs, exhibited the lowest energy penality 
associated with formation of this hydrogen bond,228 an observation that was confirmed by 
the crystal formation with this hydrogen bond present despite being crystallised from an 
environment rich with hydrogen bond partners (3:7 DMSO: methanol).230 These 
coordination complexes were all obtained from organic solvents that may allow for specific 
interactions that are either absent or exclude those that only relevant in aq solution 
therefore the question whether these complexes exist in aq or lipophilic solution, remains 
relevant. 
 
   
Figure 1.21 Crystal structures of aryl methanol (Hf) and quinoline methanol (QN and QD) drugs and 
Fe(III)PPIX. All the structures possess the proposed three-point binding mode of (1) the alkoxide bond 
from each drug hydroxyl group to the Fe(III) centre of Fe(III)PPIX. (2)  The π-stacking between the ring 
systems and (3) formation of a hydrogen bond between the propionate of Fe(III)PPIX and the 
protonated quinuclidine or aliphatic nitrogen on each drug (for adjacent Fe(III)PPIX molecules in Hf, 
not shown here). Structures reproduced from Cambridge Structural Database (CSD) reference codes: 
BOCGEG (Hf), CETTOM (QN) and CETTUS (QD).231 
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To date, no crystal structures of a 4-amino quinoline drug-Fe(III)PPIX complex have been 
published. Solid state characterisation of the precipitated CQ-Fe(III)PPIX complex from acidic 
aq solution has yielded conflicting reports of Fe(III)PPIX speciation with solid-state NMR 
studies leading to a proposed covalent CQ-Fe(III)PPIX complex.232 In contrast, Dascombe et 
al. performed mass spectrometry on an isolated Fe(III)PPIX adduct with a CQ analogue, 
metaquine with a molecular ion peak that correspond to a 1:1 complex for this drug.233 
These results contrast with those obtained from Mössbauer measurements of isolated CQ-
Fe(III)PPIX and QN-Fe(III)PPIX complexes where the former produced a distinctly different 
spectrum which was suggested to correspond to the μ-oxo dimer compared to the latter, 
which was subsequently proven to correspond to a 1:1 complex.70,230 In light of an 
alternative proposed mechanisms of action for this class of antimalarial, the possibility of 
this drug not exerting its influence through Fe(III)PPIX complexation has recently been 
explored. 
(1.5.4) Interaction of quinoline antimalarials with haemozoin/ β-Haematin  
Not all compounds that exhibit Fe(III)PPIX binding abilities are capable of inhibiting Hz 
formation in vitro.203,234,235 Neither have all Hz inhibitors been shown to associate with 
Fe(III)PPIX in solution, thus an alternative mechanism of action has been proposed and 
explored.28,63,236 Early work by Sullivan et al. using TEM detected that CQ was in close 
association with Hz crystals and later upon discovery of CQ’s ability to complex Fe(III)PPIX, 
suggested that the drug-Fe(III)PPIX complex could be incorporated into the growing crystal 
thereby preventing any further Fe(III)PPIX deposition and effectively inhibiting crystal 
growth.236 This mechanism was thought to be responsible for the exaggerated accumulation 
of  all quinoline drugs in the DV.237 Later, when it was established that Hz was not a 
coordination polymer and could not be inhibited by coordination at a single site, it was 
suggested that the quinoline antimalarials themselves act by adsorbing to the smallest and 
fastest growing (001) and (001̅) crystal faces of Hz capping further crystal growth.27  
Pagola et al. suggested this based on the amount of erythrocyte Hb, the surface area of Hz 
crystals and the proportion of CQ measured to be accumulated in the DV and the surface 
area of Hz crystals. The (001) and (001̅) Hz crystal faces are highly corrugated with grooves 
between the exposed vinyl and methyl groups of the porphyrins, as well as the flexible 
47 
 
propionic acid groups allowing for stereospecific contact with Hz inhibitors.28 A model of the 
proposed drug-Hz adsorption was published by Buller et al. using molecular modelling to 
identify four stereospecific molecular interactions between the exposed unligated porphyrin 
faces and propionic acid side chains of the crystal and monoprotic CQ (Fig. 1.22). 28  
Specifically, (i) the formation of a salt bridge between the protonated nitrogen in the CQ side 
chain and an exposed COO- of a Fe(III)PPIX propionic acid (2.7 Å). (ii) An interaction between 
the quinoline N of CQ and the proton of a vinyl group on the porphyrin (2.4 Å), (iii) an 
interaction between the 7-chloro substituent on the quinoline ring of CQ and the methyl 
group on a Fe(III)PPIX (3.0 Å) and finally (iv) a contact between the NH of the CQ 4-amino 
side chain and the π electron cloud of a C=C group on a neighbouring porphyrin (2.7 Å). 
The use of exclusively protonated CQ in this model poses a question as to the charge of the 
drug inside the parasite DV which pKa measurements have shown to be unlikely to be 
monoprotonated under acidic conditions.238 The first experimental evidence for this 
mechanism was offered by a study using GIXD techniques on the effect of 10% CQ and QN 
on βH crystal growth.144 Solomonov and co-workers reported that the rate of βH crystal 
formation was decreased in the presence of these drugs and the crystal morphology was 
affected. βH crystals grown in chloroform medium containing these drugs was found to have 
tapered ends (Fig. 1.23) which was suggested to be as a result of quinoline drug adsorption 
to exposed (001) and (011) crystal ledges. The authors rationalised that the adsorption of a 
quinoline additive to the crystal on a particular face would manifest by as a reduction in 
crystal coherence on the perpendicular face which could be observed as a broadening of the 
Bragg reflection along that length. Synchrotron PXRD measurements were able to show a 
lack of symmetry and elongated diffraction pattern of weak intensity that was suggestive of 











Figure 1.22(a) View along the a-axis of βH to show corrugated surface of the (001) face with 
‘grooves’ highlighted in yellow for the proposed quinoline antimalarial interaction which is shown in 
(b). The interactions proposed for CQ include N···HCC (2.4 Å), Cl···H3C (3.0 Å), NH···O2C (2.7 Å), 
NH···CC(π-cloud) (2.7 Å) as seen in (c) and shown perpendicular to the (001) face in (d). Images 





Figure 1.23 SEM-micrographs of βH crystals grown from DMSO-MeOH in (a) the absence of 
antimalarials and (b&c) in the presence of 10% QN and CQ, respectively. Images (d-f) were of 
crystals grown from chloroform in the absence of drug (d) and with 10% QN and CQ, respectively. 
(e&f) to illustrate the symmetrical tapered ends induced by the proposed drug adsorption. (g) 
Images of the symmetrical βH crystal grown in 10% drug solution in colour from an optical 
microscope and in blue from TEM. The ‘ledges’ for quinoline adsorption are indicated on the (001) 
and (011) faces. Images are reproduced with permission from Solomonov et al., (2007),©American 
Chemical Society.144 
 
Alternative support for this adsorption model was recently obtained from a kinetic study of 
βH formation mediated by a model lipid, MPG, in the presence of quinoline antimalarials CQ 
and QD.63 
(1.5.5) Kinetic model of β-Haematin inhibition in neutral lipid solution 
A recent investigation into the effect of two quinoline antimalarials on the rates of lipid-
mediated βH formation reported a decrease in rates observed in the presence of drug at low 
concentration leading to an eventual decrease in the yield of βH formed at higher drug 
concentrations.63 At no point over the drug range tested was complete inhibition of βH 
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formation observed. In order to explain this, the authors proposed a kinetic model that 
combined two proposed modes of inhibition to compete with the crystallisation of 
Fe(III)PPIX as illustrated in Scheme 1.2. 
To account for the initial decrease in rates of βH formation in the presence of low drug 
concentrations, the authors proposed that the quinoline antimalarials adsorbed to available 
sites on the growing βH crystal face to impede crystal growth. This process alone was 
insufficient to account for the eventual decrease in yield at high drug concentrations and so 
the ability of these drugs to complex Fe(III)PPIX was also considered. As the concentration of 
drug was increased, this complex was proposed to precipitate out of solution depleting the 
amount of Fe(III)PPIX available for crystallisation. 
The observed initial decrease in rate of crystallisation and exponential kinetic profile was 
modelled with the Avrami equation (1.2.2) and using the Langmuir isotherm to account for 
the adsorption of the drug to crystal surface sites. The experimental data was found to fit 
this adsorption model such that the strength of drug adsorption to the crystal face, Kads, was 
computed for CQ and QD with log Kads of 5.55 ± 0.03 and 4.92 ± 0.01 for each drug, 
respectively.63 Interestingly the strength of this adsorption was found to correlate with 
reported biological activity of these drugs.239 This observation was also in agreement with 
the suggestion by Buller et al. that there exists shorter porphyrin-drug contact distances 
between the (001) face of βH and CQ compared to QD.28 To account for the observed 
decrease in the yield of βH at high drug concentrations, the solution state interaction of 
these drugs with Fe(III)PPIX to form solid drug-Fe(III)PPIX complexes with a rate constant of 
k2  that was also incorporated into the kinetic model which is described by equation 1.3. 
 
        % βH =  
100Yz














Scheme 1.2 Proposed kinetic model for (1.1) βH formation with rate constant, zobs , in the presence 
of quinoline antimalarial drugs, D, in a lipid system. (1.2) The Fe(III)PPIX starting material, H, is 
thought to form a solid drug-Fe(III)PPIX complex, DH, with rate constant, k2, in a competing process 
(1.3) with the adsorption of the drug onto the βH crystal surface, Xs, with adsorption constant, Kads, 
as illustrated by the graphic. Scheme adapted with permission from Gildenhuys et al., 
(2013)©American Chemical Society.63 
 
Subsequently, independent validation of the quinoline drug adsorption to preformed βH 
crystals was provided by measuring the depletion of drug concentration in solution after 48 
hr incubation with the crystals in aq solution.240 This report showed that both CQ and QD 
adsorbed to βH crystals, however, quantitation of this adsorption was not provided. 
Regardless of their exact mechanism of action, quinoline antimalarials affect a known target 
that remains attractive for parasite specific inhibitors.  
A very recent paper by Olafson et al. utilised time-resolved AFM to show that CQ  adsorbs to 
the (001) face of  βH  between Fe(III)PPIX growth steps thereby affecting 2-D nucleation 
leading to slower step-growth and at higher concentrations ([CQ] = 2 μM), complete 
inhibition of crystal layer generation.153  This adsorption of CQ to particular sites that result 
in hindered step propagation of the crystal was proposed to be the mechanism of action of 
CQ.  The authors, however, assume that CQ forms a 1:1 complex with Fe(III)PPIX in solution 
despite the evidence of alternative speciation mentioned and thus dismiss this complexation 
as insufficient to account for the reduced growth rates measured by AFM.153 Many insights 
on the mechanism of action of active pharmaceuticals have come from study of their in vitro 
properties.122,202 To reconcile the mechanisms of action of these drugs, several approaches 
52 
 
have been taken, and integral to them was evaluation of the βH inhibition activities of 
known quinoline antimalarials. Traditionally this class of antimalarials have been very 
successful and thus efforts to design novel analogues that circumvent resistance pathways 
are ongoing.176,241–243 With reports of artemisinin resistance emerging in different regions,244 
large scale in vitro drug screening against this target has been employed to characterise 
known and unknown inhibitors with novel pharmacophores.175,176,245  
(1.5.6) Lipophilic assays for screening β-haematin inhibitors 
The ability of various compounds to inhibit βH formation has been investigated using a 
variety of methods including UV-vis spectrophotometry, fluorometric and radiometric 
assays.96,123,202,245–250 Initial screening for βH inhibitors employed actual troph lysate, Hz 
extracts and seed βH crystals to induce crystallisation and measure antimalarial effect246,251, 
however, these assays were subsequently replaced by cheaper less time-consuming 
colorimetric tests that used acetate buffer or fatty acids to initiate βH formation under acidic 
pH conditions and physiological and non-physiological temperatures.119,252–254 
Each assay has a βH initiator and a detection method for quantifying the amount of βH 
formed either directly or by measurement of the Fe(III)PPIX starting material post incubation 
with a number of different pH, temperature and incubation times used.119,255 The most 
commonly used methods of detection include the pyridine hemichrome inhibition of β-
haematin (Phiβ) assay developed by Ncokazi and Egan which exploits the ability of 5% 
aqueous pyridine solution to bind unreacted Fe(III)PPIX to form the easily quantified six-
coordinate bis-pyridyl complex that exhibits the characteristic sharp Soret band at 405 nm 
present in a typical absorbance spectrum of monomeric Fe(III)PPIX.253 Other methods exploit 
the differential solubility of the starting material, Fe(III)PPIX, and the  βH product in solutions 
of 0.15 M sodium bicarbonate and 2% SDS solution or DMSO followed by base treatment to 
isolate each fraction for quantification.118,119,250 IR spectrophotometry and PXRD techniques 
are used to confirm the presence of βH. The IC50 (50% inhibitory concentration) of each drug 
is reported as either the concentration at which only 50% βH is formed or at which 50% 
unconverted Fe(III)PPIX remains in solution. This value for a particular drug can vary from 
assay to assay but these assays usually serve to provide an indication of potential Hz 
inhibition in the parasite and are a first indication of lead properties.255 
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Recently, these assays aimed to be more biologically relevant while maintaining the 
advantage of short incubation times and cheap materials for high-throughput screening. 
Thus the use of neutral detergents as lipid ‘mimics’ to mediate βH formation for assaying 
potential inhibition activity has become standard.255 As mentioned, the first application of 
these amphiphilic solutions as initiators for βH formation was by Fitch et al. where the 
authors showed that SDS and TWEEN-80 were capable of effectively forming βH,118 later Huy 
et al. applied this in a TWEEN-20 mediated colorimetric assay to evaluate inhibition activity 
under biomimetic conditions.250 Currently another neutral detergent NP-40 has primarily 
been used in a multiwell plate assay to identify potential novel βH inhibiting 
compounds.155,175,256 The activity trends obtained with these lipophilic in vitro assays 
compare well with other assays and the biological activities of established Hz inhibiting 
antimalarials drugs so that they have been used to train in silico prediction models of 
potential drug activity.239,241,257 
Table 1.2 lists the IC50 values obtained using the NP-40 detergent and other initiator assays  
as well as those obtained in an in vitro parasite assay against the chloroquine sensitive P. 
falciparum strain, 3D7, published by Hawley et al. for each drug.239 While these values all 
differ, the observed biological trend in activity is maintained, with the 4-amino quinolines, 
CQ and AQ, showing increased activity over the quinoline methanols, QD and QN. This 
differential activity is thought to arise from a difference in their mechanism of action via 
differential interaction with Fe(III)PPIX or the crystal product itself.191,258 However, the use of 
different types of inducers that all mediate βH crystallisation has not been probed to offer a 
mechanistic understanding of their role in this process. While attempts to rationalise the 
mechanisms of lipid-mediated Hz formation and quinoline drug inhibition over the course of 
this work were unrealistic, further understanding of the processes that comprise Fe(III)PPIX 




Table 1.2 Efficacy (IC50) of drugs from two types of quinoline antimalarial families, the 4-aminoquinolines (CQ and AQ) and the quinoline methanols (QD and 






βH inhibition Assay type (βHIA) (μM) 
Phiβ equivalents 
(12.9 M acetate)b 
NP-40c TWEEN-20d Hz extracte neutral lipid f  
BHIAg in equivalents 
(acetic acid) 
CQ 14 1.19 ± 0.03 53 59 ± 6.8 45 ± 9 16.4 ± 0.5  1.63 ± 0.64 
AQ 7.8 1.45 ± 0.08 21 45.3 ± 1.2 60 ± 1 9.0 ± 0.4 0.85 ± 0.25 
QD 21.5 1.5 ± 0.1 24.7 ± 1.4* - - 51.1 ± 5.8 - 
QN 34.2 3.5 ± 0.2 52.3 ± 1.7* 170 ± 12.3 160 ± 10 73.9 ± 12.8 5.48 ± 1.31 
aBiological IC50 values
 obtained from Hawley et al. 259    
 b Phiβ values reported by Ncokazi et al.253  
 c NP-40 assay values reported by Carter et al.155  
 d TWEEN-20 initiator IC50
 obtained from Huy et al.173    
ePurified Hz initiator assay reported by Dorn et al.119  
f 
IC50 obtained from MPG/aq interface (Gildenhuys, 2013).
240    
 g BHIA from Parapini et al.255 ,  
*Unpublished results, (Egan Laboratory, 2014). 
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(1.6) Aims and Objectives 
(1.6.1) Aims 
This work aimed to probe the nature of the interaction between Fe(III)PPIX and the 
proposed biological neutral lipid blend by establishing the lipophilicity of Fe(III)PPIX, to 
investigate of the effect of known quinoline antimalarials on this lipid partitioning and to use 
detergents as lipid ‘mimics’ to evaluate their ability to mediate β-Haematin formation 
through stabilisation of a particular Fe(III)PPIX species so that insights into the behaviour of 
Fe(III)PPIX in a lipophilic environment may be made. Lastly, to investigate the kinetics of β-
Haematin formation in this detergent environment in the absence and presence of quinoline 
antimalarials to determine its suitability as a lipid ‘mimic’ in drug screening. To achieve these 
aims the following objectives were proposed: 
(1.6.2) Objectives  
 (1) Evaluate the lipophilicity of Fe(III)PPIX and measure its partitioning profile into neutral 
lipid droplets over a pH range using fluorescence quenching. 
(2) To determine the effect of quinoline antimalarials on this partitioning profile over the 
same pH range. 
(3) To use UV-visible spectrophotometry and magnetic susceptibility to analyse the 
speciation of Fe(III)PPIX in neutral, zwitterionic, cationic and anionic detergent solutions as a 
function of pH at concentrations above and below their critical micellar concentration. 
(4) To evaluate the ability of each detergent to promote β-Haematin formation under 
physiological pH and temperature conditions with regards to their established speciation of 
Fe(III)PPIX. 
(5) To determine the association constants and stoichiometry of interaction between 
quinoline drugs and Fe(III)PPIX in detergent solution and their effect on speciation. 
(6) To probe the nature of detergent-Fe(III)PPIX interaction using 1H NMR spectroscopy. 
(7) To measure the kinetics of detergent mediated βH formation in the presence of quinoline 
drugs using a proposed kinetic model to compare the effect of a neutral detergent with that 
of the neutral lipid in this process.  
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Chapter 2:   
Theoretical background to techniques employed 
(2.1) Introduction 
Several classical physical and analytical chemistry techniques were employed throughout 
this project to study the behaviour of ferriprotoporphyrin IX (Fe(III)PPIX) in amphiphilic 
solution. The primary technique used throughout this work to characterise the speciation of 
Fe(III)PPIX and to probe its drug association properties was ultraviolet visible (UV-vis) 
spectroscopy (see 2.2). Solution state magnetic susceptibility measurements, specifically 
Evans method nuclear magnetic resonance (NMR) spectroscopy (see 2.3) experiments were 
also used to confirm the prevalent Fe(III)PPIX species. Infrared (IR) spectroscopy (see 2.4) 
and powder X-ray diffraction (see Chapter 6) were used to confirm the presence of β-
haematin (βH) products. Fluorescence spectroscopy (see 2.5) was conducted in order to 
monitor the partitioning of Fe(III)PPIX into lipid droplets by Nile Red quenching experiments. 
This chapter outlines the fundaments of each technique and highlights key understandings in 
the study of metalloporphyrin chemistry and interactions with relevance to this work. 
(2.2) UV-visible spectroscopy 
(2.2.1) General theory  
UV-vis spectroscopy is a well-established versatile, sensitive and cost-effective technique for 
analytical chemistry enabling the use of dilute samples and eliminating the need for 
specialised solvents.260 This technique provides insight into the electron distribution within a 
molecule by measuring its interaction with light in the UV (wavelength (λ) = 10 - 380 nm) and 
visible (λ = 380-750 nm) portion of the electromagnetic spectrum.261 The absorbance of 
photons by molecules can result in an electronic transition from their lowest energy ground 
state configuration to a higher energy excited state.261 The types of allowed electron 
transitions upon UV-vis excitation from filled 𝜎 or 𝜋 molecular orbitals (MO’s) to empty 
𝜎∗ or 𝜋∗ MO’s (Figure 2.1) give rise to the intense spectroscopic features associated with the 
distinctive electronic distribution of a certain molecular species. 𝜎 →  𝜎∗  transitions require 
the largest amount of energy and appear at low absorption wavelengths (< 200 nm) while 
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𝑛 → 𝜎∗ transitions associated with non-bonding lone pairs on saturated compounds display 
absorption peaks in the region  of 150 -250 nm. Most UV-vis absorption peaks (200 - 750 
nm) arise from lower energy transitions from 𝑛 → 𝜋∗ and 𝜋 →  𝜋∗  excited states.262 Many 
inorganic compounds also show charge transfer (CT) absorption bands where radiation 
absorption involves the transfer of electrons (𝑒− ) from a donor component to an orbital 
associated with the acceptor component. Transitions that are observed for a particular 
molecule is dependent on the molecular structure and symmetry of that molecule.263 
 
Figure 2.1 Electron transitions as a result of excitation in the ultraviolet-visible region. 
 
As shown in Figure 2.2, a lamp source provides light which is passed through a diffraction 
grating that splits it up into its components. A monochromator (M) isolates each component 
wavelength of light which is then passed through the sample where it is either transmitted 





Figure 2.2. A schematic diagram of basic UV-vis spectrophotometer 
 
The amount of light allowed through the sample, the percentage transmittance (  𝐼/𝐼0  ×
 100) is measured by an electronic detector depicted as D. The resulting absorbed light is 
the ratio of the incident light, Io and the intensity of radiation measured by the detector, I.
264 
Typical UV-vis output is an absorbance (- log T) as this function can be linearly related to the 
concentration of the sample using the Beer- Lambert Law (Eqn. 2.1). 265 
                                                          𝑨 (𝑢𝑛𝑖𝑡𝑙𝑒𝑠𝑠) = log (
𝐼
𝐼0
) =  𝜀𝜆 𝒄 𝑙                                       (2.1)                                                                                                           
 Absorbance (A) or log of the ratio of detected light, I to incident light, I0 (Transmission) is 
related to the distance the incident light must travel through the sample (pathlength of the 
cuvette), l ( in cm) and the concentration, c of the sample (mol.dm-3) and the molar 
absorptivity at a particular wavelength (nm), referred to as the extinction coefficient,  Ԑλ is a 
measure of the  probability that  a photon of that energy will be absorbed by the sample.
266 
This linear relationship between concentration of solute and absorbance at a particular 
wavelength is widely used to quantify molecules in solution after accounting for any 
reflection of light, light scattering by aggregating solutes or excitation of any samples 
susceptible to fluorescence emission.  
(2.2.2) The electronic spectrum of Fe(III)PPIX 
Porphyrins and their metallated derivatives exhibit a unique electronic signature in the UV -
vis spectrum.267  Fe(III)PPIX is a metalloporphyrin with characteristic features arising from its 
22 conjugated π electrons in the porphyrin macrocycle, approximate four-fold D4h symmetry, 
d5 valence electron count and in this case, high-spin Fe3+ centre. These porphine properties 
along with any ligand to metal charge transfer electronic transitions contribute to its 
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chromophore and determine the prominent features of its UV-vis spectrum shown in Figure 
2.3a. 74  
Gouterman’s four orbital model is the foremost theory for the interpretation of the UV-vis 
spectrum of Fe(III)PPIX  resulting from transitions between the two highest occupied 
molecular orbitals (HOMOs) to the two lowest unoccupied molecular orbitals (LUMOs) of the 
porphine moiety predicted from a linear combination of atomic orbital (LCAO) calculation 
using an extended Hϋckel treatment for conjugation.268 The model proposes that excitation 
of ground state electrons from occupied 𝜋 MO’s (symmetry labels a2u and a1u) to unoccupied 
𝜋∗  MO’s (labelled 𝒆𝑥𝑔 𝑎𝑛𝑑 𝑒𝑦𝑔) account for the UV-vis pattern observed. Transitions 
between these orbitals produce two excited states, both of 1Eu character which are split by 
strong orbital mixing with varied energy and intensity. 269 The most intense band, the Soret 
or B band is observed in the 400 nm region with Ԑ ≃105 M-1.cm-1 (shown in blue, Fig.2.3a) 
originates from 𝜋 →  𝜋∗  transitions from the nearly degenerate au HOMOs to the doubly 
degenerate e* LUMOs. The weaker Q-bands with Ԑ ≃104 M-1.cm-1 (shown in green, 470-550 
nm) originate from another transition from the symmetrical a2u HOMO orbital to the 𝒆𝑔
∗ 
LUMOs (Figure 2.3b). 270  
 
 
Figure 2.3 (a) UV-vis spectrum of Fe(III)PPIX obtained from 40% (v/v) aq DMSO, pH 7.5 with the main 
bands highlighted, B (λ=375-425 nm) and Q (λ = 475–550 nm) bands arise from π HOMO → π * LUMO 
transitions highlighted by the Gouterman four orbital model, the CT (λ= 600-650 nm) band explained 
by the CT transitions of the LCAO model as well as higher excited state, N (λ = 350nm) band are 
depicted.  (b) Highlight of MO transitions that result in B and Q bands, the ∆𝑀𝐿 values accounting for 





The transitions leading to the B band are accompanied by quantum mechanically allowed 
changes in the angular momentum quantum number (∆ML = ± 1), the ground state electron 
and excited state electron circulate in opposite direction resulting in increased electron-
electron collisions (Hund’s rule) and therefore displaying a higher energy absorption. 269 
Upon excitation, Q band transitions have ∆ML ≠ ±1 with their electrons circulating in the 
same direction, effectively resulting in partial cancellation of dipole moments and lower 
energy bands (Figure 2.3b). 271 The difference in intensity observed between the B and Q 
bands can be explained by their difference in ∆ML. The selection rule (Laporte orbital rule) 
states that electronic transitions with ∆ML = ± 1 are allowed accounting for an intense band 
for a higher energy excited state manifested as the B band. Lower energy state Q band 
transitions accompanied by ∆ML = ± 9 are forbidden and exhibit lower oscillator strength.
271 
The electrons in the 𝒆𝑔( 𝜋
∗)  MOs can be promoted to a vibrationally excited state causing 
further splitting of the B and Q bands into Bx,y and Qx,y  bands respectively (Figure 2.4).  
 
 
Figure 2.4 Molecular orbital diagram for Fe(III)PPIX, Fe(III) and porphyrin orbitals calculated using 
LCAO theory. When irradiated (hυ), 𝜋 →  𝜋∗ transitions from the porphyrin a1u, a2u HOMO orbitals to 
the eg LUMO orbitals produce intense B (Soret) and weak Q-bands, characteristic of haem UV-vis 





The degree, position and nature of substitution on the porphyrin affect the symmetry which 
results in variation in the vibronic splitting of the Q band. 267,272 Transition moments to the 
higher excited states from the lower occupied MO’s a’2u, b2u →  𝒆𝑔( 𝜋
∗) can give rise to other 
minor bands, such as the N-band appearing as a shoulder to the intense Soret band.267 
Although sufficient to account for the 𝜋 →  𝜋∗ transitions responsible for the most intense 
bands observed in the UV-vis spectrum of haem, the Gouterman four orbital model fails to 
account for all the unique features of the spectrum that arise from the nature of the metal, 
its axial ligand and the peripheral groups on the porphyrin.273 Fe(III)PPIX  in  pH neutral 
aqueous solution is a five-coordinate, high spin (S = 5/2) with H2O as the axial ligand leading 
to d5 occupancy of the metal atomic orbitals. The Hϋckel LCAO method applied by Makinen 
and Churg to determine the MO diagram of iron porphyrins as demonstrated for H2O-
metmyoglobin is depicted in Figure 2.4.274  The peaks arising from the porphyrin transitions 
identified using LCAO theory are consistent with those identified by Gouterman’s four orbital 
model. Additional charge transfer bands visible in the 600-650 nm region of the UV-vis 
spectrum (Fig. 2.3a) of haem correspond to a1u /a2u →  𝒅𝜋   transitions from the ligand to the 
metal dxz /dyz orbitals which have been shown to be dependent on the electronic nature of 
the axial ligand.273 
(2.2.3) The electronic spectra of dimeric Fe(III)PPIX 
UV-vis spectroscopic changes have long been used to confirm the presence of and 
distinguish between porphyrin aggregates.275 While the potential speciation of Fe(III)PPIX is 
vast and complicated, it has been reported to exist in aqueous solution as two distinct 
dimeric species. The dominant species in aqueous solution has been identified as a π-π 
dimer with a characteristic UV-vis signature (Figure 2.5b).66  
(2.2.3.1) π-π dimer species of Fe(III)PPIX 
π-π Dimers are non-covalently associated five-coordinate Fe(III)PPIX molecules with axial 
ligands (-OH/H2O at a particular pH) aligned on opposite faces of interacting monomeric 
ferriprotoporphyrin units as depicted in Figure 2.5a. The main spectroscopic change 
highlighted in Figure 2.5b upon formation of a π-π dimer is a hypochromic effect including 
broadening and splitting of the B (Soret) band from a sharp single peak at 400 nm to a two-
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humped peak from 350-400 nm with Ԑmax at 396 nm. 
66 A small bathochromic shift of the Q 
bands is also observed. 
 
 
Figure 2.5 (a) Molecular structure of π-π dimer species of Fe(III)PPIX, (b) UV-vis spectrum of π-π 
dimer obtained in aqueous solution pH 7.50 HEPES 20 mM with Bv, B, Qv, Q and charge transfer (CT) 
bands highlighted. 
 
There are four possible transitions for the dimer of which none are degenerate with the 
monomer accounting for the different appearance of their UV-vis spectra. The selection 
rules can be determined from a semi-classical electrostatic vector model. The spectroscopic 
bands observed are a function of the oscillator strength of the electronic transition in each 
Fe(III)PPIX molecule, the inverse of the distance between the central metal atoms in the 
dimer and the alignment of transition dipoles in each unit.276 Kasha’s molecular exciton 
model details the treatment of excited states of weakly interacting aggregates and can 
account for the changes in UV spectra observed.276 The molecular exciton is the delocalised 
electronic excitation where the whole molecule is comprised of identical sub-units which are 
separated by a short distance (a few Å) compared to the wavelength of the incident photon ( 
≈ hundreds of nm) and therefore are both interacting with the oscillating electric field.277 
Weak coupling is described as a situation where no band shape change is observed, instead 
hypo or hyperchromism upon dimerisation is noted.277  
Traditionally, three general dimer models can exist; where the transition dipole moments of 
individual units are orientated in a parallel, in-line or co-planar fashion, these are depicted in 
Figure 2.6. The ovals correspond to individual molecules and the arrows represent transition 












Figure 2.6 Schematic representation of exciton band energy resulting from transition dipole 
moments orientated in a (a) parallel, (b) in-line and (c) co-planar fashion. Solid arrows represent 
allowed transitions and dashed lines correspond to forbidden transitions. M and D are descriptors 
for the monomer and dimer respectively. IE and IIE describe the exciton energy states. In (a) and (b) 
arrows show in phase or out-of-phase alignment of transition dipole moments. ø is the angle 
between polarisation axes and the line between the centre of each molecular unit. 
 
The molecular transition moment is given by the vector sum of the individual transition 
dipole moments of each unit. In phase orientated transition dipole moments result in an 
allowed, higher energy excited state, IIE due to increased dipole-dipole repulsion. Transitions 
from the ground state to an out of phase excited state, IE are lower in energy and are 
forbidden.  The angle, ø between interacting porphyrins determines the dimer type with ø = 
0° and ø = 90° corresponding to parallel and in-line situations respectively (see Fig. 2.6a). 
The parallel dimer therefore exhibits a blue shifted UV peak relative to the monomer as a 
consequence of this. For the in line dimer (b), the opposite case exists where a transition 
from monomer to dimer is accompanied by a red shifted UV peak (longer wavelength) for 
the allowed ‘in phase’ transition moment dipoles corresponding to the lower energy excited 
state, IIE. 276 
The co-planar or obliquely head-to-tail orientated transition moment dipoles (see Fig. 2.6c) 
with in phase arrangement of transition moment dipoles being attractive lead to a lowering 
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of exciton energy, IE corresponding to a bathochromic shift. The out of phase arrangement is 
repulsive and is consistent with an increase in energy of the excited state, IIE which is 
accompanied by a hypsochromic shift. The transition moments for electron dipole 
transitions from the ground state to the exciton state for this arrangement are both allowed. 
In a situation where ø ≈ 55°, the exciton splitting is zero, irrespective of intermolecular 
distance. The π-π Dimer species of Fe(III)PPIX displays the blue shifted B band outlined in 
situation (a), parallel dimers, and (c), co-planar oblique dimers, with the latter likely to be 
present in aqueous solution.92,278 The split soret band, B and Bv is further broadened into to 
a lower energy band with its transition moment dipole along the z axis and a higher energy 
band with its transition moment dipole along the x or y axis.279 Further broadening and 
splitting of the B band has been attributed to the loss of D4h symmetry upon dimerisation.
280   
(2.2.3.1) μ-oxo dimer species of Fe(III)PPIX 
The μ-oxo dimer is depicted in Figure 2.7.The two porphyrins are covalently linked via a μ-
oxo bridge between the central Fe(III) ions. This species of Fe(III)PPIX has strikingly different 
UV-vis features,  including a split and broadened B band (320 – 410 nm) as compared to the 
monomer and the appearance of a single broad envelope encompassing the Q and CT  
region (around 600 nm).  
  
Figure 2.7 (a) Molecular structure of μ-oxo dimer form of Fe(III)PPIX monomers covalently linked 
through an oxo bridge, (b) UV-vis spectrum of μ-oxo dimer obtained in aq 40% (v/v) DMSO, CHES 
20 mM, pH 10 with B band and charge transfer (CT) bands highlighted. 
 
The presence of two ring systems invites the possibility of increased delocalisation and a 




H2O axial ligand to form the oxide bridge can be held accountable for the changes in the low 
energy portion of the spectrum and it can be postulated that molecular exciton theory can 
explain the splitting and broadening of the Soret band.277 Density-functional theory (DFT) 
based UV-vis spectroscopic modelling of different species of Fe(III)PPIX recently identified 
the theoretical origin of the spectroscopic differences in the μ-oxo dimer species.282 The 
moderate field H2O axial ligand is replaced by a weak field O
2- ligand allowing for better 
overlap of the porphyrin 𝜋∗orbitals with metal d orbitals, thus increasing the energy of the 
Fe3+ 𝒅𝜋  and 𝒅𝑧
2
 orbitals.  The spectroscopic changes observed, are attributed to the key 
changes in MO energies of the filled 𝜋 MOs and the metal d-orbitals which result in a 
decreased energy gap between the 𝜋 and 𝜋∗ orbitals. In addition, some CT excitations (π 
→  𝒅𝜋) appear to contribute to the low energy broadening of the Soret peak.
282 
A larger proportion of CT transitions were identified when compared to monomeric 
Fe(III)PPIX involving π →  𝒅𝜋  and  π →  𝒅𝑧
2 excitations. The broad envelope appearing at 550 
– 650 nm originates from excitations that consist of transitions of admixed π →  𝜋∗  and π 
→  𝒅𝜋  character resulting in the shift of traditional Q bands to a lower energy and charge 
transfer bands to a new higher energy peak where the subsequent broad overlapped 
absorption peak has a shared classification of Q and CT bands.  
Deviations from Beer-Lambert law behaviour by a sample is a general indication of 
aggregation of chromophores. Absorbance spectra can be used to probe the formation and 
subsequent equilibrium of dimers or higher aggregates by observed spectroscopic shifts. A 
wavelength where two components or more exist in solution and appear to have the same 
molar absorptivity, Ԑλ is known as an isosbestic point, often used as a reference absorbance 
in equilibrium species calculation since the absorbance at such a point adheres to the Beer-
Lambert law regardless of species.283,284 The observed UV-vis spectroscopic differences can 
thus be attributed to a specific species of Fe(III)PPIX with unique electronic transitions which 






(2.3.1) Magnetic susceptibility measurements  
The study of how substances respond when placed in a magnetic field is well established.285 
Substances experience a magnetic flux when exposed to a magnetic field of a certain 
strength, this magnetic moment, μ is dependent on the mass susceptibility, 𝜒𝑔 (cm
3.g-1)   of a 
molecule.285  
                                     𝜇𝐵 = 2.84 √𝜒𝑔. 𝑀𝑤𝑠𝑎𝑚𝑝𝑙𝑒.𝑇  = 2.84 √𝜒𝑚. 𝑇                             (2.3.1) 
Experimentally, the value of μ can be determined from molar magnetic susceptibility, 𝜒𝑚 , 
measurements. 𝜒𝑔 is a measure of a sample’s susceptibility to being magnetised per unit 
field applied. The average magnetic moment, μ (μB) of a sample can be calculated by 
multiplying 𝜒𝑔 by the molecular weight of the substance and the temperature at which the 
experiment is performed, the product of 𝜒𝑔  and Mw yields, 𝜒𝑚 (cm
3.mol-1), the molar 
susceptibility. A theoretical μ can also be calculated from the spin state of the molecule in 
Eqn. 2.3.2.  
             𝜇 = 2 × √𝑆(𝑆 + 1)  𝑤ℎ𝑒𝑟𝑒 𝑆 = 𝑛𝑜.  𝑢𝑛𝑝𝑎𝑖𝑟𝑒𝑑 𝑒𝑙𝑒𝑐𝑡𝑟𝑜𝑛𝑠 ×
1
2
                     (2.3.2) 
Paramagnetism is derived from the spin and angular momentum of molecules.285  𝜒𝑔 can be 
either negative or positive, where     𝜒𝑔 < 0 corresponds to diamagnetic substances and 
 𝜒𝑔 > 0 corresponds to paramagnetic substances, which have permanent magnetic 
moments, even in the absence of magnetic fields.286  
Diamagnetic samples have all their electron spins paired with zero net magnetic moment 
resulting in a weakly repelled sample in a magnetic field which is temperature independent. 
Diamagnetism is inherent in all samples due to paired inner shell electrons hence the 
“diamagnetic” contribution to a paramagnetic compound’s magnetic susceptibility must be 
accounted for by use of Pascal’s constants.287 Paramagnetic samples have some electron 
spins unpaired, resulting in a stronger attraction to a magnet. Interacting paramagnets 
within a sample via the “exchange mechanism” can have three displacements; termed 
ferromagnetism and antiferromagnetism and ferrimagnetism. The orientations of magnetic 
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moments in a sample in the absence of a magnetic field of a (a) paramagnet, (b) 
antiferromagnet, (c) ferromagnet and (d) ferrimagnet are shown in Figure 2.8.  
Paramagnets (a) have randomly aligned moments of the same magnitude; antiferromagnets 
(b) have their unpaired electrons aligned in opposite directions with no net magnetic 
moment, while ferromagnets (c) have aligned electron spins and an overall magnetic 
moment and ferrimagnets (d), have electron spins aligned opposite to each other with an 
unequal no. of spins in each orientation leading to a net magnetic moment.285  These forms 
of paramagnetism display characteristic magnetic susceptibilities, 𝜒 and temperature 
dependencies. 288 The varying temperature dependence of each form of paramagnetism can 
be used to distinguish between the different types. 
 
Monomeric Fe(III)PPIX with axial ligand = H2O is high spin with spin quantum number, S = 
5/2 
and a spin- only theoretical magnetic moment, μ = 5.9 μB calculated from equation 2.3.2.
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For paramagnetic five-coordinate ferrihaems, theoretical magnetic moments, μ = 1.7, 3.9, 
and 5.9 correspond to low spin (S= 1/2), intermediate spin (S= 
3/2) and high spin (S= 
5/2) 
complexes respectively. In μ-oxo dimer type Fe(III)PPIX, μ ≈ 2 μB  
224 which  temperature 
dependence studies have shown is a result of antiferromagnetic coupling (see Fig. 2.8 b) 
between each iron centre,282 and not a low spin, S= 1/2 species, with its magnetic 
susceptibility increasing with  increasing temperature.289 The π-π dimer species of ferrihaem 
that dominates in aqueous solution has recently been shown to yield  a magnetic moment of 




Figure 2.8 Alignment of magnetic moment dipoles within a sample in the absence of a magnetic field 
at zero temperature in the absence of a magnetic field. (a) Paramagnetism, (b) antiferromagnetism, 
(c) ferromagnetism and (d) ferrimagnetism. 
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(2.3.2) Evans NMR Method - Solution-phase Fe(III)PPIX magnetic 
susceptibility measurements 
Evans noted that the chemical shift of a peak in the proton resonance spectrum of a 
molecule is dependent on the bulk susceptibility of the solvent medium.290 The shifts caused 
by the presence of a paramagnetic substance in the bulk medium can be measured relative 
to a reference sample in the absence of any paramagnetism, the difference in peak position 
of these samples allows for measurement of the paramagnetic susceptibility of substances in 
dilute solution.  
The difference in chemical shift, Δf (Hz) of a solvent (H2O) peak in a
 1H NMR spectrum is 
measured for both the inner paramagnetic sample and the outer reference sample in a co-
axial tube. The H2O signal present in small amounts in D2O in both samples is measured. The 
H2O signal frequency from the paramagnetic species, (eg. Fe(III)PPIX) present is shifted 
relatively downfield compared to the H2O peak in the reference sample. Thus Δf is negative 
(fref  - fparamagnetic sample) which can be related to μ of the Fe(III)PPIX sample via the calculation 
of the mass susceptibility, 𝜒𝑔 (𝑐𝑚
3. 𝑔−1) in equation 2.3.3, where  m is the molality of the 
sample (g.cm-3)  and 𝜒0 is the diamagnetic contribution of Fe(III)PPIX (approximated from 
Pascal’s constants) for Fe(III) and H2O/O
2- and an experimental value for PPIX contribution 
.282  f is the frequency of the NMR instrument used in Hz. Eqn. 2.3.4 can be used to 
calculate 𝜒𝑔, the paramagnetic contribution of Fe(III)PPIX as outlined in Eqn. 2.3.1 which 
yields a measured value for the μ of a specific ferrihaem species. 
                                                             χ𝑔 =  
−3 ∆ f
4 π f. 𝑚
−  χ0                                                    (2.3.3) 
                                                                 𝜒𝑔 =  𝜒 − 𝜒𝐷                                                              (2.3.4)    






(2.4) Infrared (IR) spectroscopy 
IR spectroscopy is a valuable analytical tool which provides information about the identity of 
functional groups present in a sample and their connectivity in all three states of matter. 
Molecules that show infrared absorption have a net change in their electric dipole moment 
during vibration; the intensity of the band is proportional to the magnitude of the change. IR 
peaks occur when the frequency of infra-red radiation absorbed is of a resonant frequency 
with a vibrating dipole in the molecule. Simply, a molecule can be thought of as separate 
masses connected by bonds which are treated as springs where resonant frequencies are 
related to the masses of the atoms and the strength of the bond. The bond stretching, 
contracting or bending in phase (symmetric) or out of phase (asymmetric) refer to the 3N-6 
normal modes of vibration for a non-linear molecule with N atoms. Asymmetric stretches 
produce the most intense bands. Lower energy modes include band wagging, scissoring, 
rocking or twisting. 291 The number of normal modes of vibration per molecule is related to 
the difference between the degrees of translational freedom per atom and the degrees of 
rotational freedom in the x, y, z plane. A linear molecule can only move in two dimensions 
and thus has 3N-5 normal modes. An Infrared spectrum plots the intensity of infrared 
radiation (transmittance) against the wavenumber, υ̅ (cm-1) or frequency of a band. 
Characteristic functional groups in a molecule are associated with IR peaks with specific 
wavenumbers.291 
 
(2.4.1) Fourier Transform-IR Spectroscopy (FT-IR) 
Fourier Transform IR spectroscopy is based on one fundamental technique; interferometry 
which is the interference of radiation between two beams to produce a signal that is a 
function of the change of pathlength between the two beams. A Michelson interferometer 
(Figure 2.9) analyses the frequencies present in that composite signal by dividing the 
incident beam into two beams with a path difference dependant on the location of the 
moving mirror, M1.
291 Another stationary mirror, M2 is located perpendicularly to the plane 
of the translational mirror and the broadband incident beam from an infrared source. A 
beam-splitter component is made of a semi-reflecting film and bisects the plane of these 
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two mirrors. When the two spilt beams recombine, there is constructive or destructive 
interference between the two phase shifted beams depending on the extra pathlength one 
beam has taken as a result of the translating mirror. About 50% of the beam reflected from 
the stationary mirror is transmitted through the beam splitter and detected through the 
sample while 50% of the beam is reflected back to the source. The detected signal varies 
with the distance the beams travel, d or d+x (Fig. 2.9) as the two beams alternate between 
being in and out of phase and is associated with radiation (υ̅) of the wavelength of the beam. 
The mathematical conversion of this variation in radiation with pathlength to a variation in 
intensity with wavenumber is performed by the Fourier-transformation of the electric signal 
in the detector to an IR spectrum.292 
 
Figure 2.9 A schematic depicting the components of a Michelson interferometer in a FT-IR 
spectrophotometer. The amount of transmittance of IR radiation is measured as a function of the 
path, d that the beams travel after being split into two different components. 
 
(2.4.2) Attenuated-Total Reflectance FT-IR Spectroscopy (ATR-FTIR) 
Reflectance techniques to measure the total amount of light reflected as opposed to 
absorbed by a sample, provide a convenient means of measuring the IR spectrum of a 
sample with low preparation time and cost due to direct sample measurement. This 
technique operates on the phenomenon of total internal reflection.293 A radiation beam 
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enters a less dense medium from one of greater refractive index and density and is internally 
reflected provided the angle of incidence,𝜃, is greater than the critical angle between the 
two mediums, illustrated in Figure 2.10.  A crystal with a high refractive index and ideal 
transmission properties serves as an internal reflection element and is designed to be in 
contact with the sample. Total internal reflection of radiation at the interface between the 
two media of varied refractive index, n, creates an evanescent wave that penetrates into the 
media with the lower refractive index. In the regions of the infrared spectrum where the 
sample absorbs energy, the evanescent wave is attenuated or altered; this energy is then 
transferred back to the reflected IR beam in the crystal and is eventually passed onto the 
detector as the reflected beam. A spectrum is obtained by measuring the interaction of the 
evanescent wave with the sample.291 
 
 
Figure 2.10 Schematic of an attenuated total reflectance cell, with incident beam reflectance at the 
crystal-air interface creating an evanescent wave through crystal and sample with refractive 
indexes, n1 and n2 respectively.   
 
The types of crystal most commonly used to ensure good internal reflection are zinc selenide 
or germanium, however, the use of costly diamond has been shown to be the most robust 
and durable with an optimally high refractive index and low solubility.293 
(2.4.3) ATR-FTIR of β-haematin for characterisation 
Formation of β-haematin, the synthetic analogue of haemozoin from Fe(III)PPIX using a 
variety of mediators is characterised by the coordination of a propionic acid side chain of 
one Fe(III)PPIX monomer to the Fe(III) centre of another.44 The β-haematin crystal is 
composed of these dimers hydrogen bonded to each other in a bicyclic fashion.27 Diagnostic 




upon dimerisation from 1720 and 1650 cm-1 to 1664 and 1211 cm-1 corresponding to the 
C=O and C-O stretches of the coordinated propionate moiety can be used to confirm the 
presence of β-haematin in a sample. 44 
(2.5) Fluorescence Spectroscopy  
When a photon of light is absorbed by a sample its interaction with this radiation is 
characterised by several transitions. Those of interest to fluorescence spectroscopy are 
associated with the vibrational and electronic energy levels.294 At any finite temperature, T, 
a molecules’ electrons are distributed among the energy levels available to it through 
thermal effects. The ratio of electrons in the upper and lower energy levels is given by the 
Boltzmann distribution calculated in equation 2.5.1 where the energy difference between 
the HOMO and LUMO states is ΔE and kT is the thermal energy with Boltzmann constant= 
1.3 X 10-23 J.K-1. 






)                                                        (2.5.1) 
The possibility of transitions occurring from 𝑛𝑢𝑝𝑝𝑒𝑟 → 𝑛𝑙𝑜𝑤𝑒𝑟 is as likely as those from 
𝑛𝑙𝑜𝑤𝑒𝑟 → 𝑛𝑢𝑝𝑝𝑒𝑟 such that a transition or absorption to a higher energy level can only occur 
if the difference between populations of the energy levels is significant, with the lower 
energy level having greater occupancy. At room temperature, vibrational energy level 
spacings result in a ratio of (
𝑛𝑢𝑝𝑝𝑒𝑟
𝑛𝑙𝑜𝑤𝑒𝑟
) = ~10-3, whereas for electronic energy levels where the 
spacings are greater the ratio is ~10-21. Each electronic transition has many broad normal 
vibrations from collisions and electrostatic interactions with surrounding solvent molecules. 
The vibrational sub-levels also possesses a ladder of rotational states that are significantly 
broadened due to hindered rotation upon solvent molecule collision.266 
At ambient temperature, the outer electrons of most molecules’ occupy the lowest 
vibrational level of the ground electronic state (GS) .295 Upon absorption of a photon of light, 
electrons can be promoted to an excited state (ES). Decay of an electron from an ES results 
in emission of light which is termed photoluminescence, of which there are two types 
namely fluorescence (Fig. 2.11a) or phosphorescence (Fig. 2.11b) which arise from decay 
originating from a different ES as seen in Figure 2.11.295 The former (a) occurs when the 
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electron excited to the higher energy MO has the opposite spin to the remaining unpaired 
electron in the lower MO. This electronic configuration is said to be “spin-paired” and is 
called a singlet state, since the total spin quantum number, ∑ 𝑆𝑖 , with 𝑆𝑖 =  ±
1
2
  is zero and 
the multiplicities, 𝑀 =  (2𝑆 + 1) of both the ground, S0 and excited states, 𝑆𝑛 are equal to 
1.   
 
Figure 2.11 Schematic to show the distinction between two types of photoluminescence;(a) 
Fluorescence occurs with decay from spin-paired Singlet excited states (ES) and (b) Phosphorescence 
occurs with decay from spin- parallel triplet ES’ to the ground state (GS). 
 
Phosphorescence (b) occurs when the excited electron has the same spin as the unpaired 
electron in the GS. It is termed a triplet state, characterised by a set of spin parallel electrons 
with ∑ 𝑆𝑖 = 1  and 𝑀 = 3.
295 
A chromophore that emits a photon is called a fluorophore.266 The Jablonksi energy diagram 
in Figure 2.12 illustrates some of the electronic processes that can occur upon excitation of a 




Figure 2.12 Jablonski energy diagram describing the absorption of a photon, hυ of energy by an 
electron from the singlet ground state, S0 to an excited state, S1 or S2. Some possible processes for 
energetic decay are illustrated. 
 
(2.5.1)  Fluorescence spectroscopy:  
(2.5.1.1) Theory of photophysical process  
The ground state S0, first S1 and second S2 singlet electronic states are shown with possible 
vibrational levels 0, 1, 2 and 3 indicated (Fig. 2.12).296 Excitation can result in an electronic 
transition to one of the vibrational sub-levels in S1 or S2, which rapidly decays (10
-11 – 10-14 s) 
to the lowest vibrational sub-level in S1 or S2through energy loss due to molecular collisions. 
Any molecules with electrons occupying S2 then experience an internal conversion (≤ 10
-12 s) 
to a vibrational sub-level in S1 of the same energy. This process is over by the time 
fluorescence emission (10-8 s) occurs from the lowest energy vibrational level within S1. 
Fluorescence emission occurs as energy is lost from S1 to S0 resulting in typical fluorescence 
lifetimes of the order of 10-9 seconds. The fluorescence lifetime, 𝜏 of a molecule is the 
average time taken for the electronic excitation of a molecule and the return to its electronic 
ground state. It is defined as the inverse of the combination of the rates of radiative and 
non-radiative decay of an excited state molecule.296  
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Excitation of a molecules’ electron from the HOMO to a LUMO increases the spatial 
distribution and polarisability as electron density is more diffuse.295 According to the Franck-
Condon principle, the absorption of a photon occurs practically instantaneously for electrons 
such that the heavier nuclei are not affected within the 10-15 s time frames as stipulated by 
the Born-Oppenheimer approximation and thus nuclei can only readjust afterward as 
molecular vibrations.297 During these fast electronic transitions, so-called vertical transitions 
to vibrational levels that correspond to minimal change in the nuclear coordinates are 
favoured. Nuclear movements to reorganise to the new electronic configuration manifest as 
molecular vibration dynamics and characteristically occur with electronic transitions. Some 
excitation energy is thus converted to vibrational energy. As the molecule undergoes 
conformational changes, complex formation and interaction with its molecular environment 
(external conversion), loss of vibrational excitation energy as well as thermal relaxation 
(non-radiative energy), some energy loss is observed. This is manifested as the Stokes shift 
of all fluorescent molecules, where the emitted fluorescence photons are of a longer 
wavelength (lower energy) than the wavelength of the photons absorbed. Hence the 
emission and absorption spectrum of a fluorescent molecule have maxima at different 
wavelengths and are thus detected as different colours. 266,296,298  
The entire fluorescence process is cyclical barring the irreversible loss of fluorescence during 
photobleaching; the same fluorophore gets repeatedly excited and detected. The discrete 
electronic transitions are detected as a broad emission spectrum where typical fluorescence 
output is a spectrum plot of fluorescence photon intensity (arbitrary units) versus 
wavelength (nm). The emission spectrum obtained is usually a mirror image of the S0 → S1 
portion of the absorption spectrum separated by the Stokes shift (Fig. 2.13). The Kasha rule 
which holds for most fluorescent molecules, observes that the fluorescence emission 
spectrum is independent of irradiation wavelength because upon excitation, molecules 
quickly relax to the lowest vibrational excited state following from Vavilov’s earlier 
observation that quantum efficiency is constant despite excitation wavelength. 266 The 
applicability of the Franck-Condon principle and Kasha’s observation account for the mirror 
symmetry observed. The observed wavelength and shape of the absorption and thus 
emission spectrum of a fluorophore is then characteristic of the chemical nature of its 
surroundings providing much information about a potentially unknown system. This feature 
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makes fluorescent dye molecules good probes of molecular environments in biology and 
physicochemistry.295 
As depicted in Fig. 2.12, molecules in S1 can also undergo a spin conversion from a singlet to 
a triplet excited state, T1 and emit energy upon return to the ground state in the form of 
phosphorescence. Phosphorescence inter-system crossing transitions from T1 to S0 are spin 
forbidden and hence occur at a much slower rate than fluorescence (10-3 s).  Phosphorescent 
emissions are also shifted to much longer wavelengths and lower energy relative to 
fluorescence emissions. Fluorescence is the main consideration of this PhD thesis and is 
presented here in much detail.  
Not all of the molecules initially excited return to the ground state by fluorescence or 
phosphorescence.295 Excited molecules can dissipate their energy by decomposition, 
reaction, heat (external conversion) or re-emission. Other processes like quenching 
(discussed in detail in Chapter 1 and section 2.5.2) via excited state dynamic interaction or 
complex formation or fluorescence resonance energy transfer (FRET) can occur to decrease 
the quantum efficiency, φE of a molecule, which is defined as the ratio of the number of 
quanta emitted to the number of quanta absorbed and can be anywhere between 0 (non-
fluorescent) and 1.298 The φE and fluorescence lifetime, 𝜏 of a molecule are characteristic 
with the former measured relative to a standard and the latter having typical excited state 
decay times of 0.5 – 20 x 10-9 s. 266 ,298  
 
 (2.5.1.2)  Fluorescence spectroscopy: Types and Instrumentation   
There are two main types of fluorescence spectroscopy; (1) steady-state fluorescence where 
the emission spectrum obtained is the wavelength distribution of an emission measured at a 
single constant excitation wavelength.299 Steady-state fluorescence spectroscopy provides 
an equilibrium description of excited state relaxation after the luminescent processes such 
as internal conversion and vibrational relaxation have been completed. (2) Time-resolved 
fluorescence emission is monitored as a function of time upon excitation. This technique 
offers the opportunity to obtain additional information about the molecular environment of 
the fluorophore. Essentially this is a measurement of the transient decay constant of emitted 
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fluorescence intensity with time, (k). The fluorescence lifetime, 𝜏 , can be calculated and 
used to distinguish between electronic events such as the type of quenching occurring; 
collisional or static (expanded upon in Chapter 1 and section 2.5.2), the extent of rotational 
diffusion, resonance energy transfer and neighbour interactions.300 Resolution of this data 
can be captured by fast electronics, time correlated single photon counting (TCSPC), time 
correlated fluorescence imaging or optical gating methods which fall broadly into two 
categories; (a) time-domain techniques which make use of a pulsed light source such as a 
laser or flash lamp and (b) techniques where the fluorophore is excited with intensity 
modulated light which is known as frequency-domain measurements.301 In the absence of 
machinery capable of collecting time resolved fluorescence data, the use of steady state 
fluorescence spectroscopy to monitor fluorescent probes to investigate lipid partitioning, for 
example, is well established as the instrumentation and analysis provide a simple and robust 
platform to study these systems in vitro. 294,302–304 
A typical steady state fluorescence spectrophotometer serves to transform continuous 
illumination of incident light from a lamp (usually xenon) through an excitation 
monochromator to the sample cuvette via variable slit widths to control background noise. 
Positioned at 90° to the excitation beam is an emission monochromator also with adjustable 
slit widths. The emission beam then passes through a scond monochromator before 
reaching a photomultiplier tube (PMT) where the signal is converted to a voltage and 
amplified for detection. 299 A simplified version is outlined in Figure 2.14.305 The right-angle 
placement of the sample to the excitation beam is crucial for minimisation of interference 





Figure 2.14 Schematic representation of a steady state fluorescence fluorometer to obtain a typical 
fluorescence spectrum.  
 
(2.5.1.3)  Fluorescence spectroscopy: Fluorophores and their environments   
The main considerations affecting the emission spectrum and photophysical properties; φE 
and 𝜏, include environmental effects or interactions between adjacent fluorophores. The 
microenvironment of the fluorophore is determined by solvent type including polarity, 
viscosity, dielectric constant, refractive index, hydrogen bonding capabilities and pH. The 
concentration of fluorophore, pressure, salt concentration, pH and temperature of the 
system also play a major role in the processes that dominate the fluorescence profile.295 The 
Lippert-Mataga equation (Eqn. 2.5.2) serves as a general description of the effect of these 
factors on the Stokes shift ( 𝜐𝑎𝑏𝑠 − 𝜐𝑒𝑚) of a particular fluorophore in a given solvent. This 
approximates the solvatochromatic effect displayed by several fluorescent probes in their 
microenvironments, where their emission maximum wavelength is shifted either in a 
bathochromic (red shift) or hypsochromic (blue shift) manner corresponding to an increase 
or decrease in solvent polarity for positive solvatochromatic dyes.297 










]                                    (2.5.2) 
 
The solvation shell effects like polarity, quenching interactions and solvent molecule 
readjustment are accounted for by changes in 𝜇, the dipole moments of the excited (𝜇𝑒)  and 
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ground states (𝜇𝑔) and 𝜖𝑠, the dielectric constant of the solvent. The refractive index of the 
solvent, 𝑛 contributes to vibrational relaxation and internal conversion of the fluorophore. 
The shift is also inversely dependant on the radius of the fluorophore in the solvent, 𝑎 and 
its product with the speed of light, c and Planks constant, h.266  
The structure of the fluorophore also plays a major role in the selection of a probe with 
favourable photophysical properties.295 Most fluorescent molecules are characterised by 
conjugated double bonds, particularly aromatic systems. The number of fused rings and 
degree of substitution affects structural rigidity and subsequent 𝜋 →  𝜋∗ singlet state 
stabilisation which has been shown to increase fluorescence quantum yield.307  
The main types of fluorophores that exist can be broadly classified into two classes. The first 
are intrinsic or natural probes, for example, an aromatic amino acid residue in a protein. The 
more common second class are extrinsic probes of either a covalent or associating nature, 
where a relationship between an external probe and the system or molecule of interest 
exists.308 A well-established technique of monitoring the interactions between a fluorophore 
excited state and its surroundings is to investigate the quenching of its fluorescence by 
introduction of a quencher to the system.308 This specific chemical interaction can be applied 
to gauge the local environment of the quencher as the quencher must be in close proximity 
to the probe in order for quenching to occur, as well as provide information on the type of 
interaction between the quencher and fluorophore.  
 
(2.5.2) Quenching of Fluorescence:  
The term quenching refers to the loss of or decrease in fluorescence intensity of the initially 
excited molecule.295 Many inter or intramolecular chemical processes may result in such a 
phenomenon by increasing the amount of non-radiative decay of an excited state to the 
ground state by reducing the fluorescence lifetime and the quantum yield of a fluorophore. 
This is achieved either through molecular rearrangement of the fluorophore, energy 
transfer,  excited-state reactions, excited dimer formation (excimer), ground state complex 
formation or collisions between a fluorophore and quencher via a diffusion process.308 This 
work on fluorescence quenching deals primarily with the intermolecular dynamic quenching 
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that occurs due to the introduction of a heavy metal fluorescence quencher, to a system 
containing an excited fluorophore, (F*) .  
There are two broad mechanisms of quenching relevant to this work; static and collisional 
quenching. Static quenching is the formation of a non-fluorescent ground state complex 
between fluorophore, F, and quencher, Q, such that the number of excited state F* 
molecules present is decreased (Figure 2.15 (a)).308 Hence the fluorescence lifetime in the 
presence of Q, 𝜏 is characteristically unaffected and the ratio of this to 𝜏0, the initial lifetime 
in the absence of Q is unity i.e.  𝜏0/𝜏 = 1. For this mechanism to hold, concentrations of Q 
would need to be large enough that the probability of interaction is high. Contrastingly, 
collisional quenching is a diffusion dependent process of non-radiative energy transfer 
between F and Q. The interaction between F* molecules and Q is inversely proportional to 
distance. There should be a vast excess of Q molecules to F* molecules such that 
intermolecular contact is highly likely, the probability of this occurring is given by 𝑘𝑞 , the 






  where  𝐼0  and 𝐼 are 
the fluorescence emission intensities of the F in the absence and presence of Q respectively. 
The lifetime is decreased by depopulation of the excited state and the quantum yield of F* is 
reduced by decay that is unaccompanied by emission (Figure 2.15 (b)). Since collisional 
quenching is a diffusion controlled process, its rate constant is also time-dependent.295 
The lifetimes or the temperature and viscosity dependence of quenching can be used to 
distinguish static and dynamic quenching as depicted in Figure 2.15. Quenching data 
presented as a plot of  
𝐼𝑜
𝐼
  versus [Q] conform to a linear relationship between relative 
fluorescence intensity ( 
𝐼𝑜
𝐼
 ) and the concentration of the quencher, [Q] with an expected y-
intercept of unity and a slope equal to  𝑘𝑞𝜏0(=  𝐾𝑆𝑉) and 𝐾𝑆 for collisional and static 
quenching respectively.  Collisional  fluorescence quenching can be described by the Stern-
Volmer (SV) equation (2.5.3) 308. 
 
                                              
𝐼𝑜
𝐼




𝑘𝑞 is the bimolecular quenching constant or rate at which a F* and Q come into contact; it 
can be determined experimentally given knowledge of 𝜏𝑜, practically for collisional 
quenching it should not be above approximately 2 X 1010 M-1.s-1 for a fluorophore with a 
typical 𝜏𝑜 of 1-10 ns .
309 
 
Figure 2.15 Comparison of linear plots generated from (a) static and (b) collisional quenching 
scenarios for fluorophore, F and Quencher, Q.  𝒉𝒗𝑭 represents normal fluorescence emission, F*
 
denotes the excited state. Diagram adapted from Lakowics Principles of Fluorescence 
spectroscopy.308 
 
Upon collision, the fluorophore and quencher form a dynamic complex which can decay to 
the ground state via quenching with rate constant, 𝑘1, or dissociate with rate constant, k-1. 
The quenching efficiency of this process can be calculated for effective collisional quenching, 
𝑘1 ≫  𝑘−1. 𝑘1is the diffusion controlled bimolecular rate constant and can be calculated 
from the Smoluchowski equation (2.5.4)  which incorporates the collision radii of the 
molecules, Rf and Rq.  
𝑁𝐴
1000
 is a scaling factor to convert molarity to molecules/ cm3 where 
𝑁𝐴 is Avogadro’s number, 6.022 x 10
23 . 
                                              𝑘1 =  
4𝜋𝑁𝐴
1000
(𝑅𝑓 + 𝑅𝑞)(𝑫)                                              (2.5.4) 
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                                                      𝑫 =  
𝑘𝑇
6𝜋𝜂𝑅
                                                                         (2.5.5)       
The molecular diffusion constant D, is the sum of the individual molecules diffusion 
constants, Df and Dq and can be estimated from the Stokes-Einstein equation (2.5.5) after 
considering the effects of solvent viscosity, 𝜂 and thermal energy (Boltzmann constant 
multiplied by absolute temperature), kT and molecular radius, R.309  𝑘1 is related to 𝑘𝑞 
through the quenching efficiency, 𝑓𝑄 =  𝑘𝑞/𝑘1. If 50% of encounters between the 
fluorophore and quencher result in effective quenching, 𝑘𝑞 the bimolecular quenching 
constant is half the diffusion controlled rate constant, 𝑘1.
308 
In the absence of knowledge of 𝜏𝑜, in steady state measurements, the Stern-Volmer 
quenching constant, 𝐾𝑆𝑉  (=  𝑘𝑞𝜏𝑜) , is reported as an alternative. 𝐾𝑆𝑉
−1 is the concentration 
of quencher at which  
𝐼𝑜
𝐼
= 2 or 50% of fluorescence is quenched. Without determining if 
𝜏0/𝜏 = 1, differentiation between the two mechanisms of quenching is possible through a 
variety of methods. Temperature or viscosity variations between experiments can provide 
information on the mechanism. Collisional quenching at elevated temperatures results in 
elevated diffusion coefficients, an increase in effective collisions and quenching efficiency, 
thus 𝑘𝑞 is shown to increase with increasing temperature. Conversely, an increase in 
temperature is likely to result in a decreased stability of the quencher-fluorophore 
complexes and thus lower values of the static quenching constants, Ks. By observation of 
elevated temperature or viscosity behaviour or lifetime measurements and presuming static 
quenching occurs and a ground state complex, FQ is formed, changes in the absorption 
spectrum of the ground state fluorophore can confirm complexation. 
The relationship between 
𝐼𝑜
𝐼
 and [Q] may be found to be non- linear therefore it is important 
to consider any effects that may decrease fluorescence intensity through mechanisms not 
considered to be quenching like the inner filter effect. The inner filter effect refers to the 
absorption of light at the excitation or emission wavelength by any molecules present in 
solution. This non-linear effect can be accounted for by application of a correction 
calculation (Eqn 2.5.6).309 𝐼𝑜𝑏𝑠 refers to the fluorescence emission intensity recorded and 
𝐼𝑐𝑜𝑟𝑟 refers to the intensity calculated after accounting for any absorption effects of the 
species, F and Q present. 
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)                                (2.5.6)  
A linear Stern-Volmer plot with y-intercept equal to unity is indicative of a single-class of 
fluorophores, all equally accessible to the quencher as seen in Figure 2.15 (a&b). It is also 
possible that both static and collisional quenching of F* occur simultaneously, in this case, a 
modified Stern-Volmer equation (Eqn. 2.5.7) which accounts for both quenching 
mechanisms is applied. The fluorescence emission measured is a weighted average of the 
fluorescence produced by the product of the fraction of F molecules not complexed with or 
not collisionally quenched by Q. The extra term, 𝑲𝑺𝑽𝑲𝑺[𝑸]
𝟐 results in an upward deviation 
from linearity in a plot of   
𝐼𝑜
𝐼
 versus [Q] toward the y-axis. An example of this is shown in 
Figure 2.15 (b).  
             
𝑰𝟎
𝑰
= (1 + 𝐾𝑆[𝑄])(1 + 𝐾𝑆𝑉[𝑄]) =  𝟏 + ( 𝑲𝑺𝑽 + 𝑲𝑺)[𝑸] +    𝑲𝑺𝑽𝑲𝑺[𝑸]
𝟐          (2.5.7) 
A downward deviation from linearity toward the x-axis is indicative of systems where 
fluorophore molecules can be accessible and inaccessible to the quencher, for example, lipid 
membrane dyes (Fig. 2.16 (a)). 308 The 𝐾𝑆𝑉 values obtained not only depend on the 
concentration of Q, but also on molecular contact between F and Q. The latter situation thus 
can be used to investigate the localisation of fluorophores and by extension, their 
quenchers, as well as the permeability of two phase systems for example, aqueous bulk 
solvent and fluorophore stained lipid droplets. Therefore, the  𝐾𝑆𝑉 values obtained, are also 
dependent on the relative partitioning, 𝐾𝑝 of Q into the local environment of F.
310  In steady-
state fluorescence experiments where data is found to conform to a linear SV plot, the 
quenching efficiency can be related to the total concentration of the partitioned quencher, 
[Q]T.
310 311  
A common approach to investigating the partitioning of a substance between 
compartmentalised or aq/lipid systems is by monitoring the deviation of the bimolecular 
quenching constant, kq or KSV, with variable total lipid volume, αL.
311–313 Several literature 
reports discuss the theory behind this approach and so the derivation of the major equations 
are not presented here. 310,314,315 These methods are predominantly applied to aq/ 
membrane partitioning measurement, specifically the measurement of vesicle partitioning 
for ionisable drugs. 303 316  Briefly, for the quencher, Q, partitioning into the neutral lipids to 
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quench the probe molecule, F, a few different equilibria exist. The distribution of possible 
species is depicted by the equilibrium equations shown in Fig. 2.16. The green block 
indicates the acid-base equilibrium that the quencher can undergo in aq solution shown in 
Eqn. 2.5.8. Ka refers to the dissociation constant for that process and Kp is the lipid 
membrane partition coefficient for the equilibrium between the concentration of Q in the 
aqueous phase [Q]aq and the concentration of Q in the lipid phase [Q]L shown in blue.  
 
 
Figure 2.16 A description of the dynamic equilibrium that occurs when the quencher (Q), is allowed 
to partition into the fluorophore, F, stained lipids. 𝒌𝒅, 𝒌−𝒅, 𝒌𝒎 and 𝒌𝒊 represent the rate constants of 
complex formation, dissociation and deactivation of F* and the complex, respectively. Subscripts aq 
and L refer to the aqueous and lipid phases. 
 
The interaction between the partitioned quencher and F* (excited state) inside the lipid is 
determined by the formation of a fluorophore-quencher excited state complex (FQ*L) in the 
lipid phase with rate constants 𝑘𝑑 and 𝑘−𝑑 for the formation and dissociation of the complex. 
The excited state complex, F-Q* can be deactivated by fluorescence with a rate constant of  
𝒌𝒊 and likewise the fluorophore excited state can be deactivated with rate constant, 𝑘𝑚. The 
bimolecular quenching constant, 𝑘𝑞, is defined by the ratio of these rate constants as shown 
in Eqn 2.5.9 295 The calculation of kq from KSV requires the independent measurement of 𝜏0 
of NR in SNLBDs in order for a value of kq to be obtained. In the absence of the required 
fluorescence lifetime machinery, KSV is used to approximate kq. (The use of a fluorescence 
lifetime value measured under different conditions obtained from literature implies that 𝜏0 
is independent of the change in the conditions, an assumption that must be proven for the 
value of kq to be valid.) 
317 The partition constant, 𝐾𝑝 (Eqn. 2.5.10), is the ratio of the amount 
of quencher in the lipid phase, [Q]L relative to the portion of quencher in the aq phase, [Q]aq.  
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For a monoprotic quencher, the fraction of [Q]aq can be calculated from Eqn. 2.5.8 by 
accounting for the ionisation of the quencher. [Q]L is given by the SV equation (2.5.3) and 
summed with [Q]aq yields the total amount of quencher, [Q]T, added to the experiment. 
Equation 2.5.11 relates both fractions of Q to the ratio of lipid volume to the total volume, 
which is called the lipid volume fraction and is denoted by αL. The apparent quenching rate, 
kq
app (KSV /𝜏𝑜  in Eqn. 2.5.3)  is dependent on this ratio such that a plot of 1/ kq
app
 versus αL is a 
straight line function with y intercept equal to 
1
𝑘𝑞𝐾𝑝







                                              [𝑄]𝑎𝑞   = [𝑸𝑯
+ ] 𝒂𝒒𝟏𝟎
(𝒑𝑲𝒂−𝒑𝑯)                                                (2.5.8)     
                                                     𝑘𝑞 =  
𝑘𝑑𝑘𝑖
(𝑘−𝑑 + 𝑘𝑖) 
       
⁄
                                                       (2.5.9)     
                                               𝐾𝑝 =
[𝑄]𝐿
[𝑄]𝑎𝑞                                                                    (2.5.10)
⁄  
                        [𝑸]𝑳 =
[𝑄]𝑇
{𝛼𝐿
⁄ +  (𝟏𝟎𝒑𝑲𝒂−𝒑𝑯 + 𝟏).   
(1 − 𝛼𝐿)
𝑲𝒑
} ,  𝛼𝐿 =
𝑉𝐿
𝑉𝑇  






Chapter 3:  
Materials, Instrumentation and General Methods 
(3.1)  Materials 
All the materials used in this study were of analytical grade or of the highest grade 
commercially available and no further purification was performed prior to use unless 
otherwise stated. 
All chemicals were purchased from Sigma Aldrich® (Vorna Valley, South Africa) with any 
exceptions stated specifically in the relevant sections. All consumables such as Eppendorf 
and Falcon tubes were obtained from Lasec, Kimix Chemicals or Merck South Africa. 
Double distilled deionised Millipore® Direct-Q water was used to prepare all aqueous 
solutions and is referred to as water. 
 
(3.2)  Instrumentation and Accessories 
(3.2.1) Weighing Balance 
All salts and solid substances used in this study were weighed using a four decimal place 
AdventurerTM OHAUS weighing balance or a milligram Sartorius 2006 MP balance which 
were regularly calibrated with mass standards. 
(3.2.2) Preparation of solutions 
All stock solutions were prepared by weighing each solid on an analytical grade balance and 
diluting to the required volume in Schott-Duran volumetric flasks. Where further dilution 
was required Eppendorf pipettes were used to dispense the appropriate volume accurately. 
Dissolution of all solids was achieved by use of a Snijders vortex or Bandelin Sonorex RK100H 





(3.2.3) pH Measurements 
The pH of low volume solutions (μL - 10 mL) was determined using a bench Jenway 3510 pH 
meter fitted with a 924 007 glass Jenway electrode. The pH of solutions of volumes 10 mL 
and greater was determined using a Crison MicropH 2000 pH meter and Crison 52 03 glass 
electrode. Standard solutions at pH 4.00 ± 0.01 (Buffer, reference standard, Sigma B5020) 
and 7.00 ± 0.01 (Buffer, reference standard, Sigma B4770) were used to calibrate the pH 
meter at room temperature of ~ 23 °C. Electrodes were stored immersed in a 3 M KCl 
solution obtained from Sigma Aldrich. 
(3.2.4) UV-vis Experiments 
All UV-vis spectra were recorded with a Varian Cary 100 spectrophotometer or a Shimadzu 
UV 1800 Probe at constant temperature by attachment of the cell chamber to an external 
water bath. Hellma, Suprasil® quartz cuvettes of 1 and 10 mm pathlength in varied volume 
capacity were used for all measurements. 
(3.2.5) Fluorescence Spectrophotometry 
A Varian Cary Eclipse fluorometer equipped with a regulated temperature cell holder was 
used to perform all steady-state fluorescence measurements. Hellma, Suprasil® quartz 
fluorescence cuvettes of 10 mm pathlength and 1.5 mL volume capacity were used for all 
measurements. 
(3.2.6) Fluorescence Microscopy 
Fluorescence microscopy was conducted using a Nikon Diaphot inverted fluorescence 
microscope with dichroic mirror: DM580. Filters used are mentioned where applicable. 
(3.2.7) Infrared Spectroscopy 
All IR spectra were recorded using either a Bruker Platinum ATR which was mounted onto a 
Bruker Tensor 27 FT-IR spectrophotometer or a Perkin Elmer 100 spectrophotomer using an 
ATR attachment at room temperature (~ 23 °C). The background was run on air and the 
spectra were collected from 4000 to 400 cm-1. 
88 
 
(3.2.8) Powder X-ray diffraction (PXRD)  
PXRD measurements were conducted using a Bruker D8 Advance diffractometer equipped 
with a Lynxeye detector using CuΚα-radiation (λ = 1.5406 Å) at 298 K. Samples were 
prepared by drying over P4O10 and then crushed to a fine powder which was placed on a zero 
background sample holder and scanned over the 2θ range 4- 40° with a 0.016° step size. X-
rays were generated by a current flow of 40 mA and an accelerating voltage of 30 kV. The 
receiving slit width was 0.6 mm and 0.25 mm primary and secondary slit widths were used. 
The output was converted from a text file to an Excel spreadsheet from which PXRD traces 
were generated. 
 
(3.2.9) NMR experiments 
 NMR experiments were performed on a Bruker Ultrashield 400 Plus spectrometer at 30 °C 
in deuterium oxide (D2O) at 99.9% heavy atom D obtained from Fluka Products supplied by 
Sigma Aldrich®, South Africa. 
(3.2.10) Plates and Plate Reader 
Clear 96-well flat form Kartell® plates were used to measure the UV-vis absorbance of 
multiple samples of increasing concentration on a thermostatted Molecular Devices Spectra-
Max 340 PL plate reader at 25 °C at a predetermined λmax (nm) of the absorbing substance 
for single reads or over the λ range 340-750 nm for the whole spectrum. 
(3.2.11) Centrifuge 
Centrifugation of suspensions of volumes greater than 2.0 mL were performed with an 
Eppendorf Centrifuge 5810R in plastic Greiner Falcon tubes (15 mL) or NagleneTM  3115 Oak 
Ridge polypropylene centrifuge tubes (80 mL) while volumes less than 2.0 mL were 





(3.2.12) Water Baths  
All β-haematin formation and kinetics experiments were done at physiological temperature 
(37 °C). A Fried Electric thermostat was attached to a water bath which was used to heat and 
maintain the temperature of the water. An external thermometer was also used to measure 
the temperature of buffer solution in the reaction vessel incubated in the water bath to 
confirm the required temperature prior to conducting the experiment. All 
spectrophotometer sample units were attached to an external thermostatted water bath 
which was maintained at 25 ± 1 °C for the duration of the experiment. The water baths were 
either a GRANT digital Y6 water bath or a YIH DER BL-710 water bath or a Labcon CPM 100 
bath.  
(3.2.13) Software 
GraphPad Prism version 3 (3.02, April 25, 2000, GraphPad Software Inc.)  for windows was 
used to perform all non-linear least squares analysis, as well as to compute linear 
representations of data.319 HypSpec from the HyperQuad 2008 Software package was used 
to analyse all UV-vis titrations for computation of binding constants.320 All chemical 
structures were drawn by the author in ChemBioDraw 11 or ACD/ChemSketch v 12.01 
freeware. The Cambridge Structural Database, version 5.36, February 2015, was used to 
obtain published crystal structures.231 Images of crystal structures were generated using 
OLEX2 version 1.26.321  Mendeley freeware for windows desktop and web importer was used 
to generate the bibliography for this work.  
(3.3)  General Methods 
(3.3.1) Washing Procedures 
The tendency of Fe(III)PPIX to adsorb onto glass and plastic is well established.66,72 In order 
to avoid loss of material resulting in inaccurate concentrations, all Fe(III)PPIX stock solutions 
were prepared fresh for each experiment and only kept in glass vials for the duration of the 
experiment. All glassware, Hamilton syringes, NagleneTM centrifuge tubes, stirrer bars, 
crystallisation dishes, NMR tubes, and quartz cuvettes were extensively washed with 0.1 M 
NaOH solution, followed by a single rinse with 1 M HNO3 and a few final rinses with water. 
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All glassware was dried in a 100 °C oven for 24 hrs prior to each use. Plastic tubes, 
eppendorfs and pipette tips were discarded after every use to prevent contamination. 
 (3.3.2) Preparation of Lipid Blend and SNLBDs 
A biologically established neutral lipid blend composed of lipids rac 1- monostearoylglycerol 
(MSG): 1-monopalmitoylglycerol (MPG): 1,3-dioleoylglycerol (DOG): 1,3-dilinoleoylglycerol 
(DLG), 1,3-dipalmitoylglycerol (DPG) in the biological mole ratio 4:2:1:1:1 as previously 
reported by Sullivan et al., were dissolved in 1:9 (v/v) acetone : methanol (Ace: MeOH) to 
afford lipid stock solutions.124 Individual stock solutions of each lipid were then mixed with 
each component in the correct volume ratio by sonication and heating to 40 °C to ensure all 
lipids were dissolved with the total lipid concentration equal to 3.31 mM. Synthetic neutral 
lipid blend droplets (SNLBDs) were prepared following the method of Hoang et al. on 
aqueous buffer by depositing the lipid blend stock solution onto the surface of a larger 
volume of buffer at the desired temperature and pH with a with a syringe of needle gauge 
23 (outer diameter 0.64 mm, inner diameter 0.34 mm, wall thickness 0.1524 mm) to prepare 
a layer of lipid in acetone: methanol solution.127 The organic layer was rapidly dispersed into 
the aqueous bulk by vortex to afford SNLBDs. 
(3.3.3) The pyridine hemichrome inhibition of β-haematin (Phi-β) assay 
The Phi-β assay as developed by Ncokazi and Egan provides a reliable efficient method of 
quantifying free haem in solution 253. The authors demonstrated that upon addition of a 5%, 
v/v, pyridine solution buffered at pH 7.5 to the reaction mixture of Fe(III)PPIX and βH, the 
pyridine preferentially binds unreacted Fe(III)PPIX to form a low spin bispyridyl complex that 
has been shown possible to quantify spectrophotometrically at the maximum absorbance 
wavelength of the Fe(III)PPIX soret band at 405 nm. βH solid does not react with the pyridine 






(3.3.4) Preparation of stock solutions 
(3.3.4.1) 0.1 M NaOH 
Sodium hydroxide (NaOH) pellets (1.0 g) were weighed out and dissolved in 250 mL of water, 
this solution was stored in the dark at room teperature in a tightly sealed glass bottle and 
used until finished. 
(3.3.3.2) 1: 9 Acetone: Methanol solution 
Acetone: Methanol (1:9, v/v) stock solvent referred to as Ace: MeOH was prepared from 
analytical reagent grade acetone and methanol by premixing 50 mL of acetone with 450 mL 
of methanol and storing the solvent in an airtight container. 
(3.3.3.3) Fe(III)PPIX solutions 
All aqueous Fe(III)PPIX solutions were prepared from solid porcine haematin dissolved in 0.1 
M NaOH and the required buffer solution to obtain the desired species of Fe(III)PPIX. Non-
aqueous Fe(III)PPIX solutions were prepared from solid haematin initially dissolved in DMF  
and further diluted with the specified solvent to the required concentration. 
(3.3.3.4) Antimalarial drug stock solutions 
Unless stated, all aqueous experiments involving antimalarial drugs; chloroquine 
diphosphate (CQ), amodiaquine dihydrochloride dehydrate (AQ), quinidine sulphate 
dehydrate (QD) and quinine sulphate dehydrate (QN) stock solutions were prepared from 
their salts. The free base forms of CQ, QD and QN were used to prepare their non-aqueous 
stock solutions. They were prepared according to the method outlined by Kuter et al. and 
obtained from the Egan Laboratory.322 
(3.3.3.5) 30% pyridine stock solution 
A 30% pyridine stock solution was prepared fresh for addition to Fe(III)PPIX/ β-haematin 
solutions in the pyridine hemichrome inhibition (Phi-β) assay. In a 100 mL volumetric flask, 
30 mL pyridine was added to a mixture of acetone (40 mL): water (20 mL): HEPES buffer (2 




Chapter 4:  
Partitioning of Fe(III)PPIX into Nile Red-labelled synthetic 
neutral lipid droplets  
(4.1) Introduction 
Since neutral lipids were first identified and found to be associated with haemozoin (Hz) 
crystals in vivo, synthetic neutral lipid droplets (SNLDs) have been verified as an efficient 
mediator of β-haematin (βH) formation in vitro.57,118,124,323 Several studies have 
acknowledged them as the most likely biomolecules responsible for Hz synthesis in 
vivo.120,127,143 To date, their exact role in this process is unknown. The unique composition of 
this lipid blend found to be present in the parasite digestive vacuole (DV) is the biologically-
established 4:2:1:1:1 mole ratio of acyl glycerols; MSG, MPG, DPG, DOG and DLG, 
respectively.124 The presence of this mixture presents as a challenge to elucidate the 
function of the lipid blend.  
As discussed in Chapter 1, it has been postulated that the NLDs provide a lipid-aqueous (aq) 
interface that effectively nucleates Hz crystals where, upon formation, the hydrophobic 
crystal migrates to the hydrophobic interior of the lipid.57,127 Several groups have 
investigated the interactions of Fe(III)PPIX with model lipid interfaces where the facial 
orientation and morphology of the resulting crystals imply molecular contact between polar 
lipid head groups and propionate groups on Fe(III)PPIX.118,125,128,148,324 It has been shown that 
synthetic NLDs of the biologically-established blend (SNLBDs) control the number and size of 
βH crystals formed in vitro.126 The study also demonstrated that these crystals lie on the 
surface of SNLBDs. The SNLBDs were characterised by TEM and confocal microscopy as non-
hollow with continuous hydrophobic lipid interiors occurring in two dominant size 
populations of 74-146 nm and 366-438 nm.126 Questions still remain about the nature of the 
interaction between Fe(III)PPIX and these neutral lipid droplets and their role in the 
promotion of  βH  formation is yet unknown. To date no direct measurements of Fe(III)PPIX 
partitioning into lipid droplets or its lipophilicity have been conducted. The aim of this study 
was to use fluorescence quenching to determine the partitioning profile of Fe(III)PPIX into 
SNLBDs found to be associated with Hz in situ.124 Of particular relevance is the behaviour of 
Fe(III)PPIX and these lipids at DV and cytosolic pH values.32,325 A main objective was to 
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determine the partition coefficient as measure of lipophilicity of Fe(III)PPIX under the 
relevant pH conditions. Furthermore, the effect of four quinoline antimalarial drugs on this 
partitioning profile as an indication of drug-Fe(III)PPIX complex lipophilicity is presented to 
determine if their inhibition of Hz crystal formation is related to lipid partitioning.  
The intracellular probe Nile Red (NR) is a selective lipid stain used to probe the polarity and 
location of many lipid structures by fluorescence microscopy and 
spectroscopy.120,164,165,326,327 A recent study has shown NR fluorescence in NLBs by confocal 
microscopy.127 As mentioned in Chapter 2, heavy metal atoms are known to quench 
fluorescence emission intensity by a donor-acceptor mechanism that requires molecular 
contact between the donating species (the fluorophore) and the acceptor (the quencher). 308 
Various studies have been conducted to measure the depth of liposome partitioning and 
micelle or lipid interaction of drugs using fluorescence-quenching techniques.312,313,328–330 
Thus, the relationship between the observed decrease in fluorescence intensity emission of 
the probe in the specific SNLBD environment and the local concentration of quencher is 








(4.2) Experimental Methods 
(4.2.1) Materials, Instrumentation and General Procedures 
All chemicals used were obtained from Sigma-Aldrich® (Vorna Valley, South Africa) and 
stored at 4°C in the refrigerator prior to use. Lipids were kept at -20°C. Fluorescence 
spectroscopy studies were performed at 298 K and 318 K by attachment to a thermostatted 
water bath. Both excitation and emission slit widths were set to 5 nm at an averaging time 
for data collection set to 0.5 s with scans at a rate of 120 nm/min and a PMT detector 
voltage of 700 V. The fluorometer was zeroed using the buffer or solvent of interest in the 
absence of NR. UV-vis spectroscopy experiments were conducted on a Varian Cary 100 
spectrophotometer also attached to a thermostatted water bath at 298 K. 1 cm pathlength 
Hellma® quartz cuvettes were used for all experiments. All titrations were conducted using 
an appropriately-sized Hamilton syringe. Unless otherwise stated, all experiments were 
performed at least in triplicate. Solutions prepared in cuvettes (1 mL) were always allowed 
to equilibrate to the temperature of the thermostatted fluorometer cell-holder for 5 min 
prior to any measurement. All titration data were corrected for dilution. 
Nile red (9-diethylamino-5H-benzo[α]phenoxazine-5-one) solutions (10 µM) were prepared 
in each respective solvent for calibration studies and in acetone for lipid studies. Aqueous 
buffer stock solutions (50 mM) were prepared from the appropriate salts and adjusted to 
the required pH with a NaOH slurry: (i) citrate-phosphate buffer pH 2.5-3.5, (ii) citrate buffer 
pH 3.8-5.55, (iii) MES buffer pH 5.9-6.6 (iv) HEPES buffer pH 7.0-7.9 (v) CHES buffer pH 8.0-
10.0 and (vi) disodium phosphate buffer pH 12.00. Fe(III)PPIX stock solutions (10 mM, 1 mM 
and 0.5 mM) were prepared by dissolving solid porcine haematin in 0.1 M NaOH. Drug stock 
solutions (10 mM) for chloroquine diphosphate (CQ), amodiaquine dihydrochloride 
dihydrate (AQ), quinidine sulphate dihydrate (QD) and quinine sulphate dihydrate (QN) were 
prepared in the appropriate buffer for each pH value investigated, where soluble. For drugs 
insoluble at certain pH values, a diluted stock concentration was employed to keep the final 




(4.2.2) Investigation of the relationship between NR fluorescence intensity 
and concentration  
To demonstrate the dependence of NR fluorescence intensity on concentration, NR (10 µM 
stock) was titrated into acetone. An Ex λmax = 540 nm was set (determined from the 
absorbance max of the NR spectrum). A plot of the arbitrary fluorescent intensity obtained 
from a NR concentration range of 0-5 μM in acetone was generated for the emission max 
wavelengths observed. A straight-line correlation was obtained at Em λmax = 609 nm. The 
best-fit concentration range of NR was found to be 0-2 μM. A NR concentration of 1 μM, 
well within the established linear range, was chosen for all further fluorescence studies. 
(4.3) Sample Preparation and Analysis Methods 
(4.3.1) Preparation of NR stained SNLBDs  
Synthetic neutral lipid droplets composed of the established biological blend of mono- and 
diacylglycerols (SNLBDs) in the mole ratio of 4:2:1:1:1 pre-stained with NR were 
independently prepared for each experiment. Lipid blend prepared in the manner outlined 
in Section 3.3.2 was diluted in 1:9 (v/v) acetone:MeOH (1 mM, 100 μL) and premixed with 
NR stock solution (10 μM, 100 μL) in the probe-to-lipid ratio of 1:100 by sonication. This 
premix was added drop-wise onto aqueous buffer solution (800 μL) with a syringe to afford 
NR associated SNLBDs upon mixing. To visualise the aq bulk in contrast to the lipid 
environment, sodium fluorescein stock solution was diluted in the aq buffer such that the 
final concentration was 10 μM.  
(4.3.2) Analysis of NR-SNLBD 
Visualisation of NR-labelled SNLBDs was performed on an 10 μL aliquot placed on a glass 
slide with cover slip using a fluorescence microscope. Images (100× magnification objective 
lens) were captured in brightfield and using the green light excitation filter (510-560 nm) for 
red fluorescence emission with a barrier absorption filter wavelength of 590 nm. Fluorescein 
images were captured at 20× magnification with green fluorescence excitation and red 
emission. Exposure time was set to 160-170 ms at 89% power. For fluorescence 
spectroscopy, the excitation max wavelength (Ex λmax) was determined from the UV-vis 
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absorbance max of the solution in scanning range of 800-200 nm. Fluorescence emission 
spectra at Ex λmax  were monitored over a time period of 15 min to establish emission max 
wavelength (Em λmax) and to investigate the reproducibility of fluorescence intensity signal of 
NR in SNLBDs.  
(4.3.3) (a) An investigation of Nile red fluorescence quenching dependence on 
[Fe(III)PPIX] concentration 
Nile red (1 μM) fluorescence was measured in MeOH at Ex λmax = 540 nm and Em range 560-
750 nm without Fe(III)PPIX to obtain the fluorescence intensity zero reading, INR  and Em λmax 
in MeOH. Fe(III)PPIX stock solution (0.5 mM) prepared in MeOH was then titrated into the 
fluorescence cuvette in aliquots using a 50 μL Hamilton syringe such that the effect of 
increasing Fe(III)PPIX concentration on fluorescence signal was measured after each 
Fe(III)PPIX addition. Fe(III)PPIX was added to the cuvette until the final Fe(III)PPIX 
concentration was 300 μM. A Stern-Volmer (SV) plot of the quenching data was obtained by 
plotting the ratio of fluorescence intensity at zero concentration of the quencher 
(Fe(III)PPIX), I0 , and the fluorescence intensity at a specific concentration of Fe(III)PPIX, Ia  
versus the concentration of  Fe(III)PPIX in question. A linear relationship was obtained up 
until 70 μM Fe(III)PPIX with slope giving the  SV quenching constant, 𝐾𝑆𝑉. 
(b) Investigation of the nature of quenching mechanisms for Fe(III)PPIX 
quenching of NR fluorescence 
Two methods were employed to infer whether the quenching process occurring in the 
fluorescence quenching studies described (4.3.3.a) is either (a) static or (b) collisional. (i) The 
temperature and viscosity dependence of NR fluorescence quenching in the presence of 
Fe(III)PPIX was used to distinguish static and dynamic quenching. Identical conditions for the 
quenching experiments described in section (4.3.3.a) at pH 7.51 were used but all 
fluorescence measurements were conducted at an increased temperature of 318 K as 
opposed to the standard 298 K. Linear SV plots to obtain 𝐾𝑆𝑉 were used.  
(ii) Absorption spectra were also used to aid in differentiation between the two types of 
quenching. This was investigated by measuring the UV-vis absorbance spectrum of NR in 
methanol (5 µM) from 800-200 nm. Solid Fe(III)PPIX was dissolved in MeOH (0.5 mM) and 
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then titrated in 5 µL aliquots into the cuvette, measuring the corresponding absorbance 
spectrum at each concentration of Fe(III)PPIX until a concentration of 35 μM was attained. 
The UV-vis absorbance spectrum of Fe(III)PPIX dissolved in MeOH (35 μM) was also recorded 
separately. The difference between the absorbance spectrum obtained for Fe(III)PPIX in 
MeOH alone and the spectrum obtained in the presence of NR is presented to indicate any 
possible variance between the two. The inner-filter effect (IFE) was also evaluated to 
determine if a correction was necessary under the conditions applied to quenching 
experiments. 
(4.3.4) Fe(III)PPIX quenching of NR fluorescence in various solvents 
Quenching of NR by Fe(III)PPIX was carried out in different solvents to determine whether 
the quenching process is solvent-independent. The titration procedure described in section 
4.3.3.a was followed exactly using solvents of varying polarity as given by their Dimroth-
Reichardt hydrophobicity parameter ET(30) (kcal/mol) values and viscosities (m.Pa.s).
331 The 
solvents were (from lowest to highest ET(30)): dodecane, toluene, ethyl acetate, chloroform, 
acetone, dimethylformamide, dimethylsulfoxide, isopropanol, pentanol, butanol, methanol 
and water. The UV-vis absorbance spectrum of NR in each solvent was recorded and Ex λmax 
was determined from the max absorbance peak wavelength. A plot of NR Em λmax obtained 
against solvent ET(30) was evaluated for polarity dependence.  
(4.3.5) Fe(III)PPIX titration into NR labelled SNLBDs 
(a) Quenching of NR by Fe(III)PPIX in the presence of the lipid blend was conducted over the 
pH range 2.50-8.00. A 1:100 premix (200 µL) of NR: NLB was added drop-wise to the 
appropriate aq buffer (20 mM) for each pH investigated, in a cuvette (800 μL) in such a 
way as to promote the formation of lipid droplets with minimal disturbance to the lipid-
aq interface (method and concentrations as in 4.3.3.a). A zero intensity reading was 
taken in the absence of Fe(III)PPIX and recorded as 𝐼0. Fe(III)PPIX was then titrated into 
the cuvette in µL amounts and a reading of the decreased fluorescence intensity was 
recorded as 𝐼𝑎 after each addition for each pH value. A SV plot was generated and 𝐾𝑆𝑉 
constants were obtained for quenching conditions at each pH investigated to obtain a pH 
profile for NR quenching. 
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(b) An investigation into Fe(III)PPIX quenching of NR in the absence of SNLBDs was 
conducted in a solution of similar ET(30); 50:50 v/v acetone:octanol solution. The 
quenching procedure in (4.2.5.a) was followed with the following changes. NR stock 
(acetone) was added to the acetone:octanol solvent system such that the initial 
concentration was 1 μM, the fluorescence emission at 𝜆𝑚𝑎𝑥 was recorded as 𝐼0. 
Fe(III)PPIX stock solution was prepared from haematin solid dissolved in DMF and diluted 
to 0.5 mM in the acetone:octanol solvent system. SV plots were generated from the data 
and analysed for changes in 𝐾𝑆𝑉. 
(4.3.6) Measurement of log DOW pH 7.51 of Fe(III)PPIX  
The distribution coefficient, DOW of Fe(III)PPIX between octanol and aq buffer (HEPES, pH 
7.51, 20 mM) was evaluated by the shake-flask method (OCED Guideline for testing of 
chemicals 2003) at 37°C.332 Haematin solid was dissolved in 0.1 M NaOH and premixed into 
the buffer (3 mL) at a final concentration of Fe(III)PPIX 57.8 μM. This solution was then 
mixed with an equal volume of pre-saturated (with aq buffer) octanol, shaken vigorously and 
allowed to equilibrate for 6 h. Each phase was then separated and final Fe(III)PPIX 
concentrations in each layer were determined by computing absorbance values measured 
with the extinction coefficients obtained (molar absorptivity coefficient) from linear Beer’s 
Law UV-vis spectroscopy plots in each phase within the concentration range tested.  
 
(4.3.7) (a) Exploring the effect of antimalarials on Fe(III)PPIX partitioning into 
NR-labelled SNLBDs 
To determine whether quinoline drugs CQ, AQ, QD and QN quench NR fluorescence in 
SNLBDs at the pH values of interest (pH 2.80-12.00) in the absence of Fe(III)PPIX, NR-labelled 
SNLBDs were prepared according to the method described in Section 4.3.3.a and 𝐼0 
fluorescence intensity readings were recorded. Drug stock solutions (10 mM) were prepared 
in the required aq buffer (20 mM) for the pH investigated and titrated into a cuvette 
containing NR-SNLBDs. Readings were taken immediately after each drug addition, 𝐼[𝑎], and 
checked for stability after 2 min post-stirring of the solution in separate experiments for 
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each drug. A plot of the ratio of 
𝐼0
 𝐼[𝑎]
 against drug concentration was generated for each 
antimalarial compound at each pH investigated to determine if any quenching occurred. 
(b) The effect of each of the antimalarials chosen on the SV quenching constant, 𝐾𝑆𝑉 , of 
Fe(III)PPIX quenching of NR-labelled SNLBDs over the pH range 2.80-12.00 was investigated. 
The method in section 4.2.5(a) of measuring 𝐾𝑆𝑉  was followed with the addition of drug 
stock solution to the cuvette such that the final concentration of each drug was 500 μM 
prior to any Fe(III)PPIX additions. This fluorescence spectrum was recorded as 𝐼0 followed by 
the measurement of 𝐼[𝑎] for each subsequent Fe(III)PPIX addition. The total amount of 
Fe(III)PPIX added to the NR+SNLBD+drug system was at least 75 μM for all titrations 
resulting in an end-point  Fe(III)PPIX:drug concentration ratio of 1:6.7 to facilitate drug 
complexation of all Fe(III)PPIX added. SV plots were generated for each antimalarial at each 
pH value investigated. 
(c) The SNLBD and aq buffer independent experiment conducted in section 4.3.5.c was 
performed with the inclusion of 500 μM drug stock solution in octanol prior to any 
Fe(III)PPIX additions to the cuvette. The free base forms of CQ, QD and QN were used to 




(4.4) Results and Discussion 
(4.4.1) Nile Red-stained Synthetic Neutral Lipid Blend Droplets 
To confirm incorporation of the lipophilic dye Nile Red (NR) into non-hollow synthetic 
neutral lipid blend droplets (SNLBDs), bright-field and fluorescence microscopy were utilised 
for visualisation. SNLBDs were prepared following the method first reported by Hoang et al. 
for MSG by fluorescence microscopy and later demonstrated by confocal microscopy studies 
on NLBDs. 126,127 The image in Figure 4.1(a) was captured under bright-field illumination 
which appears to show coalescence of individual SNLBDs of various sizes in the nm to μm 
range to form larger aggregates. This is consistent with the visualisation of neutral lipid 
droplets by Ambele et al.126  
Excitation with green light reveals that the NR red fluorescence emission is localised inside 
these individual lipid droplets (Fig. 4.1b). Images c-d in Fig. 4.1 contain the aqueous-specific 
dye fluorescein to show the contrast between the red-stained NR containing SNLBDs and the 
green stained aq bulk.333 The nm sized SNLBDs show a red-gold fluorescence (Fig. 4.1c&f) 
while larger μm sized SNLBDs exhibit a dark red stained interior. This is consistent with the 
observations of Greenspan et al. who monitored NR localisation in a hydrophobic lipid 
environment with fluorescence emission maxima (Em λmax) at 515-560 nm (yellow-gold) and 
at 610 nm (red).326 The presence of two distinct size populations of SNLBDs has been 
previously established.127 The filters available for this experiment were unable to separate 
these two emissions and significant fluorescence emission overlap was observed in several 
images. The possibility of photo-bleaching of NR signal from SNLBDs was monitored over 















Figure 4.1 Images of SNLBDs stained with NR fluorescent dye captured in (a) brightfield (larger aq 
bubbles around SNLBDs appear as dark lines) and (b) under green light excitation (510-560 nm), 
Aqueous dye fluorescein diluted in aq buffer (HEPES, 50 mM, pH 7.50) (c-f) appears green for 
contrast. A variation in size populations for SNLBDs can be seen with distinctly large (50- 100 μm) 
droplets and smaller droplets (1-10 μm). White arrows indicate the various sized SNLBDs within a 
sample. Thick white scale bars represent 100 μm 
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The fluorescence emission properties of the solvatochromatic dye, NR, are dependent on 
the physicochemical properties of its microenvironment, particularly its polarity.164 The 
fluorescence emission spectrum of NR in SNLBDs dispersed in aq medium displays an Em 
λmax in the range of 615-618 nm as observed in a typical fluorescence spectrum shown in Fig. 
4.2. The NR stock solution was prepared in acetone wherein NR typically displays an Em λmax 
of 608 - 610 nm.164 This red shift to slightly longer wavelength is indicative of a change in the 
local environment of NR molecules upon incorporation into the non-hollow SNLBDs. 
 
The polarity of the unique neutral lipid environment of the SNLBDs was probed by 
investigating the Em λmax of NR in various solvents with varying polarity. An examination of 
the relationship between Em λmax and the Dimroth-Reichardt polarity index, ET(30) (kcal.mol
-
1), revealed that the NR fluorescence Em λmax observed, increased linearly with increasing 
ET(30).
331 For example, the non-polar solvent toluene (ET(30) = 33.9 kcal.mol
-1) induced a NR 
Em λmax of 589 nm while NR displays an Em λmax  of 654 nm in the much more polar solvent 
water (ET(30) = 63.1 kcal.mol
-1).  
A positive linear dependence of Em λmax on ET(30)  can be seen in Figure 4.3 demonstrating 
the solvatochromism of NR. Theoretical and steady-state fluorescence emission studies 
attribute this behavior to an increase in the dipole moment of NR during the absorption 
process upon vertical excitation of the ground state.334,335 The dipole moment in the return 
to the ground state (emission process) is decreased and by using the Lippert equation (Eqn. 
 
Figure 4.2 A typical fluorescence emission spectrum (Em λmax = 615 - 618 nm) of 1 μM NR-labelled 
SNLBDs (100 μM) dispersed in aqueous solution, Ex λmax = 540 nm.  
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2.5.2) to model the molecular size and rotation of NR in a solvent of a particular dielectric 
constant, intramolecular charge transfer via the twisted intramolecular charge transfer 
(TICT) excited state of NR was proposed as the most likely mechanism. Interpolation using 
the average Em λmax (617 nm) obtained for NR incorporated into SNLBDs corresponds to an 
ET(30)  of 45 ± 4 kcal.mol
-1. This reveals that the unique interior of SNLBDs possess a polarity 
that lies between that of the solvent acetone with an ET(30)  = 42.2 kcal.mol
-1 and octanol, 




Figure 4.3 Linear correlation (r2 = 0.94) between the fluorescence Em λmax of NR and the relative 
polarity indicator, ET(30) in kcal.mol
-1
, recorded in various solvents.  The dashed interpolation lines 
indicate the relative polarity of the SNLBDs based on an Em λmax of 618 nm. 
 
In fact, as shown in Fig. 4.4 the fluorescence emission spectrum of NR (Ex λ = 540 nm) in a 
50% acetone:octanol mixture (v/v) appears to be virtually the same as that obtained in the 
SNLBDs (Fig. 4.2) with Em λmax = 618 nm. A wide range of Ex and Em wavelengths of NR have 
been employed to quantify and selectively stain polar and neutral lipids.336 Typical 
intracellular neutral LDs interiors have been classified as non-polar, however; these LDs 
include esterified cholesterol and triglycerides and they exhibit NR Em λmax in the yellow 
fluorescence range (535-590 nm). 337 NR has been shown to emit at red emission 
wavelengths of approximately 616-650 nm when staining phospholipid-cholesterol lipid 
blends, extracted intracellular lipid contents or when localised in regions of lower polarity 
within systems of mixed polarity.338–340 This measurement of the relative polarity of and 
Stokes shift upon NR incorporation into SNLBDs definitively demonstrates that the 
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fluorescence signal obtained in these and any further experiments represent NR molecular 
changes happening in the unique chemical environment of the non-aqueous interior of 




Figure 4.4 NR fluorescence emission spectrum in 50% acetone: octanol (v/v) solution showing the 
Em λmax   = 618 nm.  
 
(4.4.2) Linear dependence of fluorescence intensity of NR on concentration 
The concentration dependence of fluorescence emission intensity was determined by 
titration of NR into acetone prior to performing any quenching experiments. The 
fluorescence response was found to be linear in the range 0-1 μM NR as depicted in Fig. 4.5 
with an inset showing that the response obtained was still proportional to increasing NR 
concentration up until at least 5 μM NR. However, to avoid any inner-filter absorption 
effects (IFE), the concentration of NR for all SV experiments was kept low at 1 μM. It is well 
established that fluorescence measurements performed at sufficiently low concentrations of 
fluorophore that exhibit a linear proportionality of fluorescence intensity with concentration 





(4.4.3) Fluorescence of NR in the presence of Fe(III)PPIX:  
(4.4.3.1) Quenching investigation 
The effect of 35 μM Fe(III)PPIX on NR in MeOH is depicted in Figure 4.6. MeOH was chosen 
as a solvent in which both NR and Fe(III)PPIX are soluble. To confirm that the decrease in 
fluorescence intensity observed in Fig. 4.6 is a result of quenching and not an artifact of the 
IFE arising from the inherent optical absorption of NR and Fe(III)PPIX, at the relevant 
conditions under the which the experiment was conducted, a correction (Eqn. 2.5.6) was 
applied. There are two components to the IFE correction. Firstly, the primary inner filter 
effect (PIFE) is a decrease in intensity of the excitation energy due to the optical absorption 
of the fluorophore and quencher at the excitation wavelength. Secondly, the secondary 
inner filter effect (SIFE) accounts for a fluorescence intensity decrease that occurs due to 
fluorophore and quencher absorption of at the emission wavelength.306 
 
Figure 4.5 Linearity of NR fluorescence emission signal with concentration in acetone excited at 540 
nm with Em λmax 609 nm, r
2 = 0.98. Error bars represent the SEM (n=3). 









































Figure 4.6 The effect of addition of Fe(III)PPIX on NR fluorescence emission. The quenching effect 
manifests as a decrease in fluorescence intensity. 
 
The PIFE is of greater concern because excitation wavelengths are always shorter than 
emission wavelengths and thus correspond to greater overlap with the absorption band. 342 
A decrease in fluorescence intensity without any change in Em λmax or spectrum shape as 
observed in Fig. 4.6 is typical of dynamic fluorescence quenching.308 From this observation it 
already seemed likely that the quencher, Fe(III)PPIX, was not inducing a stronger absorption 
or an absorption band shift relative to the absorption of the fluorophore arising from some 
molecular interaction. For example, the formation of new fluorescent complex between NR 
and Fe(III)PPIX.343 
It is generally accepted that the inner-filter correction is not necessary for quencher solution 
absorbance of <0.2 in excitation and or emission wavelength regions.341,344 Recent 
investigations however, have shown that for situations where Stern-Volmer (SV) quenching 
occurs with high inverse KSV values of 50 M
-1 even if the quencher absorbance is lower than 
0.02 absorbance units, the correction needs to still be applied in order to gain corrected KSV 
values that serve as an accurate reflection of dynamic quenching.345 This was revisited upon 
analysis of KSV values obtained in section 4.4.2.5. The absorbance spectra obtained for all the 
relevant components are presented in Figure 4.7 for a comparative reference. Both the 
excitation (540 nm) and the emission (618 nm) maximum wavelength absorbance values of 
the fluorophore and quencher chromophores, as well as the medium of the experiment, the 





Due to their colloidal nature, the turbid SNLBD solution displays a high background 
absorbance resulting from light scattering by the lipid droplets as seen in Fig. 4.7. To simplify 
the correction, the absorbance of the SNLBDs was excluded from the calculation, as its 
concentration was constant across all experiments unless specifically varied and while it was 
necessary to detect a NR fluorescence signal, the lipid was presumed to affect NR quenching 
equally for all experiments. The absorbance of 1 μM NR and 35 μM Fe(III)PPIX in MeOH at 
the Ex and Em λmax was found to be 0.27 and 0.22 absorbance units, respectively. This yields 
an IFE correction calculated at 3.1 % for fluorophore and quencher chromophore 
absorbance combined. 346 This value agrees well with reported IFE corrections for this type 
of fluorescence spectrophotometer (Varian Cary Eclipse) which inherently minimizes the 
PIFE due to the use of horizontal slits allowing the measurement of fluorescence of solutions 
of high absorbance.347 To further confirm that the apparent quenching observed is not 
merely a result of increasing Fe(III)PPIX concentration and thus increasing optical density of 
the solution, but due to an interaction between NR or NR* and Fe(III)PPIX, a variety of 
methods were employed. 
 
 
Figure 4.7 UV-vis absorbance spectra of SNLBDs, the fluorophore, NR, and the quencher, Fe(III)PPIX, 
over the range 300-700 nm. The excitation and emission wavelengths of interest are highlighted for 
application to the inner filter effect correction. The concentration conditions were as follows: [NR] = 
1 μM, [SNLBDs] = 100  μM and [Fe(III)PPIX] = 35 μM dispersed in 20 mM aq citrate buffer, pH 4.80.  
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(4.4.3.2) Dependence of fluorescence intensity on NR concentration in SNLBDs with and 
without Fe(III)PPIX 
In order to infer the relative partitioning of Fe(III)PPIX into NR-labelled SNLBDs by 
measurement of NR fluorescence quenching, an initial determination of a constant NR 
fluorescence intensity in SNLBDs was established. Fig. 4.8 shows the fluorescence emission 
intensity of NR titrated into SNLBDs. The initial response of fluorescence emission intensity 
measured at an Em λmax of 618 nm with increasing NR concentration up to 0.25 μM NR was 
linear, obeying the Beer’s Law relationship, which is indicative of non-self-associative 
fluorophore behaviour.299 A further increase of NR concentration revealed a levelling-off of 
fluorescence emission intensity until a consistent signal was obtained at 1 μM NR. This 
situation was interpreted as one where the fluorescence intensity measured at 618 nm was 
from SNLBDs saturated with NR such that any increase in NR concentration would not 
produce a further increase in fluorescence intensity monitored from that concentration of 
lipid. This has been visualised for NR stained MSG SLBDs by confocal microscopy.348 
Fluorescence kinetic studies were performed on these samples for 15 min, which confirmed 
that an unchanged equilibrium signal was achieved for 1 μM NR. Finally, the initial 
fluorescence intensity reading, 𝐼0 ,  for NR labelled SNLBD preparation at each pH tested was 






Figure 4.8 The effect of titrating 10 μM NR stock solution alone (purple line) into SNLBDs (100 μM) up 
to a concentration of 1 μM. The linear response for increasing fluorescence signal with increasing NR 
concentration (at low concentration) is highlighted with the signal response shown to be steady at 1 
μM NR (r2 = 0.989). NR titration (red line) into Fe(III)PPIX+SNLBDs at 37.43 μM Fe(III)PPIX was found 
to be linear (r2 = 0.99) beyond 1 μM NR. 
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A titration of NR into SNLBDs in the presence of 37.43 μM Fe(III)PPIX solution was performed 
and the results are presented in Fig. 4.8 for comparison. In the presence of Fe(III)PPIX, the 
decreased fluorescence emission intensity is due to the dynamic quenching of NR signal and 
it is important to note that the linear concentration response is maintained beyond a 
concentration of 1 μM NR. It has been pointed out that, if fluorescence changes observed 
correspond to low enough concentrations of fluorophore and quencher to produce a linear 
signal, all inner filter effects can be ignored.347 This seems to be the case here since the 
Beer’s Law relationship is maintained.299,349 These conditions were selected as ideal for 
further quenching experiments and in order to achieve consistency between 𝐼0  readings and 
these concentrations were maintained throughout. 
(4.4.4) Fe(III)PPIX quenching of NR in SNLBDs: Static vs Collisional Quenching 
As introduced in Chapter 2, there are two main types of quenching which are relevant to this 
study; static and collisional. The differences between the two types may be explored in order 
to gain further information about the mechanism of quenching prevailing in the system of 
interest.309 Two methods were employed to infer whether the quenching process occurring 
for NR stained SNLBDs in the presence of Fe(III)PPIX adhered to a mechanism of either (a) 
static quenching through the formation of a non-fluorescent ground-state complex between 
NR (fluorophore) and Fe(III)PPIX (quencher). Or (b) collisional quenching, a diffusion- and, 
hence time-, temperature- and viscosity-dependent process.308 The temperature and 
viscosity dependence of NR fluorescence quenching in the presence of Fe(III)PPIX was used 
to distinguish between static and dynamic quenching (see Chapter 2, section 2.6 for 
theoretical background). Linear SV plots (Eqn. 2.5.3) with slopes equal to KSV were obtained 













Figure 4.9 (a) Linear SV plots of Fe(III)PPIX quenching of NR-labelled SNLBDs at pH 7.51, at 25°C 
 (r2 = 0.98) and elevated temperature of 45°C (r2 = 0.99) to demonstrate the diffusion response. In 
(b) UV-vis absorbance spectra of 5 μM NR + 100 μM Fe(III)PPIX in MeOH and a mixture of the two 
solutions, as well as the calculated difference between the mixture and NR, are shown. 
 
Collisional quenching at elevated temperatures results in elevated diffusion coefficients and 
bimolecular quenching constants (𝑘𝑞) which are expected to increase with increasing 
temperature.350 Therefore the slope and hence KSV of a SV plot conducted at 45°C is 
expected to be larger than the corresponding KSV value at 25°C. This situation is observed for 
Fe(III)PPIX quenching of NR fluorescence in SNLBDs, with KSV at 25°C = 0.0196 ± 0.0005 and 
for KSV = 0.0222 ± 0.0004 at 45 °C. This can be interpreted in terms of concentration of the 
111 
 
quencher, [Fe(III)PPIX], at which 50% of fluorescence is quenched , KSV
-1  (i.e.    
𝐼𝑜
𝐼
= 2 ), 
corresponding to  51.2 μM and 45.0 μM respectively. 
For static quenching, an increase in temperature is likely to result in a decreased stability of 
the ground state fluorophore-quencher (NRQ) complex formed and a lower value of the 
static quenching constant (Ks) is expected. This is not observed for the system under 
investigation. In the absence of time-resolved fluorescence experiments to determine if the 
fluorescence lifetime, 𝜏0 , without the quencher is affected, the possibility of formation of a 
ground state FQ complex was explored instead. For this purpose, UV-vis absorption spectra 
were used to differentiate between the two types of quenching. 
Static quenching requires the formation of a ground-state complex between NR and 
Fe(III)PPIX and would therefore result in a change in the native absorbance spectrum of both 
the NR and the Fe(III)PPIX.351 This was investigated by measuring the UV-vis absorbance 
spectrum of NR, Fe(III)PPIX and a mixture of the two solutions in MeOH from 250-750 nm , 
see Figure 4.9(b). The difference between the absorbance spectrum obtained for 
Fe(III)PPIX+NR  and the spectrum obtained is presented to indicate any possible variance 
between the two. Collisional quenching affects only the excited state of the fluorophore and 
is thus not expected to alter the absorbance spectrum observed for NR. The absorbance 
maxima of both NR and Fe(III)PPIX remain unchanged indicating that the ground state of 
both species were unaffected and no appreciable complex is formed. Indeed, the UV-vis 
spectra obtained for the NR+Fe(III)PPIX mixture appears to be a simple combination of the 
two. Clear examination of the mixture spectrum obtained when the UV-vis spectrum of NR 
was subtracted from it, confirmed that essentially no change occurs and thus strongly 
indicates that  the quenching type is collisional.352  
(4.4.5) The effect of pH on Fe(III)PPIX quenching of NR in SNLBDs 
The lipid-aq interface as well as the hydrophobic lipid droplet interior represent two unique 
physicochemical environments that are thought to facilitate the nucleation and growth 
processes of the crystallisation of Fe(III)PPIX to form Hz. The interface, composed of long 
chain acyl glycerols, which are exposed to the polar acidic aq surroundings of the DV, offer 
what is postulated to be a template for the epitaxial growth of the crystal. 126,127 
112 
 
Alternatively, the inner leaf of the diacylglycerol phospholipid membrane of the DV has been 
proposed as the site of Hz heterogeneous nucleation as revealed by water-window X-ray 
imaging. 324 Modelling of the molecular contacts between free C=O of propionic acid groups 
on the 100 face of Hz and the OH moiety of the acylglycerols has supported the proposal of 
epitaxial growth.130 These studies also propose that Hz crystal growth occurs within the aq 
environment of the DV, citing the inhibitory action of water-soluble antimalarials as the 
evidence for this. Later studies showed β-haematin (βH) crystals, (isostructural with Hz) to 
be in contact with the surface of the SNLBDs in vitro and suggested that in the absence of 
definitive evidence of the biocrystallisation process in contact with lipid droplets in vivo, the 
process may indeed occur at the inner leaflet of the DV membrane bilayer.126 Regardless of 
the exact lipid interface that mediates Hz formation in vivo, an investigation of the nature of 
Fe(III)PPIX interaction with lipids was necessary. To achieve the primary objective of this 
study, assessment of the partitioning of the Hz precursor, Fe(III)PPIX, into NLBDs over a large 
pH range was conducted. 
The introduction of soluble Fe(III)PPIX to an aq suspension of NR stained SNLBDs resulted in 
the quenching of the NR fluorescence in a concentration dependent manner. This data was 
collected up to at least 50 μM Fe(III)PPIX at a constant NR+SNLBD concentration in separate 
experiments from pH 2.80-12.00 to yield linear SV quenching plots with y-intercepts of 1 and 
KSV from the slopes. All SV plots obtained for Fe(III)PPIX quenching of NR-labelled SNLBDs 
demonstrated this behaviour, indicative of a single class of fluorophores detected at the Em 
λmax of 618 nm, all of which were equally accessible to the quencher (see Chapter 2, Section 
6.2.5).  Figure 4.10 shows two examples of the SV plots obtained which were collected at 
two pH values of interest, where (a) pH 4.80 is the approximate pH of the DV aq medium and 
(b) pH 7.00 represents the pH region where the axial ligand attached to the Fe3+ metal centre 
begins to convert from H2O to OH
-.72 It is noted that typical KSV values achieved are 









Figure 4.10 Linear SV plots for NR quenching at pH (a) 4.80 (r2 = 0.89) with KSV
-1
 = 17.6 μM and (b) 
7.00 (r2 = 0.96) and KSV
-1
 = 30.0 μM to illustrate quenching dependence on pH. Error bars represent 
the SEM (n=5). 
 
In Fig. 4.10, it is shown that for, the pH prevalent in the parasite DV, roughly 1.5 times less 
Fe(III)PPIX is required to quench 50% of NR fluorescence than under neutral pH conditions. 
KSV is the product of the fluorescence lifetime of the fluorophore (0) and the bimolecular 
quenching constant (kq) (introduced in Chapter 2.5, Eqn. 2.5.3). It is not expected to change 
as a function of pH because the lipid-interior of the NR-labelled SNLBDs is not likely to be 
altered by the pH of the aq medium. KSV was found to be dependent on pH of the aq 
medium. Since the observed NR fluorescence signal arises only from the interior of the 
SNLBDs, the variation in KSV
-1 in SNLBDs obtained from pH over the range tested, likely 
reflects the amount of Fe(III)PPIX that partitions into the SNLBDs.  
The relative partitioning of Fe(III)PPIX into the neutral lipid interior of SNLBDs appears to be 
related to the prevailing axial ligand and thus molecular charge of Fe(III)PPIX in aq solution at 
a particular pH. This is shown in Table 4.1. For example, under aq acidic pH conditions (< pH 
2.5), Fe(III)PPIX has an overall charge of +1 due to summation of the 3+ contribution of the 
metal ion and the 2- charge on the porphine core of coordinated  protoporphyrin IX. Neither 





Table 4.1 Expected partitioning of Fe(III)PPIX over the pH range investigated based on 
protonation state of the axial ligand attached to Fe(III) central atom. 
pH 
Axial 






































refers to the concentration of Fe(III)PPIX in SNLBD estimated from KSV 
 
Thus at very low pH, charged Fe(III)PPIX is not expected to partition well into neutral lipid 
bodies and more Fe(III)PPIX will be required to quench 50% of NR fluorescence (large Ksv
-1), 
since only a small fraction of uncharged Fe(III)PPIX will partition into the hydrophobic 
interior of the SNLBD where NR resides.  As the pH increases to about pH 5.5, deprotonation 
of one of the propionic acid groups occurs and partitioning of Fe(III)PPIX (μM) is predicted to 
increase to a maximum for the neutral species, resulting in a maximum Ksv value. At alkaline 
pH as the overall Fe(III)PPIX charge becomes negative, it is expected to decrease again. The 
results, presented as the log KSV or relative partitioning coefficient of Fe(III)PPIX with 
115 
 
increasing pH in Figure 4.11 confirm the expected trend between pH 2.5 and 8, such that the 
data is shown to adhere to a sigmoidal curve.  Of the most interest is the relative partitioning 
of Fe(III)PPIX at the pH values corresponding to that of DV and cytosolic pH where Fe(III)PPIX 
is most likely neutral and anionic respectively (see Table 4.1 and Fig. 4.11). The relatively 
large data scatter is an inherent result of working with SNLBDs, which scatter light strongly. 
 
 
Figure 4.11 Quenching parameter (log Ksv) of NR labelled SNLBDs by Fe(III)PPIX vs pH of the aq 
medium in which lipid droplets were dispersed. Fitting to an equilibrium equation allowed the 
putative propionate pKa1 of Fe(III)PPIX to be obtained. The fitted value was 4.62 ± 0.09. 
 
The data obtained from at least triplicate experiments for each pH value show a decrease in 
log Ksv from low pH to neutral and higher pH values which is attributed to an increase in local 
concentration of Fe(III)PPIX inside the NLBD as predicted by Table 4.1. The pH profile of 
Fe(III)PPIX partitioning into SNLBDs could be fitted to a protonation model with a single pKa  
value of 4.62 ± 0.09. The value of Ksv was 0.021 ± 0.003 M
1 in the deprotonated charged 
form (pH 7.51) and 0.124 ± 0.007 M1 (pH 2.85) in the protonated form. Assuming that this 
difference arises solely as a result of increased Fe(III)PPIX concentration in the SNLBDs, this 
indicates a 6 ± 1 fold increased accumulation of the protonated relative to the unprotonated 
form of Fe(III)PPIX in SNLBDs.   
It is interesting to note that the pH partitioning profile observed for Fe(III)PPIX resembles the 
reported pH-dependent profile for the formation of βH.127 NLDs have been shown to 
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effectively induce βH formation with the greatest conversion of Fe(III)PPIX occurring at acidic 
pH values between pH 3 and 5. The %βH formed is markedly decreased at pH values lower 
or greater than the pH conditions where Fe(III)PPIX is neutral. The authors attributed this 
trend to the ionisation states of βH at low acidic and basic conditions where both propionic 
acid groups are unionised and ionised, respectively. In the presence of SNLBDs, the observed 
trend in Fe(III)PPIX lipophilicity with pH may also account for the effective lipid-mediated 
conversion of Fe(III)PPIX into βH under DV pH conditions through lipid partitioning.135  
Indeed, the observation here supports the hypothesis that lipid interiors are the most likely 
site of βH formation. 
(4.4.6) Attempts to measure Fe(III)PPIX partitioning constant, 𝑲𝒑 
As discussed in chapter 2 (section 2.5.2), evaluation of the partition coefficient,  𝐾𝑝 , is in 
principle possible for the quencher, Fe(III)PPIX, that partitions into the interior of SNLBDs 
dispersed in aq bulk solution. 311–313,318 Unfortunately, the data scatter was simply too large 
to obtain meaningful values for 𝐾𝑝. Other attempts to obtain 𝐾𝑝 of Fe(III)PPIX from the ratio 
of the amount of NR quenching that occurred in SNLBDs (𝐾𝑆𝑉  SNLBD/aq ) and the degree of 
quenching that was measured in a system independent of lipid droplets were made. 
However, due to inherent viscosity differences between the micro-environment of the 
interior of SNLBDs and that of different solvents, this method proved inconclusive.  
(4.4.7) Measurement of log DOW for Fe(III)PPIX partitioning between octanol 
and water 
Since log Dlipid could not be determined directly from KSV data the best alternative was to 
measure the octanol-water partitioning of Fe(III)PPIX at pH 7.51 where it is soluble in both 
media. This was done by the shake flask method illustrated in Fig. 4.12. Equation 4.4.1 was 
used to arrive at a distribution constant, log DOW, of 1.8. Monomeric Fe(III)PPIX was ensured 
by performing the distribution experiment using pH 7.5 aq HEPES buffer as well as the 
addition of a 5% pyridine solution to the aq portion following separation of the layers, prior 
to measurement.253 The pKa used to calculate log P was 4.62 determined from the 
protonation model in Fig. 4.12. This value led to a log P for Fe(III)PPIX in its neutral form of 
2.8 (calculated using Eqn. 4.4.4). A log P > 0 implies the majority of the Fe(III)PPIX can be 
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Figure 4.12 The system and equations used to determine the octanol-water partition coefficient 
of Fe(III)PPIX by the shake-flask method. Ka denotes the propionic acid dissociation constant.  
 
This study reaffirms the lipophilic behaviour of Fe(III)PPIX agreeing with several literature 
reports on the ability of Fe(III)PPIX to traverse membranes and cause haemolysis.354,355 One 
study found CO-haem to be readily taken up by phospholipid vesicles in a manner that was 
dependent on membrane thickness and haem or Fe(III)PPIX speciation.356 To date no 
measurements of log D or log P are available in the literature for Fe(III)PPIX.  However, lipid 
vesicle partitioning studies on mesoporphyrin IX and deuteroporphyrin IX (pictured in Fig. 
4.13) have reported that deuteroporphyrins transfer more rapidly through bilayers upon 
decreasing the pH from 7.5 to 6.5, inferring that the passive transport of porphyrins is 
controlled by pH and ionisation state.357 Further studies found zinc protoporphyrins partition 
into membranes with their charged propionates near the lipid-aq interface.358  
       log 𝐷𝑂𝑊 = log
[Fe(III)PPIX]𝑜𝑐𝑡𝑎𝑛𝑜𝑙
[Fe(III)PPIX] 𝑎𝑞 𝑏𝑢𝑓𝑓𝑒𝑟
                        (4.4.1) 
 







                   (4.4.2)        
                    log 𝐷𝑂𝑊 = log 𝑃 + log
1
[1 + 10(p𝐾𝑎1−𝑝𝐻)]
                    ( 4.4.3) 
  
                        log 𝑃 = log 𝐷𝑂𝑊 + log[1 + 10





Figure 4.13 A schematic structural representation of the porphyrins; (a) protoporphyrin IX (vinyl 
group), (b) mesoporphyrin (ethyl group) and (c) deuteroporphyrin (H atoms) The red circle 
represents the structural differences in R group on pyrrole subunits.  
 
Actual log Dow measurements have been attempted for some porphyrin derivatives to 
compare with the predicted log P and log DpH 7.3 coefficients against lipid vesicle 
partitioning.359 Protoporphyrin IX (no metal group) was predicted to have a distribution 
coefficient at pH 7.3 of 2.01 and log P of 7.27 and ionisation constants of the propionate 
groups of 4.47 and 4.79 with experimental measurement of log D pH 7.3  of 2.12 ± 0.21 and a 
calculated log P > 5. Although, inclusion of a metal in the porphyrin core is expected to affect 
the lipophilicity of the compound, the hydrophobic nature is not expected to be radically 
changed. In a biological context, Hz has been found to be associated with and inside 
hydrophobic lipid structures within the Schistosoma mansoni parasite or blood- feeding 
organism, R. prolixus.58 The observed lipophilicity of Fe(III)PPIX supports the proposal that in 
vivo free Fe(III)PPIX concentrates in the millimolar range inside these lipid bodies to facilitate 
its conversion to Hz crystals. This data confirms the lipophilicity of the protoporphyrins and 
highlights the plausibility of the hydrophobicity parameters obtained for Fe(III)PPIX in this 
work, which is the first report of an experimentally-measured distribution coefficient and 
calculated partition coefficient of Fe(III)PPIX between aq and lipophilic environments. 
(4.5) NR fluorescence quenching by Fe(III)PPIX in the presence of antimalarial 
drugs 
Drugs belonging to the quinoline class of antimalarials have been shown to be potent 
inhibitors of the conversion of Fe(III)PPIX to βH in vitro and Hz in vivo.195,202,258,354 Leading 
theories on the mechanism of action of these types of antimalarials involve the formation of 
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a drug-Fe(III)PPIX complex in solution.215,230,360 The strength and resulting potential toxicity 
of such a complex is postulated as a measure of efficacy of antimalarial action.246,360 The 
removal of free Fe(III)PPIX from solution also leads to the formation of less Hz, causing a 
toxic build-up of Fe(III)PPIX in the DV.195 Understanding the effect of these antimalarials on 
the lipid partitioning behaviour of Fe(III)PPIX is a key objective. Monitoring the addition of 
these antimalarials to Fe(III)PPIX, resulting in a drug-Fe(III)PPIX complex, which is 
preferentially partitioned into or out of the lipid droplets and is either more strongly 
lipophilic or allowed to accumulate in the aq media is of great mechanistic interest. Indeed, 
the drug, CQ has been shown to cause a build-up of Fe(III)PPIX out of the DV, in the parasite 
cytoplasm at the trophozoite stage of its life-cycle, in a manner that has been linked to its in 
vivo efficacy.195  This work aims to gain further insight into the lipophilicity of drug-Fe(III)PPIX 
complexes and the possible role they play in drug activity.  
 
(4.5.1) The effect of known antimalarials on fluorescence of NR labelled 
SNLBDs   
As in section 4.4.1, NR labelled SNLBDs were prepared and the fluorescence spectrum was 
recorded to ensure that there was a consistent fluorescence emission signal matching that 
obtained in Fig. 4.2.  Fluorescence quenching by halogen-containing compounds has been 
reported to occur via a similar mechanism to the heavy-metal atom quenching of NR 
fluorescence investigated for Fe(III)PPIX.296 Given that the 4-aminoquinoline class of 
antimalarials chloroquine (CQ) and amodiaquine (AQ) contain a Cl atom, their potential to 
quench NR fluorescence was first investigated. For the quinoline methanol class of 
antimalarials – quinine (QN) and its diastereomer, quinidine (QD) – the non-interference of 
their inherent fluorescent properties was also investigated, although they were considered 
unlikely to cause any apparent quenching, as they do not contain a heavy atom. The 
possibility of increasing the absorbance of incident light magnifying the IFE by inclusion of 




), upon addition of aq solutions of antimalarial drugs CQ, AQ, QD and QN to NR-
labelled SNLBDs over the pH range 2.80-12.00 was investigated. Figure 4.14 shows the linear 
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SV plot from Fig. 4.10(a) in section 4.4.5 for Fe(III)PPIX quenching of NR fluorescence 
alongside the results obtained for the titration of each antimalarial tested at pH 4.80. 
 
 
Figure 4.14 SV plot to investigate the possible quenching effect of antimalarial drugs, chloroquine 
(CQ), amodiaquine (AQ), quinine (QN) and quinidine (QD) on NR fluorescence in SNLBDs in aqueous 
solution at pH 4.80. The linear SV plot obtained for Fe(III)PPIX quenching of NR fluorescence in 
SNLBDs is included for comparison.  
 
As depicted in Fig. 4.14, negligible changes in the initial fluorescence intensity, 𝐼0, were 
observed as each drug was titrated into the NR+SNLBD suspension up to a total drug 
concentration of 2.5 mM. This final concentration was considerably larger than the 1 μM NR, 
so that any additional inner filter effects ought to be evident as a considerable change in 𝐼 at 
the maximum drug concentration. When compared to the quenching of NR fluorescence 
observed for Fe(III)PPIX in Fig. 4.14, the drugs display only minor fluctuations about the 𝐼0 
value recorded. This small change relative to  𝐼0 was also observed for all other pH solutions 
examined for the antimalarial drugs tested. This invariance with concentration can be 
ascribed to two possibilities, the first being simply that the antimalarial drugs tested do not 
enter the lipid environment of NR-labelled SNLBDs at the pH values under investigation. 
Warhurst et al. have measured the log POW and calculated log D at physiologically relevant 
pH values of 5.2 and 7.4 for the quinoline antimalarials investigated here. 238,257 Table 4.2 




Table 4.2: Lipophilicity parameters of quinoline based antimalarials obtained from Warhurst et al. 
(Reproduced data from Table 1 with BioMed Central open access Charter permission)257 
 
DRUG pKa 1 pKa 2 log P  Log D 5.2 Log D 7.4 
CQ 10.18 8.38 4.72 -3.44 0.96 
AQ 8.66 7.05 4.26 -1.00 2.83 
QD 8.58 4.12 3.17 0.30 1.97 
QN 8.58 4.42 2.84 0.40 1.66 
 
The log P values reported indicate that all the unionised forms of each quinoline antimalarial 
are strongly lipophilic and thus are expected to partition into the SNLBD. Under acidic DV pH 
conditions, the log D values show that the 4-aminoquinoline drugs (CQ and AQ) are in fact 
hydrophilic and not expected to partition into a lipid environment. While this could provide 
an explanation for the observed lack of halogen quenching of NR fluorescence at low pH, it 
cannot account for the lack of effect at neutral and higher pH. The quinoline-methanols (QD 
and QN) are reported to be lipophilic under all relevant pH conditions and thus some lipid 
accumulation is expected. This indicates that the reason for the observed lack of effect of 
quinoline antimalarials on NR fluorescence is likely simply an absence of interaction between 
excited state NR and the drugs.  This is fortuitous, since it means that any differences 
obtained in the quenching behaviour of Fe(III)PPIX in the presence of these antimalarials will 
be due to changes in the distribution of Fe(III)PPIX between aq solution and lipid. This 
change must arise from the formation of a drug-Fe(III)PPIX complex and is independent of 
any spurious drug-NR effects. 
 
(4.5.2) The effect of antimalarials on Fe(III)PPIX fluorescence quenching of NR 
labelled SNLBDs : A pH study 
To investigate the effect of these drugs on the pH-dependent partitioning profile established 
for Fe(III)PPIX into NR-labelled SNLBDs (section 4.4.5), a concentration of 500 μM drug, 
where no drug quenching of NR fluorescence was evident (Fig. 4.14) was incorporated into 
the NR+SNLBD system prior to any Fe(III)PPIX addition. The Fe(III)PPIX-induced quenching of 
NR fluorescence was measured in SNLBDs dispersed in diluted aq drug medium over the pH 
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range 2.8-12.0 to generate linear SV plots for each drug. Any change observed from the pH 
partitioning profile of Fe(III)PPIX (Fig. 4.11) is as a result of the formation of a drug-Fe(III)PPIX 
complex that displays unique lipophilicity behaviour based on the physicochemical 
properties of each drug. The plots produced for a representative antimalarial drug, CQ, are 
presented in Figure 4.15(a). The log of the slopes (KSV values) obtained from those plots were 
used to generate Fig. 4.15(b) to show the pH partitioning behaviour of Fe(III)PPIX+CQ.  
(a) (b) 
  
Figure 4.15(a) SV plots of Fe(III)PPIX quenching of NR fluorescence in SNLBDs over the pH range 2.80-
12.00 with slopes equal to KSV and y int = 1. (b) A partitioning profile (log KSV) showing almost no pH 
dependence of Fe(III)PPIX induced  quenching of NR fluorescence in SNLBDs in the presence of 500 μM 
CQ. Error bars in (b) represent the SEM (n= 4). 
 
The data presented in Fig. 4.15(a) show the distribution of KSV values obtained with all 
quenching constants occurring in a narrow range about a mean value of KSV = 0.02978 ± 
0.0062 μM-1 corresponding log KSV = -1.54 ± 0.09 (Fig. 4.15(b)). The quenching behaviour of 
Fe(III)PPIX in the presence of the 4-aminoquinoline antimalarial CQ (Fig. 4.15(b)) appears to 
be essentially pH-independent in contrast to the sigmoidal pH-dependent quenching 
obtained for Fe(III)PPIX alone (Fig. 4.11). This pH partitioning profile was investigated for the 
other 4-aminoquinoline drug, AQ, and the quinoline methanol drugs, QD and QN. Table 4.3 
summarises the quenching results obtained for each drug for comparison with those of 





Table 4.3: Quenching data, KSV obtained at pH 4.80 and 7.51 for Fe(III)PPIX alone and comparison 











-1   [μM] 
Fe(III)PPIX 0.058 ± 0.004  17.14 0.023 ± 0.001 43.51 
Fe(III)PPIX + CQ 0.028 ± 0.002 35.95 0.033 ± 0.002 30.24 
Fe(III)PPIX + AQ 0.027 ± 0.002 35.19 0.017 ± 0.001 58.72 
Fe(III)PPIX + QD 0.197 ± 0.002 5.08 0.403 ± 0.070 2.48 
Fe(III)PPIX + QN 0.162 ± 0.016 6.18 0.120 ± 0.023 8.36 
 
At each pH, Ksv values and the amount of Fe(III)PPIX required to quench 50% of NR 
fluorescence, KSV 
-1, in the presence of the antimalarials differ markedly from that obtained 
for Fe(III)PPIX alone in a way that reflects the differences in each drug’s subclass. Indeed, 
this partitioning behaviour of drug-Fe(III)PPIX complexes can be seen in a plot of log KSV 
obtained for Fe(III)PPIX in the presence of each antimalarial over the pH range, displayed in 
Figure 4.16. The data were found to fit to a two-step protonation model as opposed to the 
single step model used for Fe(III)PPIX alone (Fig. 4.11) to account for the two protonation 
sites on each of the antimalarials used. 257,361  
The results show that in the presence of 4-aminoquinoline antimalarials (CQ and AQ) there is 
little change in the partitioning of Fe(III)PPIX over the whole pH range. Both drugs appear to 
decrease the observed capacity of Fe(III)PPIX to enter SNLBDs under acidic pH conditions 
where Fe(III)PPIX alone displays maximum lipophilicity. This behaviour is attributed to the 
formation of a charged complex between the 4-aminoquinolines and Fe(III)PPIX which 
favours the aq environment over that of the neutral lipid interior of SNLBDs. The differences 
in partitioning of the drug-Fe(III)PPIX complexes at both pH values, is proposed to be as a 
result of the varied  speciation and charge of the complexes, which are known to control 
permeability.362 Although some drugs have been reported to passively cross membranes in 
their ionised forms, the partitioning of antimalarials into neutral lipid droplets is expected to 
be greater for the neutral drug than the charged forms.363 The finding that the neutral form 
of Fe(III)PPIX preferentially partitions into SNLBDs (section 4.4.6) with a log P of 2.8 supports 
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Figure 4.16 Dependence of the log KSV on pH for Fe(III)PPIX quenching of NR in SNLBDs dispersed in 
diluted aq antimalarial solution. The data were fitted to a two-step pKa model for each curve. (Error 
bars calculated as standard deviations of log mean KSV and are smaller than the symbol where not 
seen. 
 
To investigate this, the percentage ionisation and estimated speciation (based on 
protonation state i.e. fully protonated, mono-protonated or neutral) of each drug was 
calculated from the Henderson-Hasselbalch equation based on reported pKa values.
364 From 
these calculations, the suggested charges of each drug and its Fe(III)PPIX complex at the 
relevant pH are displayed in Table 4.4. It must be emphasised that this is a crude 
approximation, since it assumes no changes in the component pKa values in the complex. 
The 4-aminoquinoline, CQ, induces the μ-oxo dimer (Fig. 4.17) form of Fe(III)PPIX in solution 
at pH 7.4  as shown by magnetic susceptibility experiments and Mössbauer spectroscopy (pH 
5.00).70,224 Its structural analogue, AQ, is thought to interact with Fe(III)PPIX in a similar, 1:2 
fashion. Effectively, at certain pH values, the ionisation states of each drug-μ-oxo dimer 
complex can be approximated by the charge of the drugs and of the protonation states of 
the four propionate groups in the μ-oxo dimer (Fig. 4.17). 
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Table 4.4 Speciation and charge of Fe(III)PPIX-drug complexes based on reported drug pKa values and 

















       
Fe(III)PPIXa – 0 – -1 – – 
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+1/0 0 0/-1 
a 
speciation data from Table 4.1 for Fe(III)PPIX alone 
b 
Drug pKa  values from Table 4.2 used to calculate speciation at that pH, first deprotonation at quinolinic N, second 
deprotonation in amino side chain or quinuclidine N. 
c
 Addition of Fe(III)PPIX  (μ-oxo dimer Fe(III)PPIX charge  for 4-aminoquinolines) and predominant drug charges 




Figure 4.17 A schematic of the charge distribution of the μ-oxo dimer at approximately the pH of the 
DV (pH 4.80), the four propionic acid groups are shown in red to illustrate their likely charges at this 




At the DV pH, the likelihood that at least one propionate group is charged, is high, however, 
the presence of the drugs may depress any further protonation of the other propionates to 
lower pH values. Thus the charge of the μ-oxo dimer of (-3) added to that of the drugs (+2) 
results in the formation of a charged drug-Fe(III)PPIX complex (-1) at pH 4.80 (Table 4.4). An 
increase in pH will lead to deprotonation of the propionate group, until at the cytosolic pH, 
with no propionate groups protonated (-4), CQ forms predominantly a -2 complex with the 
Fe(III)PPIX μ-oxo dimer and AQ, which is significantly monoprotonated at that pH, forms a -3 
complex with Fe(III)PPIX. Therefore as the 4-aminoquinolines are expected to form charged 
complexes with the Fe(III)PPIX μ-oxo dimer at both the cytosolic and DV pH, their 
partitioning profiles are not expected to be pH dependent. As is evident in Fig. 4.16, this is 
the case and in fact the partitioning of the charged 4-aminoquinoline drug-Fe(III)PPIX 
complexes was found to be decreased compared to Fe(III)PPIX alone which is neutral 
between pH 2.85 - 5.5. This observation was proposed in an early study on the effects of 
quinoline antimalarials on the intercalation of Fe(III)PPIX into a phospholipid monolayer 
where the authors found that the proposed large amphipathic CQ-Fe(III)PPIX dimer complex 
was unable to intercalate into the lipid monolayer.133  
The quinoline methanols (QD and QN) on the other hand do show a strongly pH-dependent 
change in log Ksv or partitioning. In Fig. 4.16, it can be seen that both drugs induce an 
apparent overall increase in the partitioning of Fe(III)PPIX into SNLBDs over the pH range 
tested. QD appears to produce the most lipophilic complex with the greatest amount of 
Fe(III)PPIX quenching occurring in the presence of this drug under the relevant pH 
conditions. This can be rationalised in the following way, the quinoline methanol drugs, QD 
and QN have been proven by crystal structure to form monomeric complexes with 
Fe(III)PPIX through an alkoxide linkage from the drug to the Fe(III) centre, in the solid 
state.230 The crystals were obtained in non-aqueous solution and it was found that the 
protonated drug quinuclidine nitrogen (N) was involved in a hydrogen bond association with 
the anionic propionate oxygen of Fe(III)PPIX to form the neutral complex seen in Fig. 4.18.365 
The presence of at least one propionic acid group was confirmed by the presence of a IR 
peak at 1702 cm-1.230 The porphyrin charge is -2, the metal is +3 and the alkoxide bond 





Figure 4.18 Representation of the structure of the neutral quinoline methanol-Fe(III)PPIX complex as 
shown from solid state X-ray crystallography.230 The porphyrin ring of Fe(III)PPIX is shown 
schematically to just show the alkoxide bond to the Fe(III)  and one propionate group involved 
information of a salt bridge with the NH+ of the drug quinuclidine ring. 
 
In an aqueous medium this complex would be expected to exhibit a charge distribution 
dependent on the protonation state of the Fe(III)PPIX propionate groups and the nitrogen 
atoms of the drug as determined by the pH of the solution. Fig 4.19 shows the protonation 
state of each component and the likely quinoline methanol drug-Fe(III)PPIX complex formed 
at a particular pH over the range investigated. The charge of the resultant complex formed is 
dependent on the alkoxide bond (-1 charge) between the drug benzylic alcohol 
(deprotonated) and Fe(III) metal and the prevalence of the intramolecular hydrogen bond 
over a certain pH range. At low pH (less than pH 4.4) where all propionates and drug N 
atoms would be protonated, the salt bridge formation would be unlikely and the overall 
charge of a drug-Fe(III)PPIX complex would be +2 resulting in low to moderate partitioning as 
observed in Fig. 4.16. Above pH 4.4, when the quinoline N and presumably at least one 
propionate group would be deprotonated, the formation of the intramolecular hydrogen 
bond is likely and thus the partitioning of the drug-Fe(III)PPIX complex would be expected to 
increase to a maximum for this neutral complex. This is also observed in Fig. 4.16. In fact the 
extent of partitioning for the quinoline methanol drug-Fe(III)PPIX complexes in this pH range 
is larger than observed for neutral Fe(III)PPIX alone indicating that the neutral drug-
Fe(III)PPIX complex is more lipophilic than neutral Fe(III)PPIX. This is probably due to the 
inherent lipophilicity of the individual quinoline methanol drugs with both drugs having a log 
P of greater than the 2.8 calculated for Fe(III)PPIX in section 4.4.7 (Table 4.2). This increase in 
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drug-Fe(III)PPIX complex lipophilicity is maintained even beyond the pH at which the other 
propionate group of Fe(III)PPIX would be deprotonated (pKa reported as  approximately 5-6 
in free Fe(III)PPIX)74,366 and the overall complex charge would be -1 (Fig. 4.19). This increased 
lipophilicity may also be due to the prevalence of the intramolecular hydrogen bond. 
 
Figure 4.19 Schematic representations to show the charge distribution across the pH range 




Possible reasons for this have previously been explored using molecular mechanics 
simulations on Fe(III)PPIX with QD and QN under conditions where their quinuclidine N is 
protonated and propionate groups of Fe(III)PPIX are unprotonated, approximating speciation 
at pH 7.5 in vacuo.228 The formation of an intramolecular salt bridge between the 
protonated quinuclidine N on the drug and the charged propionate group of Fe(III)PPIX were 
shown to be favourable in a non-aq environment with a lower strain energy penality (with 
respect to lowest energy conformation) identified for QD than QN.228 In an aq environment, 
QD-Fe(III)PPIX was found to be more likely to form this intramolecular hydrogen bond, 
independent of medium, owing to preorganisation arising from its fairly rigid structure which 
is not the case for QN-Fe(III)PPIX. The recent publication of the crystal structures of QD-
Fe(III)PPIX highlighted the ease with which QD forms this bond despite the prevalence of 
other hydrogen bond donors in the crystallisation solvent.230  
The propensity to form an intramolecular hydrogen bond in media of low dielectric constant 
was also observed for Fe(III)PPIX complexes with ferroquine and its ruthenium analogue.367 
This was correlated to their increased lipophilicity over other analogues and CQ in open 
conformations and thus enhanced antimalarial activity against sensitive and resistant strains 
in vitro.368 The presence of an intramolecular hydrogen bond would be expected to increase 
the lipophilicity of a complex, given the smaller degree of surface area that is exposed upon 
adopting a folded conformation. Indeed the observed increase in the relative amount of 
partitioning across the pH range for the QD-Fe(III)PPIX complex over QN-Fe(III)PPIX is 
interesting and perhaps can be rationalised in terms of the stereochemical difference 
between QD and QN, which is known to be a source of different chemical and 
pharmacokinetic properties.257,368 QD is also reported to form a stronger complex with 
Fe(III)PPIX in solution, relative to QN and has been shown to be a better inhibitor of βH 
formation in vitro.218,257 In light of these findings, it is proposed that QD forms a more 
lipophilic complex with Fe(III)PPIX due to structural preorganisation that may account for its 
observed increased antimalarial efficacy over its diastereomer, QN.  
The increased partitioning for the QD-Fe(III)PPIX complex and  to some extent also the QN-
Fe(III)PPIX complex relative to Fe(III)PPIX alone appears to persist to pH values above pH 8.5, 
after which the quinuclidine N is deprotonated and the overall charge of the quinoline 
methanol drug-Fe(III)PPIX complex would be -2 (Fig. 4.19). As shown in Fig. 4.16, above this 
130 
 
pH, the partitioning of these complexes was observed to decrease to a minimum, even lower 
than that measured for Fe(III)PPIX alone.  
It must be noted that confirmation of the formation of this type of coordination complex 
between Fe(III)PPIX and the quinoline methanol drugs has so far only been confirmed in the 
solid state where the crystals were formed from evaporation of each solution in organic 
solvents.230 An alternative hypothesis that the same complexes do not form in aqueous 
solution has been suggested even in these crystal structure publications, where the authors 
state that no evidence of this complexation was observed in aqueous solution where 
unchanged UV-vis spectra in the charge-transfer region of Fe(III)PPIX were observed when 
mixed with QD.HSO4 in aqueous solution.
220,230 While it is known that QN associates with 
monomeric Fe(III)PPIX in aqueous solution, whether this association is as a result of direct 
coordination of the benzylic alcohol or π-stacking interactions or both, remains 
undetermined.369 If the drug-Fe(III)PPIX complexes partitioning into SNLBDs are not alkoxide 
coordination compounds, the charge distribution of the complex would simply be a 
combination of the protonation states of the individual components (see Fig. 4.19) over the 
pH range tested. This means that the only pH range at which a neutral complex would be 
formed would be between pH 6-8.6, which may account for the increase in partitioning 
observed for these drugs over this range (Fig. 4.16). The overall increase in lipophilicity 
observed for these drug complexes compared to neutral Fe(III)PPIX alone would then 
probably simply be a result of the contribution of the lipophilic drug to the complex.  
A third hypothesis also exists, in which the coordinating ligand is not an alkoxide but the 
drug benzylic alcohol. Such a model has previously been proposed, since the typical pKa of an 
uncoordinated benzyl alcohol is about 14.3 suggesting that under acidic pH conditions, if 
metal coordination did not depress the pKa drastically, this group would be protonated.
370 
This was addressed for the solid state complexes in the report of the crystal structures by 
analysis of the Fe-O bond length and an IR peak at 1702 cm-1 which was found to be 
consistent with an alkoxide rather than OH coordination, but the possibility that the alcohol 
complex prevails in solution state cannot be discounted.230 This would affect the charge 
distribution of the complexes in the same way as the non-coordination complex discussed in 
the previous paragraph. However, the increased lipophilicity of these complexes over 
131 
 
Fe(III)PPIX can still be explained by the formation of the folded hydrogen bonded structure 
seen in Fig 4.18, with OH as the coordinating ligand instead of the alkoxide.  
Thus, while the exact nature of the quinoline methanol drug-Fe(III)PPIX complex in solution 
remains unclear, the result that these drugs markedly increase the observed neutral lipid 
partitioning of Fe(III)PPIX is clearly shown by the experiments reported in Fig. 4.16. There is 
support for this increased lipophilicity in the literature as QN has been shown to increase 
Fe(III)PPIX phospholipid monolayer intercalation.133 It was suggested that the quinoline-
methanol drug interacts with Fe(III)PPIX differently to CQ in solution and proposed that 
monomeric Fe(III)PPIX, which is the most likely form of Fe(III)PPIX in the QD/QN-Fe(III)PPIX 
complex, exerted a greater effect on the surface pressure of the monolayer than dimeric 
Fe(III)PPIX, implying greater intercalation.  
 
(4.5.3) Evaluating the distribution and partition coefficients, log DOW and log P 
of Fe(III)PPIX in the presence of known antimalarials 
Attempts to directly measure the partitioning of Fe(III)PPIX-drug complexes between octanol 
and water proved unsuccessful owing to changes in the extent of complex formation in each 
layer as a function of concentration. Estimation of the distribution coefficients of Fe(III)PPIX-
drug complexes was attempted by using the sum of the literature log P  values for each drug 
and that calculated using Eqn. 4.4.3 for Fe(III)PPIX, based on the principle of a fragment 
approach utilised in clogP predictions.257,371 This calculation however, assumes that 
formation of the complex does not alter the lipophilicity and acid dissociation constants of 
each of the individual components which experimentally has been proven invalid.372 
Although the effect of these antimalarials on Fe(III)PPIX partitioning into SNLBDs has been 
found to display a pH dependence for the quinoline methanol drugs and not the 4-
aminoquinolines which can be rationalised by the charge of the drug-Fe(III)PPIX complex 




Neutral lipid blend droplets (NLBDs) with non-hollow hydrophobic interiors,  were confirmed 
to form from the unique blend of neutral acylglycerols found in the parasite DV in vitro.124 
Nile Red (NR) was found to localise and fluoresce inside these lipid droplets in a 
concentration dependent manner with Em λmax = 618 nm, establishing the relative polarity of 
these NLBD interiors to be between that of acetone and octanol with an ET(30)  of 45 ± 4 
kcal.mol-1. Soluble Fe(III)PPIX was shown to quench NR fluorescence in a concentration-
dependent manner by a collisional quenching mechanism that conforms to a linear Stern-
Volmer model. The current study has shown, by measuring the extent of this quenching, that 
Fe(III)PPIX spontaneously and rapidly accumulates in SNLBDs. The extent of this localisation 
was found to occur in a pH-dependent manner such that a pH partitioning profile of 
Fe(III)PPIX in SNLBDs was obtained. This pH partitioning profile was found to fit to a single 
protonation model with pKa1 for Fe(III)PPIX of 4.62 ± 0.09. The greatest amount of Fe(III)PPIX 
partitioning into SNLBDs was observed under acidic pH conditions correlating with the 
prevalence of the neutral species of Fe(III)PPIX. Interestingly, this pH dependence was found 
to mirror that of βH formation in the presence of NLBDs.127 Measurement of the octanol-
water partitioning of Fe(III)PPIX revealed a log DOW of 1.8. This allowed the first report of the 
partition coefficient of the unionised form of Fe(III)PPIX (log P), calculated to be 2.8. 
Effectively, this indicates that Fe(III)PPIX is strongly lipophilic suggesting approximately a 
400-fold partitioning of the neutral form of Fe(III)PPIX into SNLBDs relative to the aqueous 
medium.  
Quinoline-based antimalarials were found not to quench NR fluorescence in SNLBDs at any 
pH despite their reported lipophilicity. The 4-aminoquinoline antimalarials form Fe(III)PPIX-
drug complexes that, although they quench NR fluorescence, do so in a manner that displays 
almost no pH dependence. These charged complexes were found to be less lipophilic than 
the individual drug and neutral Fe(III)PPIX at the DV pH. In the presence of Fe(III)PPIX, drugs 
in the quinoline methanol class of antimalarials exhibited a pH-dependent partitioning 
profile with respect to NR quenching with the greatest amount of partitioning occurring 
under acidic pH conditions that approximate those in the parasitic DV. This observation was 
rationalised by their ability to form a neutral complex with Fe(III)PPIX in solution. Quinidine 
(QD) was found to form the most lipophilic complex with Fe(III)PPIX probably due to a 
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previously-established “preorganisation” effect for formation of the intramolecular 
hydrogen bond which results in a relatively closed structure of the complex, increasing its 
lipophilicity.228,230 This relative measure of the effect of known antimalarials on the 
lipophilicity of Fe(III)PPIX is the first report of its kind and the relevance of this trend for 
biological activity requires further investigation. This work also highlighted the difficulty in 
studying lipid systems due to their colloidal nature. Studies on detergents as lipid mimics to 
enable more robust investigation into the nature of Fe(III)PPIX-“lipid” interactions were thus 





















Chapter 5:  
An investigation of the speciation of Fe(III)PPIX in 
amphiphilic solution  
(5.1) Introduction 
Fe(III)PPIX exhibits a complicated speciation profile in solution.72 In aq solution at the 
optimal pH for βH formation (pH 4.80), the dominant Fe(III)PPIX species is the π-π dimer, 
characterised by two five-coordinate Fe(III)PPIX molecules that interact via π-π stacking 
interactions of their non-coordinated faces, with their axial ligands facing outward. 66,72 It 
was recently proposed that the conversion to βH from Fe(III)PPIX π-π dimers is facilitated by 
the spontaneous formation of a carboxylate linkage between one of the propionate groups 
of each Fe(III)PPIX to the Fe(III) centre of the opposite Fe(III)PPIX, assisted by loss of the axial 
ligand in a lipophilic environment.132 The π-π dimer is thought to serve as the nucleation 
precursor of βH.55 After probing the Fe(III)PPIX monomer - μ-oxo dimer equilibrium, 
Casabianca et al. proposed that the strong interaction between the μ-oxo dimer species and 
certain antimalarials, inhibits the conversion to βH in solution.223 The hypothesis that the 
prevailing Fe(III)PPIX species in solution can effectively hinder βH formation in detergent 
solution is explored here.  
Unavailability of the means for direct study of the conversion of Fe(III)PPIX to Hz inside the 
parasite  DV remains a barrier to elucidating the mechanism of its formation. While several 
studies on the behaviour of Fe(III)PPIX in aqueous and organic solvent systems have 
provided insight into its nature, only an indirect comparison between these systems and the 
lipid environment found to be associated with Hz, in the DV, is possible. 66,68,72,373,374 To aid in 
understanding the role of this lipid environment in promoting βH formation, it has been 
proposed that detergents can act as suitable ‘lipid mimics’ for the study of the Fe(III)PPIX 
speciation and the formation of βH.118,375 Several reports have exploited the ability of certain 
detergents to effectively mediate the formation of βH in acidic solution as initiators for 
evaluating the potential βH inhibition activity of lead compounds.154,155 Though these assays 
provide an effective means to determine whether a compound can inhibit βH formation, the 
role of the detergent is not well understood. This chapter aims to investigate the interaction 
between several detergents and Fe(III)PPIX in solution.  
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Detergents comprise of an extensive category of amphiphilic molecules that exhibit unique 
interfacial and surface tension properties that can be classified according to the charge of 
the polar head group.376 The three broad categories are ionic, non-ionic and zwitterionic 
detergents. This study was aimed at investigating the species of Fe(III)PPIX in amphiphilic 
solution and ability to form βH, so that a detergent belonging to each class was initially 
chosen for study. The charged detergents that bear anionic and cationic head groups chosen 
were, sodium dodecyl sulfate (SDS) and hexadecyl-trimethyl-ammonium bromide (CTAB), 
respectively. Neutral detergents, octylphenoxypolyethoxyethanol (NP-40) and 
polyoxyethylene (20) sorbitan monolaurate (TWEEN-20) were selected for further study as 
they have previously been shown to effectively produce βH (Fig. 5.1). 154,155  Finally, for the 
zwitterionic detergent, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate 
(CHAPS) was also chosen. It has been long believed that detergents induce monomeric 
Fe(III)PPIX in solution since Simplicio first showed that haemin monomers exist in SDS 
micelle solution.377,378 Hence, it is often assumed in the literature that all detergents 
monomerise Fe(III)PPIX, however, subsequent spectroscopic investigations have revealed a 
diverse speciation profile in different detergent systems in a manner that may be related to 
the nature of the detergent head group. 223,379 Therefore the main objective of this work was 
to study the effect of detergent monomers and micelles on Fe(III)PPIX speciation in solution 
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(5.2) Experimental Procedures 
(5.2.1) Materials, Instrumentation and General Procedures 
All chemicals used were obtained from Sigma-Aldrich® (Vorna Valley, South Africa) except 
Nonident P-40 (NP-40, Shell Chemical Co.) detergent was obtained from Pierce 
Biotechnology, Rockford, Illinois and was used without further purification. It was stored as a 
167 mM stock solution at 4 °C in the fridge. Detergent stock solutions were prepared from 
standard solutions of each detergent in water in volumetric flasks. All Fe(III)PPIX stock 
solutions were prepared fresh for each experiment by dissolving haematin porcine solid in 
0.1 M NaOH solution. Aqueous drug stock solutions were prepared from the appropriate 
salts.  
(5.2.2) Spectrophotometric titrations 
(5.2.2.1) Determination of the critical micellar concentration (CMC) of detergents 
The detergent CMC was determined in aq buffer solution by monitoring the fluorescence 
intensity response of the lipophilic fluorescent probe, NR, upon increasing detergent 
concentration in the fluorescence cuvette. The technique used was adapted from published 
methodology.161,380 Detergent stock solutions (30 mM) were prepared in acetate buffer (50 
mM, pH 4.80) and diluted step-wise in the buffer in separate volumetric flasks to produce a 
series of detergent solutions of increasing concentration. NR stock solution (10 mM) was 
prepared in methanol and diluted to 1 μM in each aq buffer-detergent solution so that the 
total NR concentration was constant for each reading. Final solutions were mixed well in the 
dark for 1 hr and allowed to equilibrate in a covered cuvette at 310 K for 20 mins prior to 
fluorescence measurement. The excitation wavelength, Ex λmax (550 nm) was determined 
from the peak maximum of NR in the UV-vis absorbance spectrum recorded in an aq-
detergent solution. An aliquot from each solution containing NR+detergent was excited at 
550 nm and the fluorescence intensity response was recorded at 310 K. The change in Em 
λmax was plotted against the concentration of detergent in the cuvette. The CMC value was 
taken as the mid-point of the discontinuity in the plot determined using linear extrapolations 
in GraphPad Prism. The point of intersection of two linear least-squares functions were 
calculated by evaluating the change in the y-intercept divided by the change in the slope for 
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all three replicates. The CMC is reported as the mean with the error estimated as the 
standard error in the mean. 
(5.2.2.2) Investigation of speciation of Fe(III)PPIX in amphiphilic solution over the  
pH range 4.0-8.2 
The changes in intensity of the absorbance profile of Fe(III)PPIX with decreasing pH were 
monitored using UV-vis spectroscopy from 200-800 nm. All experiments were conducted in a 
2 mL 1 cm pathlength quartz cuvette at 298 K. Fe(III)PPIX stock solutions (0.01 M) were 
prepared fresh for each experiment from 0.1 M NaOH. A working solution of Fe(III)PPIX in 
the appropriate detergent was prepared by diluting the Fe(III)PPIX in an aq detergent 
solution, the final Fe(III)PPIX concentration was 100 μM and the detergent concentration 
was either (i) below or (ii) above the CMC determined in 5.2.2.1. The final concentrations 
used for each detergent are listed in Table 5.1. 
Table 5.1 Tabulated concentrations (M) of each detergent used for study either below or above the 
CMC values determined in 5.2.2.1. 
Detergent Below CMC (M) Above CMC (M) 
SDS 4.0 X 10-3 16.0 X 10-3 
CTAB 0.5 X 10-3 6.00 X 10-3 
 NP-40 1.0 X 10-4 6.50 X 10-4 
TWEEN-20 4.0 X 10-5 2.5 X 10-4 
CHAPS 3.0 X 10-3 12.0 X 10-3 
 
 This working solution was diluted in aq CHES buffer (0.02 M) solution so that the initial 
volume and concentration of the Fe(III)PPIX solution was 1 mL and 7.45 μM at pH 8.15. All 
titrations were performed by lowering the initial pH with μL additions of perchloric acid of 
variable concentrations using a Hamilton syringe, the pH was measured after each addition 
and the spectrum recorded after 2 min to allow for equilibration. A continuous blank 
absorbance of the background was automatically subtracted from the spectrum by titrating 
acid into a solution containing all the experimental constituents except Fe(III)PPIX. Each 
absorbance spectrum was individually corrected for dilution.  
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(5.2.2.3) Association constants of Fe(III)PPIX and antimalarial drugs in NP-40 solution 
NP-40 solution (0.2 mM) and HEPES buffer (20 mM) were premixed to prepare aq 
buffer+detergent titration solutions at pH 7.5. Aqueous drug stock solutions (0.1 mM) were 
made and added to the NP-40 and HEPES buffer solution so that the working solution 
concentration of drug was 0.02 mM. Fe(III)PPIX stock solution (1 mM) was prepared from 
haematin solid dissolved in 0.1 M NaOH and the aq buffer-detergent solution. Fe(III)PPIX 
solution was titrated in μL amounts using a Hamilton syringe into the aq drug-detergent 
solution in the sample cuvette. The UV-vis spectrum from 200-800 nm of this solution was 
recorded after each addition.  A reference cuvette served as a blank solution where the 
same volume of the Fe(III)PPIX solvent system was added and its background absorbance 
was automatically subtracted from the sample absorbance. Each absorbance reading was 
corrected for dilution. Titration data were analysed using the HypSpec® software package 
over the wavelength range tested.  
 
(5.2.2.4) Fluorescence emission response of NR in TWEEN-20 solution 
The fluorescence emission response of the dye NR in TWEEN-20 solution was investigated.  
Several solutions of increasing TWEEN-20 concentration from 0 - 0.25 mM were prepared in  
aqueous buffer solution (HEPES, 20 mM) at pH 7.00 and 298 K and premixed with NR (1 μM) 
prior to fluorescence measurement. The excitation wavelength used in section 5.2.2.1 was 
employed to obtain fluorescence spectra. The shift in maximum fluorescence intensity and 
wavelength of the NR emission peak was monitored as a function of increasing detergent 
concentration. A stock solution of Fe(III)PPIX (0.5 mM) was titrated into the maximum NR+ 
detergent concentration solution (0.25 mM) to monitor the fluorescence quenching 







(5.2.3) Job Plots 
To determine the stoichiometric ratio of the Fe(III)PPIX-drug interaction, a Job plot for each 
drug with Fe(III)PPIX was constructed by monitoring the UV-vis changes at the most intense 
absorbance band as the drug and Fe(III)PPIX mole fraction was varied from 0-1.381 All 
solutions were prepared in the solvent system used for determination of drug-Fe(III)PPIX 
association constants in 5.2.2.2. The total combined molar concentration of drug and 
Fe(III)PPIX solutions was kept constant at 20 μM. Drug stock solutions (0.5 mM) were 
prepared in 0.02 M HEPES (pH 7.5) and NP 40 (0.2 mM). Fe(III)PPIX stock solution (0.4 mM) 
was prepared afresh for each experiment by dissolving haematin solid in 0.1 M NaOH and NP 
40 ( 0.2 mM). Fifteen working solutions were prepared containing Fe(III)PPIX present in a 
mole fraction (x[Fe(III)PPIX]) of 0, 0.1, 0.2, 0.3, 0.4, 0.45, 0.5, 0.55, 0.6, 0.65, 0.70, 0.75, 0.80, 
0.9 and 1.00 by varying the volume of Fe(III)PPIX added. The drug stock solution was added 
to this so that each solution contained a mole fraction of drug equal to 1.0 – x[Fe(III)PPIX]. 
Each solution was diluted to the final volume and concentration with the addition of a 
solution of NP-40 (0.2 mM)/ HEPES (20 mM)/ water to maintain the pH and detergent 
concentration. The UV-vis spectrum of each solution was measured at 298 K and analysed at 
the maximum absorbance wavelength.  
(5.2.4) Evaluation of detergent ability to mediate β-haematin formation  
Detergent stock solutions were diluted to the appropriate concentrations listed in Table 5.1 
above and below their determined CMC (section 5.2.2.1) in sodium acetate buffer (0.02 M, 
pH 4.80).  50 mL of this solution was allowed to reach 37°C by pre-equilibration for 30 min in 
five Schott-Duran crystallisation dishes in a thermostatted water bath. A haemin stock 
solution (0.01 M) was prepared in 0.1 M NaOH and added dropwise to the detergent 
solution so that the final Fe(III)PPIX concentration was 100 μM.  The solution was left to 
incubate for 5 h at 37°C. A control experiment was set up and incubated in the absence of 
any detergent. The resultant brown precipitate or solution was collected by centrifugation in 
80 mL transparent polycarbonate Nalgene centrifuge tubes at 10 000 rpm for 20 min using 
an Eppendorf 5810R centrifuge. The clear supernatant was discarded for reactions where a 
precipitate was observed and the pellet was washed with a 30% v/v pyridine stock solution 
(1 mL, 30% pyridine; 40% acetone, 25% H2O, and 10% HEPES buffer (2 M, pH 7.5) to complex 
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unreacted Fe(III)PPIX. After a second centrifugation, the pellet was washed with H2O and 
collected by vacuum filtration. The amount of βH formed (% yield) for each detergent was 
evaluated by quantifying the amount of bis-pyridyl-Fe(III)PPIX complex in a 200 μL extract of 
supernatant, measured by UV-vis absorbance at 405 nm in a clear 96-well plate, in the 
manner of the pyridine hemichrome inhibition (Phi-β) assay previously described by Ncokazi 
and Egan.253 The absorbance value obtained for each sample was subtracted from that of 
the control and converted to a percentage by taking the ratio of that difference and the 
absorbance of the control multiplied by 100. The solid was was dried and stored in a 
desiccator over P4O10 until characterised by IR spectroscopy.  
 
(5.2.5) Surface tension of detergent solutions 
Solutions of each detergent at the concentrations specified in Table 5.1 were prepared from 
acetate buffer (50 mM, pH 4.80) to measure the dynamic surface tension, γ, using a Du Nouy 
ring tensiometer (Kruss K12 with standard platinum ring) and a glass vessel of diameter 50 
mm and height 43 mm. All components were cleaned using absolute ethanol. The detergent 
solution was allowed to equilibrate to 25 ± 1°C in the tensiometer chamber for 5 min prior to 
measurement. All measurements were corrected using a Harkins and Jordan correction.382  
 
 (5.2.6) Magnetic susceptibility 
Magnetic susceptibility measurements of Fe(III)PPIX in detergent solution was performed 
using the Evan’s NMR method (introduced in section 2.3). Fe(III)PPIX solution was prepared 
from haemin solid (0.010 g) dissolved in 0.1 M NaOD (1 mL). The appropriate detergent was 
diluted to a concentration above its CMC in D2O and added to the Fe(III)PPIX solution. The 
required pD was achieved by addition of 1 M deuterated hydrochloric acid (DCl) in μL 
amounts before diluting the solution in a volumetric flask with D2O. The final Fe(III)PPIX 
concentration was either 3.15 or 0.790 mM. This solution (300 μL) was then transferred to 
the inner tube of a co-axial NMR tube. The reference sample in the outer tube was prepared 
from the same components with the exclusion of the Fe(III)PPIX. A diamagnetic correction of 
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-5.09 x 10-7 cm3 g-1 was used (in the manner outlined in section 2.3) to calculate the magnetic 
susceptibility, μ, of Fe(III)PPIX in each detergent solution. 
 
(5.2.7) 1H Nuclear magnetic resonance (NMR) spectroscopy 
Haemin solid (0.010 g) was dissolved in 0.1 M NaOD (1 mL) to afford a 15.34 mM stock 
solution.  An aq TWEEN-20 detergent stock solution (1 mM) was prepared in D2O, the pD 
was adjusted to 7.00 with 0.1 M DCl. The 1H NMR spectrum of the detergent solution was 
recorded at 310 K. The Fe(III)PPIX stock solution was then diluted to 0.5 mM in a deuterated 
aq-detergent solution and the 1H NMR spectrum was recorded at 310 K for comparison.   
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(5.3) Results and Discussion 
(5.3.1) Use of a fluorescent probe to determine the CMC of detergents 
Above a certain concentration in solution, detergent molecules form self-assembled 
aggregates that change the surface properties of the solution.383,384 Below this threshold 
concentration detergents exist as monomers or premicellar aggregates that, upon reaching 
the critical micellar concentration (CMC), form detergent micelles, where the solution is 
characterised by a new set of defined physicochemical properties.159,171 The presence of 
aqueous buffers in addition to a variation in pH and temperature are known to affect the 
CMC of a particular detergent solution.385,386 Thus, any studies performed in the presence of 
a detergent require precise knowledge of the aggregation state of the detergent in the 
solution under the experimental conditions.  The use of detergents to determine the 
behaviour of Fe(III)PPIX in amphiphilic solution was investigated under the prevailing pH and 
temperature conditions of the parasitic DV namely, pH 4.80 and 37 °C. The lipophilic probe, 
NR was employed to measure the CMC of each detergent used by monitoring the increase in 
fluorescence emission intensity upon increasing the detergent concentration using a 
reported assay.161 Figure 5.2 depicts the increase in NR fluorescence emission as the 




Figure 5.2 An example of the graph obtained when monitoring NR fluorescence intensity at Em λmax 
upon increasing detergent concentration. The detergent studied was SDS and the CMC obtained 




NR is known to exhibit very  low fluorescence in aq solution, as the CMC of SDS was 
approached, a rapid increase in the non-polar environments in the solution was observed, 
corresponding to a marked increase in NR fluorescence intensity from those regions.161 The 
CMC value is approximated by calculating the detergent concentration at the point of 
intersection of linear regression lines generated upon fitting the linear response regions of 
the graph separately.161 This procedure was performed for all the detergents utilised and the 
CMC values obtained under the specified conditions are shown in Table 5.2. A direct 
comparison to literature values is not possible as most reported CMC values are obtained for 
aq solutions with high NaCl concentrations.385 However the ranges of CMC values obtained 
are within the expected range given the reported CMC values of each detergent.387  
Table 5.2 CMC values obtained for each detergent determined by fluorescence spectroscopy at pH 
4.80, 50 mM buffer and 310 K. 
Detergent observed CMC  (mM), (n=3) 
SDS 8.5 ± 0.4 
CTAB 1.6 ± 0.6 
NP-40 0.4 ± 0.2 
TWEEN-20 0.10 ± 0.01 
CHAPS 6.1 ± 0.2 
 
It must be noted that the CMC is an equilibrium property of the bulk solution and the values 
reported here are only expected under the described conditions.388 Hence, the detergent 
concentrations for each experiment were chosen to be either well above or below this 
range.  
(5.3.2) Evaluation of the ability of detergents to promote β-haematin 
formation 
To mimic the neutral lipids that have been reported to mediate Hz formation in vivo, 
detergents have been employed to catalyse the formation of βH in vitro for assaying 
potential drug candidates.154,155,173 The ability of each detergent to mediate βH formation at 
pH 4.80 and 37 °C was evaluated by incubation with Fe(III)PPIX at concentrations above and 
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below their CMC values (concentrations listed in Table 5.1). βH formation was confirmed by 
the presence of characteristic stretching frequencies at 1657 and 1208 cm-1 in the ATR-FTIR 
spectrum of the dried product.44 The IR spectrum of the product is shown in Fig. 5.3 for the 
detergent, TWEEN-20, at a concentration below its CMC and exhibits the strong absorbance 
bands that correspond to the C-O and C=O stretching frequencies of the coordinated 
carboxylate moiety of βH as discussed in Chapter 2.44 
 
Figure 5.3 ATR-IR spectrum of βH produced from TWEEN-20 detergent incubated at pH 4.80, 37°C 
overnight with Fe(III)PPIX at a concentration below its CMC. The diagnostic stretching frequencies of 
the coordinated carboxylate group in βH occurring at 1660 and 1208 cm-1, are indicated by arrows. 
 
The total percentage yield of βH formed as mediated by a particular detergent at a 
concentration either above or below its CMC value are listed in Table 5.3. Both neutral 
detergents were found to mediate βH formation above and below their CMC values. The 
charged detergents failed to initiate βH formation at either concentration. Interestingly, the 
zwitterionic detergent, CHAPS proved capable of mediating βH formation, but only when 
micelles were present in solution was enough βH formed for analysis. CHAPS detergent 
monomers have previously been reported to mediate βH formation, however, that study 
reported an equally low yield of 7% βH.155 Previous studies have reported that neutral 
detergents are capable of promoting βH formation below their CMC values in a pH 
dependent manner such that NP-40 and TWEEN-20 have been used to prepare βH for 
assaying drug inhibition activity . 9,11,12 SDS micelles have been reported to mediate βH 
formation but in very low yields.9,30 Here, however, if any βH did form, it was present at a 
concentration below the limits of detection. These observations indicate that the charge of 
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the detergent affected their ability to facilitate the conversion of Fe(III)PPIX to βH, 
consequently, the properties and effects of the detergent warranted further investigation. 
Table 5.3 Detergent ability to mediate βH at pH 4.80, 37°C as confirmed by ATR-IR spectroscopy. The 
presence of βH is indicated by +, while its absence is denoted by  - .  
 










above + 91 ± 1   
below + 95 ± 0.2 
TWEEN-20 
above + 94 ± 0.3 
below + 64 ± 2 
CHAPS 
above + 62 ± 3 
below - a  11 ± 3.5 
a % yield too low to detect by FTIR 
 
(5.3.3)  The surface tension of detergent solutions  
It was recently found by Huy et al. that a series of small normal alcohols were capable of 
inducing βH formation at 37 °C and pH 4.80.148 It was reported that the ability of these 
alcohols to induce increasing yields of βH was correlated with their degree of hydrophobicity 
(hydrocarbon chain length) and their ability to solubilise Fe(III)PPIX in aq acidic buffer 
solution. An overall reduction in the surface tension of aqueous solution was suggested to 
facilitate favourable interactions with nuclei on specific faces of the growing crystal.148 It had 
been previously suggested that a limiting step in the crystallisation of βH was low levels of 
Fe(III)PPIX solubility in acidic solution.67 A later study on the ability of DMSO and a series of 
variable chain length polyethylene glycols (PEGS) confirmed that an increase in Fe(III)PPIX 
solubility at acidic pH was correlated to βH formation.150 Furthermore, the authors suggest 
that the solubilised Fe(III)PPIX acts as a source for nucleating βH and not precipitated 
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Fe(III)PPIX deposits. The conclusion that a microenvironment of reduced polarity favours this 
solubilisation of Fe(III)PPIX and is correlated to βH formation echoed Huy’s findings.  
It was noted in this study that all the detergents increased the solubility of Fe(III)PPIX in 
acidic solution to pH values below that of the DV environment. Consequently, the ability of 
the neutral and zwitterionic detergents to promote βH formation to varying degrees can 
probably not be attributed to increased solubilisation alone. In light of that observation, the 
equilibrium surface tension of each detergent at a concentration above and below its CMC 
value was measured and compared with the value obtained for aq acetate buffer at pH 4.80. 
The results are displayed for comparison in Table 5.4.  
Table 5.4 Surface tension (mN.m-1) of the detergents solutions in acetate buffer (50 mM, pH 4.80) 
under investigation.  
Detergent below CMC above CMC 
SDS 32.61 ± 0.01 32.54 ± 0.01 
CTAB 37.06 ± 0.02 39.53 ± 0.01 
NP-40 29.80 ± 0.03 30.14 ± 0.02 
TWEEN-20 35.84 ± 0.86 34.88 ± 0.18 
CHAPS 44.87 ± 0.61 44.21 ± 0.33 
Acetate buffer 71.90 ± 0.04 
 
Interestingly, there appeared to be minimal difference between the surface tension 
measured for each detergent under both concentration conditions. In the literature, it has 
been reported that the CMC can often be determined using surface tension measurements, 
where the region of micellisation corresponds to either an initial discontinuity in the surface 
tension value with increasing detergent concentration or a marked decrease in surface 
tension upon micellisation.389,390 A report on the CMC determination of TWEEN-20 using 
surface tension measurements found that the surface tension decreases linearly with the log 
of the detergent concentration until just below the reported CMC value and then stays 
constant at higher concentrations.391 The results found here suggest that under the 
conditions used and at concentrations below each detergent CMC, these detergents exist in 
a metastable aggregated state that displays most of the physicochemical properties of 
detergent micelle solution. What can be concluded from the surface tension measurements 
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is that all the detergents tested decreased the surface tension of aq acetate buffer solution 
considerably, regardless of their ability to mediate βH formation.  
(5.3.4) The effect of pH on Fe(III)PPIX speciation in detergent solution 
In solution, Fe(III)PPIX has been shown to exist as a monomer, π-π dimer or μ-oxo dimer 
depending on the pH, salt concentration or nature of the solvent environment.72 In aqueous 
solution, Fe(III)PPIX is predominantly a π-π dimer with hydroxide (-OH) or water (H2O) as the 
axial ligand at high and low pH, respectively.66 The acid dissociation constant (pKa) for this 
conversion has been determined at 7.1 ± 0.2.66 However, in aqueous solution at very high pH 
values in the range 11-12 and increased salt concentrations, Blauer et al. reported bands in a 
Fe(III)PPIX UV-vis spectrum characteristic of the μ-oxo dimer species with a split Soret band 
at 340 and 380 nm and the charge transfer (CT) band at 565 nm with a distinct shoulder at 
600 nm.79 The characteristic features of the UV-vis spectrum of each species has been 
discussed in detail in Chapter 2. To determine if different detergents stabilise a particular 
Fe(III)PPIX species in solution, the effect of pH on Fe(III)PPIX speciation in the detergent 
solution, was explored quantitatively. It has been shown that UV-vis is a viable tool to 
distinguish between Fe(III)PPIX speciation in solution based on identification of characteristic 
bands in the spectrum.66,72,282 Since the spectra give qualitative information only, it was 
necessary to support this with other evidence. In this regard, magnetic measurements are a 
useful tool. As discussed in Chapter 2, a theoretical magnetic moment, μ, of the monomeric 
species of Fe(III)PPIX can be determined using the Evans NMR method (see section 2.3, Eqn. 
2.3.2), of which, there are several possibilities corresponding to the number of unpaired 
electrons in each Fe(III)PPIX species of interest. 
The Fe(III)PPIX species in each detergent was interpreted based on comparison with 
reported literature magnetic moment  values for each Fe(III)PPIX species in conjunction with 
the findings from UV-vis spectroscopy. The results for selected detergent solutions above 
their CMC values are shown in figures 5.4-5.6. The magnetic susceptibility of Fe(III)PPIX could 
only be measured in detergent solutions above their CMC values as a consistent frequency 
shift was not obtained at concentrations below the CMC. A meaningful reading could also 
not be obtained for NP-40 as the stock solution was already diluted in non-deuterated 
aqueous solution. Of particular interest, were the differences in the Fe(III)PPIX spectrum 
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obtained with detergents that do not mediate βH formation compared with those that do at 
pH 4.80.  
(5.3.4.1) Charged Detergents 
Neither the anionic SDS detergent nor the cationic CTAB detergent were capable of 
promoting βH formation at concentrations above or below their CMC. 
(5.3.4.1.1) SDS  
The UV-vis spectra of Fe(III)PPIX in anionic SDS micelles under basic pH (10.0) and acidic pH 
(4.8) conditions are presented in figure 5.4. The Q bands (450-550 nm) and CT regions (550-
650 nm) in each spectrum are expanded to provide information about the Fe(III)PPIX species 
present under those conditions. A comparison of the spectra obtained to a Fe(III)PPIX 
spectrum acquired in solvent systems known to promote a particular species, are 
presented.72  
(a) SDS above CMC (b) 
  
Figure 5.4 UV-vis spectra of Fe(III)PPIX in SDS detergent micelle solutions (solid lines) under basic (a) 
and acidic pH conditions (b) corresponding to pH 10.0 and 4.8, respectively. Traces obtained were 
compared with a Fe(III)PPIX spectrum (dashed lines) obtained from a solvent system that was known 
to favour monomeric Fe(III)PPIX with -OH axial ligand (aq 80% MeOH, 20 mM CHES buffer, pH 10, 
grey) or with axial H2O ligand (aq 80% MeOH, 20 mM acetate buffer, pH 4.8, purple).
72   
 
At  pH 7 - 12.5, Fe(III)PPIX has been reported to be encapsulated into SDS micelles in its 
monomeric form, although earlier studies assumed this Fe(III)PPIX to be six-coordinate.377,379 
Later studies provided UV-vis evidence of this when Blauer et al. dissolved haemin 
(Fe(III)PPIX where X=Cl) in SDS solution and reported a spectrum that was characterised by 
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the diagnostic Q bands (450 -550 nm) and prominent CT band at 605 nm of the hydroxyl (-
OH) monomer form of Fe(III)PPIX.392 Indeed, at pH 10.0, the Fe(III)PPIX spectrum in SDS 
micelles, appears to be that of a Fe(III)PPIX monomer with an -OH axial ligand (Fig. 5.4(a)).  
As the pH is decreased to pH 4.8, the equilibrium in SDS micelles, appears to favour the 
monomeric Fe(III)PPIX species with H2O axial ligand since the spectrum is similar to this 
species. The same changes in Fe(III)PPIX speciation were noted for Fe(III)PPIX in SDS below 
its CMC, however, at pH 4.8, some degree of -OH monomer was still present. Acid 
dissociation constant measurements have been conducted for Fe(III)PPIX in SDS detergent 
micelles, with a reported pKa value of 5.5, indicating that the presence of this detergent may 
depress the observed protonation equilibrium to lower pH values than in pure aq solution.393 
These assignments were confirmed for Fe(III)PPIX in SDS micelles as  the magnetic moment, 
μeff, obtained was 4.03 μB under basic pH conditions (pH 8.35) corresponding to a Fe(III) spin 
state of S = 3/2. The intermediate spin monomeric Fe(III)PPIX species with 
-OH as the axial 
ligand and a resultant spin state of S = 3/2 , yields a theoretical magnetic moment of 3.9 μB. 
This has been reported for intermediate spin five co-ordinate Fe(III) 
octaethytetraazaporphyrins with magnetic moments between 3.9-3.94 μB.
394 Studies on a 
heme peptide model, have demonstrated that the presence of the weaker field axial -OH 
ligand at high pH causes a decrease in the magnetic moment observed, arising from a 
mixture of the admixed, S= 3/2 spin state and high spin, S= 5/2 state.395 At pH 4.8, the μeff 
was measured to be 4.95 μB, a value that is indicative of the presence of a significant 
fractions of high-spin (S = 5/2), pentacoordinate Fe(III) with H2O as the axial ligand as recently 
reported by Stanek and Dziedzic-Kocurek for solid monomeric Fe(III) complexes using SQUID 
and Mössbauer spectroscopy.396 They showed that monomeric Fe(III)PPIX corresponds to a  
magnetic moment of 5.92 μB.
282,396
  These data indicate that a prevalence of monomeric 
Fe(III)PPIX at acidic pH appears not to favour βH formation. 
(5.3.4.1.2) CTAB 
By contrast, the cationic detergent, CTAB, induced the μ-oxo dimer species of Fe(III)PPIX at 
high pH in aq detergent solution. This was shown by a clear match of the spectra obtained in 
this detergent to that of Fe(III)PPIX in 40% dimethyl sulfoxide (DMSO) in aq buffer at pH 
10.0, a solution reported to induce the μ-oxo dimer species as seen in figure 5.5(a).72 The 
Fe(III)PPIX spectrum at both pH values was characterised by the split Soret band at 400 nm 
151 
 
and the double-humped CT/Q bands at 550-650 nm (Fig. 5.4(b)).282 This behaviour has been 
noted before in cationic detergent solutions of ferrimyoglobin, where the authors reported a 
stabilisation of the Fe(III)PPIX spectrum corresponding to the μ-oxo dimer species at pH 
8.35.397,398 As the pH was decreased, CTAB micelles seemed to stabilise the μ-oxo dimer 
species to some extent, such that the Fe(III)PPIX spectrum obtained at the pH of the DV (pH 
4.80) appeared to still be predominantly the μ-oxo dimer with possibly some of the H2O 
monomer species (Fig. 5.4(b)).  
(a) CTAB above CMC (b) 
  
Figure 5.5 UV-vis spectra of Fe(III)PPIX in CTAB detergent micelle solutions (solid lines) under basic 
(a) and acidic pH conditions (b) corresponding to pH 10.0 and 4.8, respectively. Traces obtained 
were compared with a Fe(III)PPIX spectrum (dashed lines) obtained from a solvent system that was 
known to produce either the μ-oxo dimer (40%  aq DMSO, 20 mM CHES buffer, pH 10, green), or the 
monomer with axial H2O ligand (aq 80% MeOH, 20 mM acetate buffer, pH 4.8) or a mixture of two 
species 76% μ-oxo dimer and 24 % aqua monomer (red) , as was the case for CTAB at acidic pH.72   
 
The magnetic moment of Fe(III)PPIX in CTAB solutions at high pH was measured as 2.26 μB. 
Although the μ-oxo dimer species of Fe(III)PPIX has been shown to have a lower magnetic 
moment, it does not correspond to a spin state of S = 1/2, as sometimes stated. Rather it 
exhibits strong antiferromagnetic coupling between the Fe(III) centres that has a 
temperature dependent J-coupling constant of −110 ± 15 cm−1.224,396 Kuter et al. reported a 
measured magnetic moment of the μ-oxo dimer at 303 K, as 2.13 μB which compared well 
with a computed value using this J-coupling constant of 2.0 μB.
282
 Low spin species, like a 
reported (imidazole)2-Fe(III)PPIX complex, with S = 
1/2 have a theoretical magnetic moment 
of 1.78 μB.
224,399,400 Under acidic pH conditions, a magnetic moment of 3.75 μB was 
determined, the presence of a significant fraction of the μ-oxo dimer species likely decreases 
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the magnetic contribution from the high-spin H2O monomeric Fe(III)PPIX species, effectively 
decreasing the μeff to 3.75 μB. This value of μeff could also be ascribed to the ad-mixed π-π 
dimer, but the UV-vis spectrum (Fig. 5.5b) is not consistent with this interpretation. This 
observation clearly dispels earlier misconceptions that all detergents induce monomeric 
Fe(III)PPPIX regardless of pH, owing to the idea that the hydrophobic interactions between 
the porphyrin and micelle interior were proposed to be stronger than the porphyrin-
porphyrin interactions that drive aggregation.378,379,401  
(5.3.4.2) Neutral and Zwitterionic Detergents 
The neutral and zwitterionic detergents that do promote βH formation, at concentrations 
both above and below their CMC values, also exhibit an effect on the aq speciation of 
Fe(III)PPIX. The spectra of Fe(III)PPIX in these detergent solutions are shown in Fig. 5.6. Like 
the detergent, CTAB, the neutral detergents (NP-40 and TWEEN-20) and CHAPS, at 
concentrations both above and below their CMC values, promote the μ-oxo dimer species of 
Fe(III)PPIX in basic pH solution (Fig. 5.6 (a,c&e)). Confirming this, the magnetic moments 
obtained for Fe(III)PPIX in both TWEEN-20 and CHAPS under basic pH conditions were found 
to correspond to a μ-oxo dimer at μeff  of 1.72 and 2.1 μB, respectively.  
However, unlike CTAB, at low pH, these detergents, promote the formation of the π-π dimer 
species of Fe(III)PPIX characterised by the broad Soret band between 350-400 nm and a 
single CT band at 650 nm (Fig. 5.6(b,d&f)). The neutral detergents were found to do so at 
concentrations above and below their CMC values. The zwitterionic detergent, CHAPS, 
below its CMC appears to induce a species at low pH that is a mixture made up of 
predominantly monomeric Fe(III)PPIX. Interestingly, under these conditions only very low 
yields of βH were formed by this detergent. At acidic pH, assignment of the dominant 
Fe(III)PPIX species in TWEEN-20 solution was possible using magnetic susceptibility 
measurements. TWEEN-20 which mediates βH formation at low pH, was confirmed to do so 
from an ad-mixed spin-state, S= 3/2, 
5/2, with a μeff of 4.62 μB, which has been shown in 





(a) NP-40 below CMC (b) 
  
(c) Tween-20 above CMC (d) 
  
(e) CHAPS above CMC (f) 
  
 
Figure 5.6 UV-vis spectra of Fe(III)PPIX in neutral and zwitterionic detergent solutions under basic 
(a,c&e) and acidic conditions (b,d&f)  corresponding to pH 10.0 (solid black lines) and 4.8 (solid red 
lines), respectively where at the latter pH, βH formation is induced. Dashed lines correspond to the 
characteristic spectrum of either the μ-oxo dimer (40%  aq DMSO, 20 mM CHES buffer, pH 10, green) 
or π-π dimer (aq 20 mM MES buffer, pH 6.0, blue) species of Fe(III)PPIX the in solvent systems where 




The presence of  five-coordinate Fe(III) porphyrins in quantum mechanically ad-mixed spin 
states of S = 3/2, 
5/2, has been confirmed, for example in the tetraphenyl porphyrin derivative, 
Fe(TTP)(B11CH12).C7H8, which was found by crystal structure analysis to possess a face to face 
(π-π) dimer structure of two non-covalently associated Fe(III) porphyrins.402 The 
temperature dependence of the magnetic susceptibility of this compound was measured 
and the magnetic moment was found to vary from 2 μB at 6 K to 4.2 μB at 300 K, with the 
proposed predominant S = 3/2 state making a larger contribution to the quantum mechanical 
mixing of each spin state to account for the lower value.402 The zwitterionic detergent, 
CHAPS, was found to stabilise the μ-oxo dimer species to some degree at acidic pH as the 
magnetic moment obtained (μeff of 3.53 μB) is lower than expected for the spin ad-mixed π-π 
dimer species alone. 
It was reported by Casabianca et al. that TWEEN-20 and DTAB, at concentrations above their 
CMC values, induce the μ-oxo dimer form of Fe(III)PPIX at higher pH, and the monomeric 
form at lower pH values.223 This assignment was based on the incorrect assumption that 
Fe(III)PPIX in aqueous solution is a μ-oxo dimer at pH 7.00 and thus these detergents were 
judged not to affect the aqueous speciation of Fe(III)PPIX.220 In fact, this result led the 
authors to suggest that the presence of the μ-oxo dimer species may serve as a precursor to 
βH formation, citing the observed strong interaction of the antimalarial drug, CQ, with the μ-
oxo dimer form of Fe(III)PPIX in these solutions, as the proposed mechanism of βH 
inhibition.223 However, as mentioned, it has been shown that in aqueous solution at neutral 
pH, Fe(III)PPIX is predominantly a π-π dimer.66,68,72 Subsequently, it has also been shown that 
CQ is responsible for inducing μ-oxo dimer formation in aqueous solution, the presence of 
which has been correlated to absence of βH formation.224  
These spectra appear to indicate that for the detergents tested, those that stabilise the π-π 
dimer species of Fe(III)PPIX  at the pH of the DV, are the only ones that form βH. The other 
detergents, that fail to promote βH, all seem to induce a different Fe(III)PPIX species or the 
presence of mixed speciation at low pH. However, these techniques could not be used to 




(5.3.5) Evaluation of the speciation changes of Fe(III)PPIX in detergent 
solution 
To measure the extent of μ-oxo dimer formation spectrophotometric titrations to determine 
the effect of pH on Fe(III)PPIX in detergent solution at concentrations both above and below 
the detergent CMC values was conducted. The data were analysed according to the 
equilibrium speciation changes observed from the UV-vis spectra and magnetic susceptibility 
data such as those in Fig 5.5 and 5.6. The changes observed in the UV-vis spectrum of 
Fe(III)PPIX in selected detergent solutions that exhibited a dimer equilibrium between the μ-
oxo dimer, [(𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋)2𝑂], and the π-π dimer, [𝐻2𝑂/𝐻𝑂 − 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋]2 , species over 
the pH range investigated (described in Eqn. 5.1.1), were fitted to a sigmoidal curve to first 
establish the log of the ratio of π-π dimer (M2Hn) to μ-oxo dimer, (abbreviated as M2). This 
simplified model makes the assumption that, at no point in the titration do these detergents 
result in significant concentrations of monomeric Fe(III)PPIX. This was considered valid as the 
characteristic UV-vis spectrum features and high spin magnetic moment  of the monomeric 
Fe(III)PPIX species were absent in these detergents at all pH values investigated. A plot of the 
log ratio of these dimer absorbance values versus the pH at which the absorbance was 
collected was linear. In this analysis the y-intercept corresponds to log K and the slope, n, the 
number of protons released in converting the π-π dimer species either with hydroxide, 
water, or both as the axial ligands on the Fe(III) ions to the  μ-oxo dimer (Eqn. 5.2). This 
analysis was adapted from Brown’s original dimerisation equilibrium outlined in Chapter 
1.374  
 [𝐻2𝑂/𝐻𝑂 − 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋]2  
𝐾
 [(𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋)2𝑂](𝑎𝑞) + 𝒏 𝐻
+ (𝑎𝑞) + 𝐻2𝑂 (𝑙)  (5.1.1) 




                                                                    (5.1.2) 
                                    log 𝐾 = log
[𝑀2]
[𝑀2𝐻𝑛]
− 𝑛. 𝑝𝐻                                                           
                                           log 
[𝑀2] 
[𝑀2𝐻𝑛]




The dimer equilibrium constant, K, (Eqn. 5.1.2) was then used to calculate the distribution of 
each species as a function of the total Fe(III)PPIX concentration added to the detergent 
solution, MT, using Eqn. 5.3.1 From this, the total % μ-oxo dimer species at the pH and 
Fe(III)PPIX concentration at which the detergent produced βH was determined. The value 
obtained in Eqn. 5.3.2 was converted to a percentage of total Fe(III)PPIX in solution. 
                                               [𝑀𝑇] = 2[𝑀2𝐻𝑛] + 2[𝑀2]                                                         (5.3.1) 
                                                 [𝑀2] =
  𝐾 [𝑀𝑇]  
2([𝐻+]𝑛 + 𝐾)
                                                               (5.3.2) 
 
An example of a detergent that promoted this equilibrium, TWEEN-20 (above its CMC 
concentration) is shown in Fig. 5.7. The titration data and resultant sigmoidal fit of the 
change in absorbance at the Soret region are depicted in (a-b). The straight line fit of the log 
ratio of each species versus pH is shown in Fig. 5.7(c) to obtain the dimer equilibrium 
constant as a log 𝐾 of -6.6 for the conversion of the π-π dimer to the μ-oxo dimer. The 
observed slope of unity indicates that the π-π dimer consists of one Fe(III)PPIX molecule with 
a -OH axial ligand and another with a H2O axial ligand (Fig. 5.7(c)). 
 
Unlike the neutral detergents, the charged detergents did not at any point in the titration 
induce the π-π dimer species of Fe(III)PPIX. Therefore an alternative equilibrium was set-up 
to describe the absorbance changes observed in those solutions.  As the concentration of H+ 
ions was decreased in solution, the monomeric Fe(III)PPIX species, MHn, bearing either the 
–
OH or H2O axial ligand was converted into the μ-oxo dimer species, M2, which is described by 
the equilibrium in Eqn. 5.4.1. The dimerisation equilibrium constant, log K, could then be 
calculated in the same manner as above using Eqn. 5.5. 
    2 [𝐻𝑛𝑂 − 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋]  
𝐾
 [(𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋)2𝑂] (𝑎𝑞) + 𝒏 𝐻
+ (𝑎𝑞) + 𝐻2𝑂 (𝑙)  (5.4.1) 
 





                                                              
 (5.4.2)  
                                              log 
[𝑀2] 
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Figure 5.7(a) An example of the spectroscopic changes observed for Fe(III)PPIX in TWEEN-20 
solution, above its CMC, over the pH range  3.75 - 8.2. The arrow indicates the direction of the π-π 
dimer to μ-oxo dimer equilibrium corresponding to the spectrum at low to high pH at 400 nm. The 
sigmoidal pH dependence of the maximum absorbance at the Soret band, λ=400 nm is shown in (b). 
A plot of the log ratio of μ-oxo dimer (M2) to π-π dimer, (M2Hn) versus pH (c) was linear with slope of 
1.3 ± 0.04 and y-intercept = -6.6 ± 0.2, r2 = 0.99. 
 
 
The value of log K, allowed for the calculation of the percentage (%) μ-oxo dimer species in 
each detergent, this speciation can be predicted at any pH or Fe(III)PPIX concentration in the 
manner illustrated by Asher et al. for the 40% aq DMSO solutions, using the total Fe(III)PPIX 
concentration, MT, in Eqn. 5.6, which can be substituted in to 5.4.2 to yield the proportion of 
M2 at a particular pH and Fe(III)PPIX concentration.
72  




A three-dimensional surface plot could be rendered from the pH, total [Fe(III)PPIX] and the 
corresponding % μ-oxo dimer prevailing in detergent solution under a specific combination 
of conditions. The plots showing the distribution of the μ-oxo dimer species for the 
detergent, TWEEN-20, below its CMC value and for CTAB, above its CMC value are shown in 
Fig. 5.8(a) and (b). The neutral detergent, TWEEN-20, induces the μ-oxo dimer at high pH 
regardless of Fe(III)PPIX concentration. It can be seen from the shape of the speciation curve 
(Fig. 5.8(a)) that the % μ-oxo dimer does not show any dependence on Fe(III)PPIX 
concentration and this species was found to be stable only at pH values above pH 6.5. By 
contrast, it can be seen that the cationic detergent, CTAB, stabilises the μ-oxo dimer species 
to much lower pH values, especially at higher Fe(III)PPIX  concentrations. At the Fe(III)PPIX 
concentration (100 μM corresponding to log [Fe(III)PPIX] = -4) and pH at which the test for 
βH formation was conducted, over 90 % of the total Fe(III) in the solution was present as the 
μ-oxo dimer. However, at very low Fe(III)PPIX concentration values, the μ-oxo dimer species 
is not prevalent below pH 5, an observation which was consistent with the mixed UV-vis 


















Figure 5.8 The dependence of the % μ-oxo dimer species on pH and Fe(III)PPIX concentration 
prevalent in detergent solution that  (a) forms βH, TWEEN-20 (above CMC) and  (b) fails to promote 
βH , CTAB (above CMC). The black dot indicates the % μ-oxo dimer under the pH and total Fe(III)PPIX 
concentration conditions employed for the βH formation experiment. This is 0.7% in TWEEN-20 and 




These calculations were performed for all the detergents at concentrations both above and 
below the CMC except SDS which produced the monomeric species regardless of pH. The 
results are presented in Table 5.5 to offer a comparison of the total % μ-oxo dimer present 
in a particular detergent solution at the Fe(III)PPIX concentration and pH conditions of the 
βH formation experiment. 
Table 5.5 Equilibrium constants, log 𝐾, for the formation of the μ-oxo dimer species from π-π dimeric 
and monomeric Fe(III)PPIX, obtained from spectrophotometric pH titration data. The corresponding 
% μ-oxo dimer prevalent under the experimental pH and Fe(III)PPIX concentration conditions for the 
formation of βH experiment is listed for each detergent. 
Detergent  CMC slopeb 
n 
log Kc  
% μ-oxo 
dimer  
CHAPS below 1.2 ±0.06 1 -1.3 ± 0.3 32 
𝑀2𝐻𝑛 𝑀2 + 𝑛𝐻
+ above 0.85 ± 0.1 1 -5.06 ± 0.6 26 
CTAB below 0.99 ± 0.04  1 0.59 ± 0.03 87 
2𝑀𝐻𝑛 𝑀2 + 2𝑛𝐻
+ above 0.86 ± 0.001  1 1.07 ± 0.25 92 
NP-40 below 1.8 ± 0.13 2 -10.1 ± 1.5 0 
𝑀2𝐻𝑛 𝑀2 + 𝑛𝐻
+ above 1.5 ± 0.25 1/2 -11.1 ± 1 0 
TWEEN-20 below 1.3 ± 0.04 1 -7.5 ± 0.5 0.2 
𝑀2𝐻𝑛 𝑀2 + 𝑛𝐻
+ above 1.4 ± 0.09 1 -6.6 ± 0.2 0.7 
SDS a below - - - 0 
𝑀𝐻𝑛 above - - - 0 
a     
SDS induces monomeric Fe(III)PPIX over the pH range used in equilibrium fitting. 
b    
slope of linear plot of the log ratio of each species vs pH. The integer, n corresponds to the total number of     
H
+ 
released by the formation of μ-oxo dimer, described by Eqn. 5.2 and 5.5. 
c     
Equilibrium constants calculated from the y-intercepts of straight line fits described using Eqns. 5.2 and 5.5 
 
 
A negative log 𝐾 indicates the equilibrium disfavours the μ-oxo dimer at pH 0. Thus the 
smaller (ie. more negative) the value, the lower the proportion of μ-oxo dimer at pH 4.8, the 
value at which βH is prepared. While the dimerisation equilibrium constant, has been 
reported for conversion of monomeric Fe(III)PPIX species to dimers, and the conversion 
between the μ-oxo dimer and the π-π dimer in mixed aq solvents has been observed, this is 
apparently the first report of an equilibrium constant (log 𝐾)  for the conversion of the π-π 
dimer to the μ-oxo dimer.72 A pH-dependent conditional dimer equilibrium constant can be 
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calculated for the transformation of the π-π dimer species to the μ-oxo dimer using Eqn. 
5.7.1 and 5.7.2.  
 
                                                               𝐾𝑜𝑏𝑠 =  
𝐾
[𝐻+]𝑛
                                                                  (5.7.1) 
                                                       log 𝐾𝑜𝑏𝑠 = log 𝐾 + 𝑛. 𝑝𝐻                                                       (5.7.2)  
 
For NP-40 above and below its CMC value, the conditional dimer equilibrium constant, log 
𝐾𝑜𝑏𝑠 was calculated at a basic pH of 8.0 and the acidic pH of the DV, pH 4.8. These values are 
shown in Table 5.6. At pH 8, where the μ-oxo dimer is prevalent, log 𝐾𝑜𝑏𝑠 is large and 
positive, however, at pH 4.80, where the π-π dimer species is prevalent, negative log 𝐾𝑜𝑏𝑠 
values were obtained. It is interesting to note that this detergent was the only one found to 
favour the π-π dimer Fe(III)PPIX species with both axial ligands being H2O. This was evident 
from the number of protons released upon formation of the μ-oxo dimer which was found 
to correspond to two (n ≈ 2). This is in accord with the following equilibrium: 
[𝐻2𝑂 − 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋]2  
𝐾
 [(𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋)2𝑂](𝑎𝑞) + 2𝐻
+ (𝑎𝑞) + 𝐻2𝑂 (𝑙)   
By contrast, TWEEN-20 and CHAPS promote formation of a mixed π-π dimer with one axial 
H2O and one 
-OH ligand, resulting in the release of only one proton (n=1) with an equilibrium 
corresponding to: 
[𝐻𝑂 − 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋][𝐻2𝑂 − 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋]  
𝐾
[(𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋)2𝑂](𝑎𝑞) + 𝐻
+(𝑎𝑞) + 𝐻2𝑂 (𝑙) 
The dimerisation equilibrium constant, log 𝐾𝑜𝑏𝑠, for the monomer to μ-oxo dimer 
equilibrium in CTAB detergent was also calculated and the values at pH 8.0 and 4.8 are 
presented in Table 5.6. The corresponding pH-dependent dimerisation constant for the μ-
oxo dimer- monomer equilibrium has been previously investigated in 40% aq DMSO at pH 
10.0 and 7.4 and log 𝐾𝑜𝑏𝑠 was reported as 7.69 and 2.5, respectively.
72 The log 𝐾𝑜𝑏𝑠 values 
obtained here indicate that in the cationic detergent, CTAB, the μ-oxo dimer species is 
stabilised to much lower pH values. A further observation is that CTAB appears to stabilise 
the monomer with -OH as the axial ligand, even at low pH. The equilibrium (with n= 1), thus 
corresponds to:  
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  [𝐻𝑂 − 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋] + [𝐻2𝑂 − 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋]  
𝐾
 [(𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋)2𝑂] (𝑎𝑞) + 𝐻
+(𝑎𝑞) + 𝐻2𝑂 (𝑙) 
This is probably as a result of the positively charged detergent favouring the negatively 
charged Fe(III)PPIX species. 
Table 5.6 Conditional dimerisation constants, log𝐾𝑜𝑏𝑠 , of Fe(III)PPIX for the conversion of the π-π 




log 𝑲 log 𝑲𝒐𝒃𝒔𝒑𝑯 𝟖 log 𝑲𝒐𝒃𝒔𝒑𝑯 𝟒.𝟖 
NP-40 
below -10.1 ± 1.5 5.9 ± 0.6  -0.50 ± 0.05 
above -11.1 ± 1.0 4.9 ± 0.5 -1.50 ± 0.15 
CTAB below 0.59 ± 0.03 8.59 ± 0.4  5.39 ± 0.3 
 above 1.07 ± 0.25 9.66 ± 2.2 5.87 ± 1.3 
 
The data presented here show that the prevalence of the π-π dimer form of Fe(III)PPIX at 
acidic pH in selected detergent solutions is correlated with their ability to mediate βH 
formation. This in itself does not provide evidence of a definitive nucleation species of βH 
since the π-π dimer is already established as the dominant form of Fe(III)PPIX in aqueous 
solution at the pH of the DV, but it does show that promotion of either the monomer or μ-
oxo dimer by detergents disfavours βH formation. It has been previously suggested that the 
π-π dimer Fe(III)PPIX species prevalent in aqueous solution is converted to the μ-propionato 
form of Fe(III)PPIX upon association with a lipid environment.55,132 These findings are 
consistent with this hypothesis. Owing to their lipophilic nature, it is proposed that the 
ability of selected detergents to mimic a lipid environment allows for facilitation of 
formation of this μ-propionato form of Fe(III)PPIX. In a non-polar hydrophobic environment 
this dimer can then associate via hydrogen bonding to form the growing βH crystal. On the 
other hand, the hypothesis that detergent micelles mimic lipid droplets at first sight fails to 
explain the observed ability of the neutral detergents to promote significant amounts of βH 
formation at concentrations well below their observed CMC values. 
 As mentioned above and in Chapter 1, detergent monomers have been reported to 
aggregate into pre-micellar aggregates at concentrations below their CMC values which are 
capable of exhibiting unusual bulk solution properties. 167,170,171,403,404 Early computational 
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studies on the structure of detergents at various concentrations in solution have 
demonstrated the existence of dimers and higher aggregates that adopt conformations 
which align their outer fatty acid-like chains with more than half their hydrophobic surface 
removed from contact with water.167 Later works by Hadgiivanova and Diamant, showed 
both experimentally, by demonstrating the polydispersity of detergent solutions below their 
CMC values and theoretically, by using proposed thermodynamic models and Kramers’ 
reaction rate theory to compute the lifetimes of these aggregates, that once the required 
activation energy barrier to achieve a degree of monodispersity has been realised, 
metastable premicellar aggregates exist at sizes that do not significantly differ from the 
micelle size.169,170,388 This phenomenon probably explains the observed ability of these 
neutral detergents to mediate βH formation at concentrations both above and below their 
CMC values. It is suggested that the Fe(III)PPIX can interact with the detergent premicellar 
aggregates in the same way that it interacts with the micelles to form βH. Having found that 
this interaction is between the π-π dimer species and the neutral detergents plays an 
important role in βH formation, an experiment was next performed to establish which part 
of the detergent molecule is involved in this interaction with Fe(III)PPIX. For this purpose 1H 
NMR spectroscopy was performed using TWEEN-20, which was available as a solid.  
(5.3.6) Probing the interaction between neutral detergent micelles and 
Fe(III)PPIX by NMR spectroscopy 
The ability of neutral detergents to induce a particular Fe(III)PPIX species at the pH of the 
digestive vacuole may be the sole determinant of their ability to mediate  βH formation, 
however, the mechanism by which they do so is unknown. To investigate the interaction of 
Fe(III)PPIX with TWEEN-20 micelles, a comparison of the 1H NMR spectrum obtained for the 
detergent in the absence and presence of Fe(III)PPIX was made and is shown in Fig. 5.9. 
TWEEN-20 is an ethoxylated sorbitan monolaurate compound (Fig. 5.9(a)) that has been well 
characterised in aqueous solution by 1H NMR in the literature.405,406 The characteristic 
structural components such as the sorbitan ring protons, the methylene protons of the 
polyethoxylate chains and the monolaurate fatty acid chain methyl protons are the most 
diagnostic signals in the spectrum, appearing at specific chemical shifts as seen in Fig. 5.9(b). 
The most deshielded protons are those that comprise the fatty acid chain. The terminal 
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methyl protons appear at 0.9 ppm, followed by the aliphatic methylene groups at 1.3 ppm, 
with the satellite peaks corresponding to the α and β CH2 protons adjacent to the ester of 
the fatty acid group, at 2.4 and 1.6 ppm, respectively. The largest proton signal arises from 
the methylene protons of the polyethyleneoxide chains at 3.7 ppm. A small shoulder signal is 
seen which corresponds to the methylene protons on the sorbitan ring whose chemical shift 
coincides with the polyethyleneoxide signal. A separate downfield signal appearing at 4.2 
ppm corresponds to the methyl protons of the polyethylene glycol adjacent to the fatty acid 
ester (Fig. 5.9(c)).  
The presence of unpaired electrons in a compound have been shown to be useful for 
characterising its distance and orientation-dependant effects on a bulk sample by measuring  
the changes in the NMR spectrum of that sample.407 This method of exploiting the 
paramagnetism of the compound of interest has been applied widely in the field of 
membrane bound peptide or protein structure determination.408,409 Fe(III)PPIX is 
paramagnetic in its π-π dimer state and any effect it has on the reported 1H NMR chemical 
shifts of specific protons from the functional groups in TWEEN-20 micelles would signify a 
proximity interaction. The 1H NMR spectrum of the Fe(III)PPIX π-π dimer in D2O has been 
reported in the literature with assignments of proton signals that appear well above 4.5 
ppm,  therefore it was judged that any shifted or new signals observed in the TWEEN-20 1H 
NMR spectrum from 0-4.5 ppm arose from an interaction with the paramagnetic centre of 










Figure 5.9 (a) The molecular structure of TWEEN-20 with each functional group moiety highlighted 
and labelled corresponding to the peaks observed in (b), the 1H NMR spectrum of TWEEN-20 
detergent micelles in D2O with peak chemical shifts indicated. A comparison of this native TWEEN-20 
spectrum and that obtained with increasing concentrations of paramagnetic Fe(III)PPIX is presented 
in (c), with the diagnostic proton peaks assigned to the functional groups illustrated on the structure. 
The deshielding effects of Fe(III)PPIX on the fatty acid proton signals (1 and 2) and upfield shift of 
signal 3 of TWEEN-20, (1mM at pH 7, blue) for increasing concentration from 0.1 mM (red) to 0.5 
mM (green) were observed until finally at 1mM Fe(III)PPIX (purple), all the fatty acid signals are 






It can clearly be seen in Fig. 5.8(c) that increasing Fe(III)PPIX concentration in micellar 
TWEEN-20 solution results in a marked effect on the fatty acid chains of the molecule with 
significant peak broadening observed from 0.1-0.5 mM Fe(III)PPIX. Furthermore, the 1H NMR 
signals from the terminal methyl group and methylene protons of the hydrocarbon chain 
appear to have disappeared from their native peak frequencies in the aliphatic proton region 
(1.3-2.4 ppm) entirely at the maximum concentration of Fe(III)PPIX used (1 mM). All the 
other functional group proton signals appear to be unaffected apart from the general line 
broadening reported for sample NMR signals in the presence of paramagnetic compounds. 
In the previous chapter, it was shown that Fe(III)PPIX is lipophilic and partitions into neutral 
lipid droplets. As pictured in Chapter 1 (Fig. 1.18), TWEEN-20 detergent micelles can be 
considered as spherical structures with their polar headgroups exposed to the aqueous bulk 
and their fatty acid chains comprising the hydrophobic interior of the structure.162 The 
hydrophobic nature of the interior of TWEEN-20 micelles was confirmed by monitoring the 
maximum emission intensity wavelength shifts of the solvatochromatic dye, NR, with 
increasing detergent concentration. The effect of micellisation on NR fluorescence emission 
intensity and wavelength is shown in Fig. 5.10. A hypsochromic (ie. to shorter λ) shift upon 
incorporation of NR into the hydrophobic interior is noted in the inset of Fig. 5.10.  
Indeed, addition of an aq Fe(III)PPIX stock solution to the NR stained micelle solution 
investigated in Fig. 5.11, resulted in linear Stern-Volmer quenching plot up to 25 μM 
Fe(III)PPIX with 10.2 ± 0.3 μM required for 50% quenching of NR fluorescence inside the 
micelle. Interestingly, the λmax of this NR signal (629 nm) indicates that the interior of the 
TWEEN-20 micelle has an ET(30) of 50.2 ± 4 kcal.mol
-1 (interpolation from Fig. 4.3, Chapter 4), 
this is more polar than the interior of the SNLBD and closer to the polarity of soluble alcohols 
like 1-propanol (50.7 kcal.mol-1) which incidentally have also been found to be capable of 
promoting βH formation.148,331 The ET(30) of TWEEN-20 micelles has not been determined 
under these conditions, however, ET(30) values for other neutral detergents such as Triton-X-






Figure 5.10 Fluorescence emission response of solvatochromatic dye, NR (1 μM), in increasing 
concentrations of TWEEN-20 solution, the direction of intensity increase upon detergent 
micellisation is highlighted with the solid black arrow. The inset shows the wavelength shift of the 
maximum emission intensity (670 nm to 629 nm) upon NR incorporation into the hydrophobic 
micelle interior. 
 
From the effect of Fe(III)PPIX on the 1H NMR signals of TWEEN-20 micelles observed in Fig. 
5.9(c), and the quenching of NR localised in the hydrophobic detergent micelle interior (Fig. 
5.11),  it can be concluded that under these concentration conditions, Fe(III)PPIX partitions 
into the neutral detergent micelles and interacts with the hydrophobic fatty acid interior. 
Whether this interaction is responsible for the detergents ability to promote the π-π dimer 
and βH formation from Fe(III)PPIX in solution seems likely but remains unproven.  



















































Figure 5.11 Linear SV plot for Fe(III)PPIX quenching of NR fluorescence inside neutral detergent, 
TWEEN-20, micelles at pH 7.0, (r2 = 0.99). 
 
(5.3.7) The effect of neutral detergent on drug-Fe(III)PPIX association 
It was recently shown by UV-vis and IR spectroscopy, diffusion and magnetic susceptibility 
measurements and magnetic circular dichroism (MCD) techniques that the antimalarial drug, 
CQ, induces the μ-oxo dimer form of Fe(III)PPIX in solution.224 Kuter et al. reported a log 
association constant for CQ and Fe(III)PPIX, log 𝐾′ of 6.5 ± 0.2, which when added to the 
established dimerisation constant for Fe(III)PPIX at the pH investigated (log K pH 7.4 = 6.82 ± 
0.06)  amounts to a log Kobs  of 13.3 ± 0.2 for the interaction of two Fe(III)PPIX molecules to 
one drug molecule.66,224 In the present study, NP-40 was found to produce the largest yield 
of βH at a concentration below its CMC value, which was shown to correspond to a 
Fe(III)PPIX dimer equilibrium that favoured the π-π dimer species at the acidic pH of the 
experiment. In fact, this detergent was found to favour the π-π dimer species of Fe(III)PPIX 
beyond neutral pH.  
Therefore, in an effort to determine if the manner in which this neutral detergent stabilises 
the π-π dimer Fe(III)PPIX species in solution affects the established interaction of Fe(III)PPIX 
with antimalarials in aq solution, the association constant of Fe(III)PPIX with CQ in the 
presence of NP-40 below its CMC was determined by spectrophotometric titration of 
Fe(III)PPIX solution into a drug and detergent solution at pH 7.50. The changes in the UV-vis 
spectrum shown in Fig. 5.12(a), noted upon increasing Fe(III)PPIX concentration in solution, 
were analysed over the entire spectrum in the Hypspec® program using the simplified model 
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proposed by Kuter et al.  for  the conversion of predominantly dimeric Fe(III)PPIX to the CQ-
μ-oxo-Fe(III)PPIX complex.224  The equilibrium is shown in Eqn. 5.8.1, from which the 
association constant for CQ and the Fe(III)PPIX dimer, 𝐾′, could be determined using Eqn. 
5.8.2. This association was added to the pre-established dimerisation constant, K, 
determined for conversion of monomeric Fe(III)PPIX to the μ-oxo dimer form in aqueous 
solution under the pH conditions of the experiment as shown by Eqn 5.8.3.  
 
𝑀2 + 𝐶𝑄 
𝐾′




                         𝐾′ =  
[𝐶𝑄. 𝑀2]
[𝑀2][𝐶𝑄]
                                        
 (5.8.2) 
                         𝐾′ ×  𝐾 = 𝐾𝑜𝑏𝑠                                 (5.8.3) 
 
The theoretical absorbances generated for the drug-Fe(III)PPIX complex by the fitting the 
model described in Eqn. 5.8.1 were compared to the experimental absorbance values 
measured at the wavelength that corresponded to the region of greatest change (λ =390 
nm) upon increasing Fe(III)PPIX concentration, this is shown in Fig. 5.12(b). Analysis of the 
UV-vis spectrum changes upon addition of Fe(III)PPIX with the development of the 
characteristic split Soret band at 400 nm and the appearance of the double humped Q/CT 
peak between 550 and 650 nm in the experimental and calculated data for the complex 
confirmed that the μ-oxo dimer species of Fe(III)PPIX was present in the complex that 
formed in detergent solution.  
 The stoichiometry of binding between Fe(III)PPIX and CQ in the presence of NP-40 was 
confirmed using Job’s method of continuous variation.381 The Job plot determined for the 
Fe(III)PPIX.CQ complex in NP-40 detergent solution at 25 °C, displayed in Fig. 5.12(c), 
indicated that the binding occurred in a 2:1 stoichiometry of two Fe(III)PPIX molecules to 










Figure 5.12(a) The UV-vis spectrum changes upon titration of Fe(III)PPIX and NP-40 detergent stock 
solution (1 mM) into a solution of CQ ( 0.02 mM, pH 7.5) and NP-40 (0.2 mM). The arrow indicates 
the direction of increasing Fe(III)PPIX concentration. (b) The most pronounced changes in the UV-vis 
spectrum were found at 390 nm and were plotted against the predicted absorbance values for the 
complex from the fit of the data to the equilibrium in Eqn.5.8.1.  (c) The stoichiometry of Fe(III)PPIX 
binding to CQ to form the Fe(III)PPIX.CQ complex was determined from a Job plot by the intersection 
of the solid black and red lines, the black dashed line shows the mole fraction of Fe(III)PPIX present 
in the complex, as 0.66 ± 0.02. The dashed blue line represents the theoretical Beers law 
relationship for increasing Fe(III)PPIX concentration.  
 
This indicates that the detergent had no effect on the binding stoichiometry for this complex 
compared to pure aq solution.224 Similarly the value obtained for log 𝐾′ for the association 
of Fe(III)PPIX and CQ in NP-40 solution was 6.7 ± 0.01, which when added to the dimerisation 
constant, log K (6.82 ± 0.02) yielded a log 𝐾𝑜𝑏𝑠 of 13.5 ± 0.02, that matched the association 
obtained in pure aq solution.224 Similarly, measurements of the association constants of the 
quinoline methanol antimalarials, QD and QN, in pure aqueous solution and in NP-40 
solution below its CMC value, yielded approximately the same log 𝐾′ values for each drug 
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with and without detergent , these are listed for comparison in Table 5.7. Likewise, the 
stoichiometry of interaction determined at pH 7.50 revealed a 1:1 interaction of these drugs 
with monomeric Fe(III)PPIX, under both conditions. 
Table 5.7 Association constants, log 𝐾′ for quinoline methanol drugs with Fe(III)PPIX at pH 
7.5 ( 20 mM HEPES) with a 1:1 stoichiometry in pure aq and NP-40 (0.2 mM) solution. 
Drug log 𝑲′ aq log 𝑲′ NP-40 
QD 5.23 ± 0.06 5.10 ± 0.05 
QN 5.03 ± 0.02 4.80 ± 0.03 
 
These results indicate that although certain detergents stabilise a particular species of 
Fe(III)PPIX in solution, the drug-Fe(III)PPIX interaction that has been established to favour a 
different Fe(III)PPIX species dominates this equilibrium. This suggests that the observed 
association between these antimalarials and Fe(III)PPIX is stronger than the detergent effect, 
at least below their CMC values. Ideally, measurement of the effect of detergent micelles on 
this association would provide more insight into the nature of the Fe(III)PPIX-detergent 
interaction,  however, these solutions proved too turbid to allow measurement of the small 
changes that occur in the UV-vis absorbance spectrum upon drug-Fe(III)PPIX complexation. 
In spite of this, given that this neutral detergent appears not to be strongly associated with 
Fe(III)PPIX in solution, further investigation of its interaction with Fe(III)PPIX to effectively 
form βH was undertaken via kinetic investigation. This is described in the next chapter.   
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 (5.4) Summary 
The ability of various detergents to mediate βH formation at the pH and temperature of the 
parasite DV was explored. The anionic and cationic detergents, SDS and CTAB, respectively, 
failed to promote βH formation at concentrations both above and below their measured 
CMC values. The uncharged neutral and zwitterionic detergents, TWEEN-20, NP-40 and 
CHAPS were found capable of initiating βH formation at both concentrations. However, the 
efficiency at which they did so varied. To explain this, a comprehensive study of the effect of 
each detergent (above and below their CMCs) on Fe(III)PPIX speciation in solution using UV-
vis spectroscopy and magnetic susceptibility measurements was conducted. The pH 
response of this speciation profile was measured and a pH independent dimerisation 
constant was calculated for each detergent above and below the CMC. These data showed 
that the detergents that significantly stabilised the π-π dimer form of Fe(III)PPIX in acidic pH 
solution, were able to promote βH formation. Those that induced a significant percentage of 
either the monomeric or μ-oxo dimer form of Fe(III)PPIX at low pH, resulted in no βH 
formed. To illustrate this for the most efficient βH initiator, NP-40, below its CMC value, a pH 
dependent π-π to μ-oxo dimer equilibrium constant, log 𝐾𝑜𝑏𝑠, was determined at basic pH 
8.0 and found to be 5.9, favouring the μ-oxo dimer and -0.5 at pH 4.8, favouring the π-π 
dimer species. However, this π-π dimer species stabilisation was not found to prevent CQ-
Fe(III)PPIX association to form the μ-oxo dimer with a stoichiometry and association 
constant essentially unchanged from aqueous solution. 
It was also shown by fluorescence quenching and 1H NMR spectroscopy that Fe(III)PPIX 
partitions into the hydrophobic interior of the detergent micelle to interact with the fatty 
acid part of the detergent. While, there can be no doubt that all detergent solutions increase 
the solubility of Fe(III)PPIX and decrease the surface tension in acidic aq solution in a manner 
that provides a favourable environment for its crystallisation, the point of differentiation 
between the detergents tested that do not promote βH formation and those that do, 
appears to be related to their ability to induce the π-π dimer form of Fe(III)PPIX, coupled to 
the favourable hydrophobic microenvironment that the detergent micelles and premicellar 
aggregates provide. The correlation of uncharged detergents with this ability to favour the π-
π dimer form of Fe(III)PPIX in solution at low pH is interesting in the biological context of this 
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process given the probable role of neutral mono and diacylglycerols and/or zwitterionic 




























Chapter 6:  
Kinetics of NP-40 mediated β-haematin formation and 
effect of known quinoline antimalarials 
 (6.1) Introduction 
The biocrystallisation of Hz remains an essential target in the development of novel 
antimalarials. Quinoline antimalarials are known inhibitors of βH formation although their 
precise mechanism of inhibition is still unclear.239 In the absence of definitive knowledge of 
the mechanism of formation of βH, the rate determining step is not entirely certain. 
Nonetheless, as discussed in Chapter 1, the processes of crystal nucleation and growth are 
thought to be rate-determining and their inhibition can occur through several proposed 
mechanisms, namely; the precipitation of Fe(III)PPIX 57,411, the formation of a drug-Fe(III)PPIX 
complex,208,234 or interference in crystal growth when a drug binds to the fastest growing 
face of the crystal.28,236 Recently, Gildenhuys et al. proposed a crystal growth kinetic model 
that can account for the exponential kinetics observed at a lipid-aqueous interface.63 The 
kinetics of βH formation and its inhibition by antimalarials was shown to conform to an 
apparent first order process that can be fitted to the Avrami equation (6.1) when the Avrami 
constant, n, is 1 corresponding to random (non-spontaneous) nucleation and crystal growth 
in one dimension.63 
                                                     
𝑚𝑅
𝑚0
 =  𝑒−(𝑧𝑡
𝑛)                                                            (6.1)      
The model proposed that the observed decrease in the rate and hence in percentage of βH 
formed, at a given t, in the presence of drugs is due to the existence of two processes which 
compete with the formation of βH from Fe(III)PPIX.  One reaction involves the irreversible 
formation of a precipitated drug-Fe(III)PPIX complex that removes a portion of the Fe(III)PPIX 
available for conversion to βH at higher drug concentrations. Another process where the 
drug was proposed to adsorb onto the growing crystal surface was suggested to account for 
the observed decreases in rate of βH formed and dominates at lower drug concentrations.63 
It has been proposed that by assaying the strength of adsorption of lead drug compounds 
onto βH at a lipid-aq interface, it may be possible to predict their potential as βH inhibitors 
by this process. 
175 
 
Although lipids are likely responsible for mediating βH formation in vivo, the lipids 
comprising the droplets that are found to be associated with Hz, are expensive and often 
difficult to study because of large data scatter in the presence of lipid emulsions, an effect 
also noted in Chapter 4.124,126 On the other hand, in Chapter 5, under physiological pH and 
temperature conditions, NP-40 was shown to effectively mediate the formation of βH and 
has been used as a cheaper ‘lipid-mimic’ in assays for potential βH inhibitors.155,174,175 
Measurement of the kinetics of NP-40 mediated βH formation is a useful way of comparing 
the mechanism of inhibition in these two systems. The key objective of this chapter was thus 
to compare the kinetic profiles obtained in this detergent solution with those reported for 
neutral lipid droplets. A further objective was to directly investigate the proposed process of 
drug adsorption onto the βH crystal surface in a detergent environment. These observations 
were aimed at establishing to what extent this neutral amphiphilic detergent is a genuine 

















 (6.2) Experimental Methods 
(6.2.1) Materials, Instrumentation and General Procedures 
Nonident P-40 (NP-40, Shell Chemical Co.) detergent was obtained from Pierce 
Biotechnology, Rockford, Illinois and was used without further purification. It was stored as a 
167 mM stock solution at 4°C in the fridge.  All other chemicals were purchased from Sigma 
Aldrich® (Vorna Valley, South Africa). A Fe(III)PPIX stock solution (0.0023 g, 10 mL) was 
prepared by dissolving solid haematin (porcine) in 0.1 M NaOH (4 mL) and acetone:MeOH 
(1:9, v/v, 6 mL). Plastic sterile Greiner bio-one CELLSTAR® 15 mL tubes were employed as 
vessels for each experiment. Spectrophotometric assay experiments were analysed using a 
plate-reader and Graph Pad Prism v3 software was employed to calculate all models and to 
plot curves. Characterisation of βH was done by ATR-FTIR spectroscopy 44 and PXRD analysis 
by comparing characteristic stretching frequencies and diffraction peaks respectively with 
those reported in the literature (discussed in Chapter 2, section 2.4). 45  Unless otherwise 
stated, all experiments were performed at least in triplicate. Acetate buffer stock solutions 
(1 M) were prepared fresh for each experiment by dissolving sodium acetate solid in an 
appropriate amount of acetic acid solution in a volumetric flask so that the final pH of the 
buffer was 4.80 ± 0.01. 30% pyridine stock and 2 M HEPES buffer (pH 7.5) solutions were 
prepared daily according to the method outlined in Chapter 3. Aqueous stock solutions of 
chloroquine (CQ) and quinidine (QD) were prepared fresh for each sample set by dissolving 
the solids from the free base drugs at 10 mM and 5 mM respectively in acetate buffer (1 M).  
(6.2.2) Sample Preparation and Analysis Procedures 
(6.2.2.1) Evaluating the kinetics of β-haematin formation in the presence NP-40  
(below the CMC) 
In a 15 mL Falcon tube, acetate buffer (4.9 mL, 1M, pH 4.8) was premixed with aqueous NP-
40 detergent stock (100 μL, 2.5 mM) so that the final concentration of detergent was 50 μM. 
The mixture was equilibrated at 37 °C for 30 min in a thermostatted water bath prior to the 
start of the experiment. Fe(III)PPIX stock solution (363 μM, 50 μL) was added to the buffer-
detergent solution in the reaction tubes with a Hamilton syringe. The final Fe(III)PPIX 
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concentration in the Falcon tube was 3.58 μM. The solution was briefly vortexed and 
allowed to incubate at 37 °C in the water-bath for variable time periods. To test if any βH 
formed during the experiment that was not as a result of the presence of NP-40, a control 
experiment with the 1M acetate buffer, not containing NP-40 was tested for %βH formation 
for each time point in every experiment. The absorbance recorded at 405 nm for this control 
was used as the zero reading and any signal detected was subtracted from each sample. 
(6.2.2.2) Measurement of percentage β-haematin formed 
Modification of the pyridine hemichrome inhibition (Phi-β) assay 
The amount of βH (% yield) formed was calculated using the pyridine hemichrome inhibition 
(Phi-β) assay method previously described by Ncokazi and Egan.253 After the designated 
incubation time (0 - 420 min), the reaction in the Falcon tube was stopped for individual 
tubes by immediate quenching, facilitated by addition of 30% v/v pyridine stock solution (1 
mL, 30% pyridine; 40% acetone, 25% H2O, and 10% HEPES buffer (2 M, pH 7.5), to each tube. 
Tubes were then vortexed and centrifuged at 4000 rpm for 15 min. 200 μL aliquots from the 
supernatant of each tube were measured at the Soret band absorbance of Fe(III)PPIX at 405 
nm using a clear 96 well plate. The control Fe(III)PPIX reading was set up for each 
experiment with the same constituents with the exception of NP-40. Upon addition of the 
5% pyridine solution, the absorbance detected at 405 nm in this sample corresponds to the 
initial concentration of Fe(III)PPIX in the reaction mixture. Any βH formed corresponding to 
the recorded decrease in the amount of Fe(III)PPIX available for reaction with pyridine that 
resulted from incubation of Fe(III)PPIX in aqueous acidic buffer at 37 °C in plastic tubes was 
thus accounted for in all experiments. This absorbance was converted into a % βH formed by 
normalisation relative to the control described in equation 6.1. Data for each time point was 
collected with several replicates in separate experiments and analysed using the in-built 
exponential decay equation by nonlinear least squares fitting in GraphPad Prism v3 to 
determine the rate constant, z (min-1) and the time taken to form 50% of the final βH yield, 
t1/2 (min) .  
% 𝛽𝐻 = (
𝐴405𝑛𝑚  𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋 𝑡=0 − 𝐴405𝑛𝑚𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋 𝑠𝑎𝑚𝑝𝑙𝑒
𝐴405𝑛𝑚  𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐹𝑒(𝐼𝐼𝐼)𝑃𝑃𝐼𝑋 𝑡=0
) × 100         (6.1) 
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(6.2.2.3) Evaluating the kinetics of β-haematin formation in the presence NP-40 detergent 
and antimalarials 
The potential of known antimalarials to affect the observed kinetic profile of βH formation in 
NP-40 was investigated by the following experiment. The protocol described in section 
6.2.2.1 was set up with the addition of the desired antimalarial drug (CQ or QD) stock 
solution to each tube of acetate buffer at the pre-incubation stage. The final drug 
concentrations investigated ranged from 0 to 0.2 mM for each time point from 0 - 420 min. 
Each drug concentration, at each time point served as a separate experiment which was 
investigated at least in triplicate for both antimalarial drugs. The kinetic parameters of each 
drug concentration were measured and analysed as described in 6.2.2.2.  
To prove that the dark pigmented solid isolated from the reaction mixture left over after the 
addition of 30% pyridine was in fact βH, the ATR-FTIR spectrum of the dried product was 
obtained and is shown in Fig. 6.1. The characteristic stretching frequencies of the 
coordinated propionate moiety were observed at 1660 and 1208 cm-1 as expected (see 
Chapter 1 and 2) for βH. 
 
 
Figure 6(a) ATR-FTIR spectrum of the reaction product of NP-40 mediated βH formation in the 
presence of 0.05 mM CQ after 6 h incubation. The diagnostic stretching frequencies at 1660 and 






(6.2.3) Adsorption of CQ and QD onto preformed β-haematin 
(6.2.3.1) β-haematin preparation and analysis 
βH was prepared from a pentanol-aqueous interface according a recently reported method 
adapted from earlier publications by the Egan group. 57,126,412  Citrate buffer solutions (20 
mM, 50 mL × 6, pH 4.80) prepared from solid sodium citrate salt and a NaOH slurry was 
transferred to several Schott-Duran crystallisation dishes of 9 cm internal diameter. Pentanol 
(15 ml × 6) was added to each dish forming a distinct interface which was allowed to 
incubate at 37 °C in a thermostatted water-bath for 60 min. Haemin solid was dissolved in 
0.1 M NaOH with sonication and then mixed with acetone:MeOH (1:9 v/v) in a 6:4 v/v ratio 
to make a 2mg/ mL Fe(III)PPIX stock solution. The Fe(III)PPIX stock solution (1.5 mL) was then 
gently added to the top of the pentanol layer in each dish with a 23 gauge needle syringe. 
Migration of the Fe(III)PPIX solution to the aq-pentanol interface was observed to be 
immediate and the crystallisation reaction was allowed to proceed under a watch-glass at 
37°C for 6 h. The reactions were quenched by agitation of the interface and addition of 
water to each dish. The contents of the crystallisation dish were filtered by vacuum filtration 
using Whatman® filter disks (0.22 μm). The resulting crystals were washed with 1 ml of a 
solution of the 30% pyridine solution to bind unreacted Fe(III)PPIX in the manner of the Phi-β 
assay in section 6.2.2.2. The contents of each dish were then transferred to 80 mL 
transparent polycarbonate Nalgene centrifuge tubes and centrifuged at 10 000 rpm for 20 
min using an Eppendorf 5810 R centrifuge. The crystals were washed extensively with water 
and centrifuged again, the supernantent was discarded and the resultant dark brown solid 
was dried and stored in a desiccator over P4O10.  
(6.2.3.2) Adsorption experiments 
The adsorption of antimalarial drugs, CQ and QD to preformed βH crystals was tested in the 
presence and absence of detergent NP-40.  Aqueous drug solutions (2 mL) in acetate buffer 
(1 M, pH 4.80) at drug concentrations of 0.1 mM were pre-equilibrated at 37°C in a 
thermostatted water-bath in glass vials. Separate experiments were set up for each drug, in 
the absence and presence of NP-40. NP-40 stock solution was added to the mixture so that 
the final NP-40 concentration was 0.05 mM in 2 mL of drug and acetate buffer solution. The 
UV-vis absorbance spectrum of the contents of each vial was recorded from 200 - 800 nm at 
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37°C. βH crystals (1 mg) were added to a vial containing each drug in the presence and 
absence of NP-40 and the mixture was allowed to incubate at 37 °C for 55 h. Control 
experiments containing each drug or βH crystals only in the presence and absence of NP-40 
were also incubated. 1 mL aliquots were extracted from the supernatant of each vial and the 
UV-Vis absorbance spectrum was recorded of the supernatant above settled βH. A Beers law 
plot of each drug absorbance in the presence and absence of NP-40 was generated and used 
to calculate the molar absorptivity coefficient (Ɛ) at their λmax (343 nm for CQ and 332 nm for 
QD). The final concentration of each drug post-incubation was calculated from the 
absorbance obtained and Ɛ calculated using Beer’s Law to measure of the amount of crystal 




(6.3) Results and Discussion 
(6.3.1) Kinetic profile of β-haematin formation mediated by NP-40  
The ability of amphiphilic solutions to mediate βH formation has been well 
established.67,141,148,154,155 To ensure the process had proceeded successfully in the presence 
of NP-40 and the correct product was obtained, the dark brown product was isolated from 
the reaction solution and dried for 48 h prior to performing solid state characterisation. ATR-
FTIR spectroscopy and PXRD were employed to characterise the reaction product. These 
methods have previously been used to definitively prove the formation of βH initiated by 
lipophilic systems.63,127,155   
(6.3.1.1) Characterisation of NP-40 product 
Figure 6.1 depicts an ATR-FTIR spectrum that is characteristic of βH with the diagnostic 
carboxylate peaks at 1660 and 1208 cm-1 corresponding to the C=O and C-O stretches of the 
coordinated propionate moiety (Discussed in Chapter 1 and 2). The spectrum of the 
unreacted Fe(III)PPIX starting material is presented to highlight the differences. The 
positions of the stretching frequencies of both uncoordinated carboxyl groups were present 
at 1714 and 1620 cm-1 justifying the conclusion in Chapter 5 that NP-40 induces π-π dimers 
and not μ-propionato dimers that would exhibit the characteristic stretching frequencies at 
1660 and 1208 cm-1. 
 
 
Figure. 6.1 Infrared spectra of Fe(III)PPIX starting material (black) and the product obtained when 
Fe(III)PPIX was incubated in the presence of NP-40 (red). Characteristic stretching frequencies of βH 




The PXRD pattern obtained with the same sample shown in Fig. 6.2 confirms the identity of 
the product as βH with the dominant 100 and 131 reflections labelled. The pattern obtained 
matches well with those previously reported for βH formed from an NP-40 solution.155 The 
results from these techniques agree well with the literature standards of βH characterisation 
and confirm that NP-40 efficiently facilitated βH formation. 27,44 
 
 
Figure 6.2 PXRD pattern of βH obtained from NP-40 solution (black), with the characteristic (100) 
and (131) reflections labelled. The calculated PXRD pattern obtained from the structure reported by 
Pagola et al is shown for comparison (blue).27 
 
(6.3.1.2) NP-40 kinetics 
NP-40 is known to promote βH formation, although the kinetics of this process have not 
been reported.155 To address this, the % βH formed from Fe(III)PPIX in an acidic aq solution 
of NP-40 over the course of 7 h was measured and the rate constant, z, was determined. 
Data were fitted to a non-linear least squares exponential function to generate the kinetic 
profile shown in Fig. 6.3. Incubation of Fe(III)PPIX in acetate buffer (4.5 M) under acidic pH 
conditions has been reported to initiate  βH formation with a half-life of approximately 30 
min.67 However, under these much lower temperature and acetate concentration 





Figure 6.3 The kinetic profile of NP-40 mediated βH formation over the time period  of 0-420 
min. Data as fitted with a non-linear least squares exponential function in GraphPad Prism , r2 =0.93. 
The error bars represent standard error of the mean (SEM) values, n= 5.  
 
The observed kinetic profile is exponential in shape (Fig. 6.3), corresponding to the Avrami 
equation with, n=1 (Eqn. 6.1). Mathematically, this is indistinguishable from first-order 
kinetics and can be fitted with a simple exponential function. This can be interpreted as 
instantaneous nucleation of βH crystals with growth in one-dimension.138,139 The growth rate 
resembles that observed for the formation of βH at a lipid-aq interface, where the mode of 
nucleation has been proposed to occur from a fixed number of preformed nuclei templated 
by the lipid OH head groups at the air-aq interface. 63,127,143 This proposal is supported by 
evidence that when layered on an aq surface, a model lipid, MMG forms clusters with its OH 
groups exposed. Preferential Fe(III)PPIX interaction with that surface, effectively induces 
oriented βH crystals via their 100 faces.125 Indeed, the kinetic profile observed for NP-40, 
indicates that no induction period of slow nucleation occurs at the early time-points and the 
time-dependent data was found not to be sigmoidal as previously reported for acetate 
buffer-mediated βH formation at 60°C.67 In that case, an Avrami constant of n= 4 correlating 
to sporadic nucleation and three-dimensional crystal growth was observed.67  
A total yield of 56 ± 2% βH was calculated according to Eqn. 6.1 with a rate constant, z of 
0.037 ± 0.003 min-1, corresponding to a half-life (t1/2) of 19 ± 1 min.  This yield is somewhat 
lower than the earliest report of NP-40 mediated βH formation (74%) and the yield obtained 
in Chapter 5.155 It should be noted however, that direct comparison between experiments 
can only be done if both the concentrations of initial starting material and NP-40 are 
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consistent. When testing the effects of inducer and Fe(III)PPIX  concentration on inhibition of 
crystallisation assay results, Nhien and co-workers found that both components as well as 
the incubation time affected the outcome of the tests.173 This needs to be considered when 
comparing results from assays performed under varied concentration conditions. 
Previous studies have reported z values for the biologically-established neutral lipid blend 
(NLB) on the order of 1.6 ± 0.02 min-1 with t1/2 of approximately 26 seconds to form 80-90 % 
βH.143 The lipid blend components were found to mediate the formation of βH with rate 
constants of DOG > DLG > MPG > MSG in an order found to be inversely correlated to their 
activation energy established in an earlier study.135 The monoacylglycerol component, MPG 
was found to facilitate conversion of almost 80% Fe(III)PPIX to βH on a  favourable time scale 
with t1/2 equal to 8.15 min, such that the kinetics of inhibition of βH formation could be 
measured.63 NP-40 mediated βH formation occurs much more slowly than the MPG lipid 
mediated process.  
The observed ability of NP-40 to promote Fe(III)PPIX π-π dimers in solution (Chapter 5) 
cannot be assumed for the neutral lipid. And so if indeed, NP-40 detergent polar head 
groups can serve as a nucleation template for βH crystal formation in the manner reported 
for lipid OH groups, this process must be much less efficient in detergent solution than at the 
lipid-aq interface. While the rate is lower, it is still sufficient to form βH on a reasonable time 
scale. Thus given that the detergent is more stable and cheaper, it remains a viable 
alternative to lipids for the production of βH, especially for its application in high-throughput 
screening.  
 
(6.3.2) Kinetics of β-haematin formation mediated by NP-40 in the presence 
of antimalarial drugs 
Chloroquine (CQ) and quinidine (QD) are known to target the process of βH formation and 
are believed to act against the malaria parasite by inhibiting Hz formation. 67,208,246  The exact 
mechanism by which this is achieved has been a matter of dispute, but recent research has 
proved that at least for CQ, Hz formation in P. falciparum is inhibited in a dose-dependent 
manner which correlates with an observed increase in free Fe(III)PPIX that correlates with 
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parasite death.195 Use of the NP-40 system as a mediator of βH formation to assay the 
inhibitory activity of antimalarial compounds is well-established and is widely employed to 
determine the 50% βH inhibitory concentration (IC50) of prospective novel drugs.
155,176 This 
method has been used to screen large compound libraries for hit compounds as it provides 
an indication of efficacy at decreasing the amount of βH formed. Furthermore, comparisons 
can be made relative to known βH inhibitors and antimalarial standards.174,175  
A detailed investigation of the time dependence of NP-40 mediated βH formation in the 
presence of known inhibitors, CQ and QD was undertaken. Figure 6.6 is a composite of all 
the kinetic curves obtained for βH formation in the presence of increasing drug 
concentration, over the time period of 0 - 360 min. The kinetic profiles obtained and seen in 
Fig. 6.4(a and b), show a gradual decrease in the observed rate constant, zobs, in the presence 
of increasing drug concentration. This is evident from the fact that the exponential curves 
converge to the maximum yield at longer times in the presence of higher drug 
concentrations. Both graphs (a) and (b) indicate that over 6 h, the two drugs CQ and QD, 
exhibit similar kinetic profiles despite the fact that the former is a member of the 4-amino 
quinoline family and the latter, a quinoline methanol.  
Figure 6.4(c) shows the dose-dependent decrease in zobs which is in agreement with 
previously reported inhibition studies with the drug, CQ.63,142 A comparison of the change in 
rate constant between the two drugs reveals that the  rate constants in the presence of CQ 
are higher than those observed with QD and the decrease in zobs for QD is sharper than CQ 
over the same concentration range despite CQ being reported as the more efficient 
inhibitor.239 A slice through the kinetic data after 90 min of incubation with CQ and QD was 
evaluated to determine if an IC50 could be obtained from the dose-response behavior, the 











Figure 6.4 Kinetic curves for inhibition of βH formation in the presence of increasing doses of (a) CQ 
and (b) QD from 0 - 360 min. Rate constants, zobs, were obtained by fitting the data to an exponential 
function. (c) The effect of increasing drug concentration on zobs is shown for CQ (green) and QD 




Figure 6.5 Dose response curves of the amount of unreacted Fe(III)PPIX measured at A405 nm in the 
presence of NP-40 and drugs at the 90 min time point; (a) chloroquine (r2 = 0.99) and (b) quinidine 
(r2 = 0.99). The data was analysed with a sigmoidal curve function in GraphPad prism. The IC50 points 
are highlighted by dotted lines on each graph. The error bars represent SEM, (n= 4). 
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Figure 6.5(a) depicts the efficacy of CQ in inhibiting βH formation at 90 min. An IC50 of 54 ± 
2.8 μM was determined. The IC50 for QD (Fig. 6.5(b)) was found to be 82.26 ± 4.7 μM. The 
smaller the IC50, the better the drug activity against βH formation, this is a trend observed 
for CQ and QD not only in lipophilic assays but for in vitro anti-parasitic activity against drug-
sensitive strains as well.239,413 The detergent system yields IC50 values for CQ and QD that are 
higher than those reported in the lipid system after 30 min of incubation, where CQ and QD 
showed an IC50 of 16.4 ± 0.5 μM and 51.5 ± 5.8  μM, respectively.240 While the values 
obtained here are within the same order of magnitude, this observation highlights that 
despite the widespread use of detergent systems to assay for potential βH inhibitors, the 
detergent system does not appear to show the same time and rate dependence of βH 
inhibition by known antimalarials as the biologically relevant neutral lipid. Furthermore, IC50 
values are dependent on incubation time. 
Although an IC50 can be approximated from the kinetic data at 90 min and the initial rates of 
βH formation from 0 – 180 min are relatively slower for both drugs when compared with NP-
40 (Fig. 6.3), the final yield of βH is independent of inhibitor identity and even concentration 
once the reactions have reached completion. This can be clearly seen in Fig. 6.4 (a&b). For 
CQ, the drug concentration is seen to affect the rate of βH formation over the early 
incubation time-period with the initial yield calculated to be markedly lower than the drug-
independent value, below 120 min. Beyond the 2 h point, the yields appear to be virtually 
identical to NP-40 in the absence of drug. By contrast, the decrease in rate constant the 
presence of QD appears to be about twice as low as for CQ (Fig. 6.4(c)). Interestingly, the 
observed final yield appears to plateau at an average of 52 and 55 % βH for incubation with 
CQ and QD, respectively, with no apparent decrease in yield at very high drug 
concentrations. The fact that both known antimalarial drugs fail to fully inhibit the formation 
of βH has been previously observed with different βH initiator systems, where the inhibition 
mechanism was proposed to be as a result of a reversible reaction between Fe(III)PPIX and 
the drug to form a solution complex of drug-Fe(III)PPIX.142,246,414 Pre-formed βH seed crystals 
incubated for 48 h with quinoline antimalarials were shown to exhibit an inhibitory effect on 
the lag and crystal growth phases of βH  crystallization that is reversible after 40 h.246 This 
observation contrasts with the reported kinetic profile for CQ inhibition of βH formation in 
the presence of lipid droplets, where it was shown that at sufficiently high concentrations of 
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the drug, the final yield of βH decreased.63 The authors proposed that the inhibition that 
occurred at very high drug concentrations, was irreversible resulting in a precipitated drug-
Fe(III)PPIX complex.63  
(6.3.3) A mechanism to account for the kinetic behaviour of βH formation in 
the presence of CQ and QD. 
Gildenhuys et al. investigated the kinetics of βH formation in the presence of a model 
neutral lipid mediator, MPG, and antimalarials CQ and QD. They proposed a theoretical 
crystal growth kinetic model that endeavours to explain why these known antimalarial drugs 
fail to fully inhibit βH formation at low concentrations.63 In the absence of any inhibitor, the 
process describing the growth of βH crystals from free dissolved Fe(III)PPIX designated H(aq) 
in scheme 6.1, proceeds with rate constant, z (described section 6.3.1.2). Introduction of a 
drug, D, to this system, scheme 6.1(A), causes this growth to proceed with a decreased rate 
constant, zobs.  The model was based on the proposal that quinoline antimalarials bind to the 
fastest-growing face of βH crystals , Xs,  in process C of scheme 6.1 which reduces the 




Scheme 6.1: Kinetic model to describe the inhibition of βH formation in the presence of drug, D. 
Competing processes are depicted with rate constants zobs, for (A) growth of βH crystals at growth 
sites (Xs) from Fe(III)PPIX (H) in aqueous solution. k2 and Kads are respectively, the rate and 
adsorption equilibrium constants for (B) the formation of an irreversible precipitated 
drug+Fe(III)PPIX complex (DH) and (C) reversible drug adsorption to crystal surface growth sites to 






In the presence of a drug, D, which can occupy sites on the growing crystal surface, the 
continued growth of the βH crystal is dependent on the concentration of drug bound via the 
number of unoccupied sites onto which further Fe(III)PPIX molecules attach. Since, the 
adsorption of drug onto the βH crystal face in process C can be equated to the formation of 
a drug monolayer, the process could be modelled using the Langmuir isotherm to describe 
the equilibrium adsorption process. The rate constant for formation of βH in the presence of 
an adsorbing drug, zobs, is then given by Eqn. 6.2. Where, z is the rate constant of βH 
formation in the absence of drug and (𝟏 − 𝜽) refers to the number of unoccupied sites on 
the βH crystal.  
                                           𝒛𝒐𝒃𝒔 =  𝒛(𝟏 − 𝜽) =  
𝒛
𝟏 + 𝑲𝒂𝒅𝒔[𝑫]
                                            (6.2) 




versus drug concentration, [D] to yield a y-intercept of  
𝟏
𝒛
,  and slope, 
𝑲𝒂𝒅𝒔
𝒛
  (Eqn. 6.3.)63  






[𝑫] +  
𝟏
𝒛
                                                     (6.3) 
 
To explain the decrease in yield observed at higher drug concentrations, the complexation of 
free Fe(III)PPIX, H(aq) with drug in solution to form an insoluble drug-Fe(III)PPIX complex, DH 
(B), which precipitates irreversibly, thus, removing a portion of Fe(III)PPIX, (H) from the 
reaction was postulated. The theoretical kinetic curves predicted by Scheme 6.1 are 
presented in Fig. 6.6(a) and the effect of this additional process on the plot of 
𝟏
𝒛𝒐𝒃𝒔
 vs [D] is 
shown in Fig. 6.6(b). As seen in Fig. 6.4, in contrast to the lipid catalysed process, NP-40 
mediated βH formation in the presence of antimalarials, CQ and QD, does not display a 
decrease in % yield of βH even at the highest drug concentrations. This suggests that the 
irreversible precipitation step (B in scheme 6.1) does not occur and an alternative scheme 







Figure 6.6(a) The theoretical prediction of the kinetics describing the conversion of Fe(III)PPIX to βH 
as a function of drug concentration with a decreased yield at higher drug concentrations according to 
scheme 6.1 as previously reported in a lipid-mediated system.63 (b) Linear dependence of the inverse 
rate constant on drug concentration at low drug concentration. At high drug concentrations, a 
deviation from linearity is predicted according to scheme 6.1. The crosses indicate behaviour not 
observed for NP-40 mediated βH formation in the presence of drugs. 
 
In the absence of this predicted decrease in yield, a plot of the inverse of the rate constants, 
zobs, against drug concentration was predicted to be linear. This was indeed found to be the 




Figure 6.7: Plots of  
𝟏
𝒛𝒐𝒃𝒔
  versus [D] for (a) CQ (r2 =0.85 , P = 1.00). P-values > 0.5 from a runs test 




It is observed in Fig. 6.7 that the dependence of 1/ zobs on drug concentration was linear up 
to the highest drug concentration tested, unlike the lipid system, where at higher drug 
concentrations, a deviation from linearity was observed.63 The values obtained for both 
drugs are listed in Table 6.2. The z values determined from the reciprocal y-intercepts of 
each graph in Fig. 6.7 are the same (within one standard deviation), having an average value 
of 0.039 ± 0.005 min-1 for βH formation in NP-40 solution. This corresponds to a half-life of 
17.5 ± 0.3 min for the reaction and is comparable with the independently measured half-life 
of 19 ± 1 min in section 6.3.1.2 for NP-40 in the absence of drug.  
Table 6.2: Adsorption and rate constants evaluated for antimalarial drugs from kinetic data obtained 
for NP-40 mediated βH formation.  
 
Drug 














CQ 168 ± 27 24 ± 3 7 ± 1 3.85 ± 0.07 0.043 ± 0.005 
QD 837 ± 101 28 ± 3 30 ± 4 4.48 ± 0.05 0.036 ± 0.004 
 
Adsorption equilibrium constants, Kads, were calculated from the slope of the plots in Fig. 6.7 
multiplied by z, for each drug tested, indicating that QD was more strongly adsorbed than 
CQ, with a higher log Kads. While the strength of drug adsorption of QD is similar to that 
reported for the lipid system, CQ was found to adsorb more strongly than QD in that 
system.63 
In a possible alternative model (scheme 6.2), K1, is a measure of the affinity that each drug 
has for Fe(III)PPIX in solution. Indeed, some studies have claimed that the ability to bind 
Fe(III)PPIX to form a drug-Fe(III)PPIX complex is correlated to βH inhibition and even 
antimalarial strength.208,230 Quinoline drugs have also been claimed to block incorporation of 
Fe(III)PPIX into the growing crystal by forming a drug-Fe(III)PPIX complex that exhibits 
superior solubility over Fe(III)PPIX in aq solution.415 While the observed kinetics here are 
consistent with the proposed adsorption process in scheme 6.2(B), kinetic experiments are 
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insufficient to demonstrate this, since model (C) in which equilibrium association of drug 




Scheme 6.2: Proposed processes to describe the kinetics of the inhibition of NP-40 mediated βH 
formation in the presence of drug, D. The growth of βH crystals from Fe(III)PPIX (H) in aqueous 
solution (A) is depicted with rate constants zobs,. (1) The adsorption process (B) for the drug binding 
to crystal surface, Xs to form a drug+ βH crystal complex, D(Xs), is described by rate constant, Kads. 
(2) Process C describes the association of drug and Fe(III)PPIX in solution to form a drug+Fe(III)PPIX 
complex (DH), the association is given by, K1.  
 
(6.3.4) Adsorption of antimalarial drugs to βH crystal surface 
Since kinetics experiments cannot distinguish between the two models in scheme 6.2, an 
effort was made to directly determine whether these drugs adsorb onto pre-formed βH. βH 
crystals for adsorption were collected from the interface between pentanol and aq buffer 
according to a published procedure. 57,126 The identity of βH was confirmed using ATR-FTIR 
and PXRD techniques, the characteristic reflections and stretching frequencies are shown in 








Figure 6.8 (a) PXRD pattern with the labelled characteristic (100) and (131) reflections (b) ATR-FTIR 
spectra of the starting material, Fe(III)PPIX, (black) and βH prepared at the pentanol-aq interface 
(red) with diagnostic stretching frequencies at 1660 and 1211 cm-1 indicated by red arrows.  
 
The concentration of drug in solution pre and post-incubation with βH crystals at 37 °C was 
recorded using UV-vis spectroscopy (Fig. 6.9). A reduction in drug concentration was 
observed for both drugs which was attributed to drug adsorption to the βH crystals. No such 
decrease was evident in the absence of βH. Standard drug concentration curves and Beer’s 
Law were used to generate the molar absorptivity constant, Ɛ of CQ  at λmax 343 nm (17 ± 1 
M-1.cm-1) and QD at λmax 332 nm (11.9 ± 0.9 M
-1.cm-1 ) under the conditions employed which 
were used to calculate the concentration of drug adsorbed. In aq solution at 0.2 μmol drug/ 
mg βH added, QD has been reported to adsorb almost three times as much as CQ.230,240 The 
effect of NP-40 detergent on this adsorption profile for CQ and QD was investigated.  
 
Figure 6.9 UV-vis absorbance spectra of CQ (0.05 mM) before and after a period of incubation with 
βH at 37 °C in the absence and presence of NP-40. The post adsorption decrease in absorbance of 




A comparison of the concentration of drug adsorbed in the absence and presence of NP-40 
at 0.2 μmol drug/ mg βH added is shown in Fig. 6.10. The presence of the NP-40 detergent at 
the concentration used for the kinetics experiments was determined to have no effect on 
the adsorption of the drugs. This indicates that the ability of this detergent to promote βH 
formation, centres around the initial step of the crystallisation reaction as well as any 
detergent-Fe(III)PPIX interactions that are relevant to its mechanism and not any association 
between the βH product and NP-40.    
 
Figure 6.10 Average adsorption of antimalarials CQ (42 %) and QD (75 %) to βH crystals in the 
absence and presence of NP-40.   
 
The adsorption profiles of the two drugs differ where QD displayed almost twice the 
adsorption of CQ. This is consistent with the measured adsorption constant from kinetics, 
which gave a larger value for QD.230,240 This independent experiment confirms the stronger 
adsorption of QD to crystals, in both aq and detergent solution, further highlighting the 
differences between this system and the lipid environment.  
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(6.4) Summary  
The neutral detergent, NP-40 was observed to initiate βH formation, doing so at rates that 
are at least forty times slower than that reported for the biologically prevalent neutral lipid 
blend.143 Despite this, the exponential-shaped kinetic profile found closely resembles that 
obtained at a neutral lipid-aq interface and similarly, the data was also found to fit the 
Avrami equation, with n = 1, correlating to a random nucleation mechanism and one-
dimensional crystal growth that results in linear βH crystals.63 The yields of βH formed with 
NP-40 were approximately 56% compared to 80% conversion for the neutral lipid blend. 
While the kinetics are slower and less efficient in NP-40 solution than at a lipid-aq interface, 
βH is still formed, fortuitously at half-life times that are sufficiently slow to study the efficacy 
of inhibitory drugs tested in vitro.  
The inhibitory activity of the 4-aminoquinoline drug, CQ and quinoline-methanol, QD was 
determined from the dose-dependent kinetic data at 90 min incubation time and the trend 
in activity observed correlates with that found for previously reported biological-activities 
against a CQ-sensitive parasite strain.239 Detailed kinetics of each drug over the 
concentration range 0-0.2 mM were also investigated to afford zobs, the rate constant of βH 
formation in the presence of drug. zobs was found to decrease in a dose-dependent manner 
for both drugs, but the same final % yield of βH after 6 h was consistently achieved. The 
inhibition reaction in NP-40 solution was thus concluded to be reversible at extended 
incubation times under the drug concentrations tested, with no precipitation of a drug-
Fe(III)PPIX complex detected.  
To explain the observed decrease in the rate βH formation in the presence of drug, a model 
utilised for the lipid-aq system was simplified, incorporating only the possibility of a 
competing reaction involving the adsorption of drugs to βH for the NP-40 system. In the NP-
40 system, the decrease in rate constant of βH formation found to be caused by 
antimalarials, CQ and QD, could be used to measure the adsorption of these drugs to a βH 
crystal face. The strength of this adsorption, determined from both the kinetics data and an 
independent experiment, was larger for QD than CQ. This time dependence is important to 
be aware of when using detergents as βH initiators for assaying potential βH inhibition 
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activity at different incubation times can affect the IC50 obtained. Indeed, this has been 
observed for other βH inhibition assays.253 
Kinetic experiments do not provide a conclusive means to distinguish between mechanisms. 
Thus the possibility that an association between Fe(III)PPIX and these drugs in solution, 
which may be responsible for their reported antimalarial activity, could not be discounted.  
The adsorption was, however, directly detected by depletion of the drugs from solution by 
βH. This work serves to illustrate the differences in behaviour of the detergent system versus 
the lipid droplet system when mediating βH formation and need be considered when 
assaying for potential βH inhibitors, using detergents. While the two systems are similar, 






Chapter 7:  Conclusions and Future Work 
(7.1) Overall conclusion 
Achieving the sustainable development goal of complete malaria eradication is a priority for 
improved healthcare in the ninety-seven affected countries, the majority of which are on the 
African continent. With the emergence of widespread resistance to frontline drug 
treatments and the complications of co-infections, the need to develop novel and targeted 
drug therapies is still relevant.416 During the intraerythrocytic stage of its life-cycle, the 
malaria parasite is thought to convert at least 80% of the host’s red blood cell 
ferriprotoporphyrin IX (Fe(III)PPIX) into the crystal, haemozoin (Hz) inside an acidic organelle 
called the digestive vacuole (DV).16 Hz is composed of hydrogen bonded cyclic dimers of 
Fe(III)PPIX coordinated through the propionic acid of one porphyrin ring to the Fe(III) of the 
other porphyrin in a reciprocal fashion (μ-propionato dimers).27 The precise steps involved in 
the biomineralisation of the potentially toxic, Fe(III)PPIX, to the relatively benign, Hz crystal, 
are yet to be elucidated, however, this parasite specific pathway represents a unique drug 
target with a significant success rate.417 To understand the mechanism of Hz formation, in 
vivo, pertinent questions about the state of Fe(III)PPIX under the acidic pH conditions that 
prevail in the parasite DV, need be addressed. Furthermore, as a growing amount of recent 
evidence suggests that lipids are involved in the biomineralisation process, further insight 
into their possible roles was necessary. Despite mixed proposals on the specific type and 
location of lipid involved in this process, recent works have identified a unique  blend of 
neutral acylglycerol lipid droplets (NLBDs) present in the DV to efficiently mediate 
biologically relevant concentrations of Hz formation.113,124 This thesis aimed to provide some 
understanding of the interaction between Fe(III)PPIX and the proposed NLBDs that have 
been reported to be associated with Hz, in vivo.  
To achieve this, Chapter 4 measured the extent of Fe(III)PPIX quenching of nile red (NR) 
labelled NLBDs. The results presented there have shown that soluble Fe(III)PPIX is lipophilic 
and capable of partitioning into synthetic NLBDs in a pH dependent manner. This pH 
dependence was found to reflect the ionisation state of Fe(III)PPIX in solution as the largest 
proportion of Fe(III)PPIX partitioning and NR quenching was observed for the neutral species 
at approximately the pH of the parasite DV (pH 4.80) which coincidently correlated with the 
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reported pH dependence of neutral lipid mediated β-haematin (βH) formation.127 A plot of 
the inverse of the Stern-Volmer quenching constant, KSV 
-1, against pH was found to fit a 
single-step protonation model with a pKa1 of 4.62 ± 0.09 for Fe(III)PPIX. Validation of the 
lipophilicity of Fe(III)PPIX was provided by measurement of the octanol-water partition 
coefficient at pH 7.5. The charged form of Fe(III)PPIX at pH 7.5 was found to be lipophilic 
with a log Dow of 1.8 corresponding to a log P of 2.8 for the still more lipophilic unionised 
form. This represented a 400-fold accumulation of neutral Fe(III)PPIX in SNLBDs compared to 
the aqueous bulk medium. This study confirmed that Fe(III)PPIX prefers a non-aqueous 
environment, which is capable of facilitating its conversion to βH. 
The 4-amino quinoline drugs, chloroquine (CQ) and amodiaquine (AQ) were shown to form 
charged complexes with Fe(III)PPIX that decreased the proportion of Fe(III)PPIX partitioned 
into SNLBDs with no pH dependence observed over the range investigated. Conversely, the 
quinoline-methanol drugs, quinidine (QD) and quinine (QN) were found to form neutral 
drug-Fe(III)PPIX complexes at low pH that readily partition into SNLBDs. This increased 
partitioning was found to persist up to pH 8.5 after which, both the quinuclidine and 
quinoline ring nitrogens are deprotonated, resulting in a charged drug-Fe(III)PPIX complex 
that exhibited less partitioning. QD was found to effect the greatest increase in lipid 
partitioning of Fe(III)PPIX which was thought to arise from the lower strain energy associated 
with the formation of a pre-established intramolecular hydrogen bond between the +NH of 
the drug quinuclidine ring and the COO-  of a Fe(III)PPIX propionate group.228 This suggests 
that QD possesses a degree of preorganisation to adopt the folded conformation which has 
been shown to increase lipophilicity that is absent for its diastereomer, QN.367 These data 
suggest that these two different families of quinoline antimalarials affect the lipophilicity of 
Fe(III)PPIX according to the types of complexes they form with Fe(III)PPIX in a lipid 
environment. While it appears that the biological activity of the more effective 4-
aminoquinolines over the quinoline methanol drugs can be rationalised by their effect of 
decreasing Fe(III)PPIX partitioning, a systematic study on antimalarials of variable potency 
and their lipophilicity effects would need to be made to confirm this. 
The use of an established lipophilic fluorophore, NR, to monitor Fe(III)PPIX partitioning into 
NLBDs represents a unique model system to study Fe(III)PPIX metabolism in other systems. 
This methodology provides a biologically relevant indication of how Fe(III)PPIX interacts with 
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lipids over a pH range that can be useful when applied to the different blood-feeding 
organisms or other Fe(III)PPIX associated diseases.  
For many years, a poor understanding of the complicated speciation of Fe(III)PPIX in solution 
has hampered the understanding of its self-association to form the μ-propionato dimer that 
comprises the unit cell of a βH crystal. Furthermore, the colloidal nature of the biological 
lipid blend was found to incur a large amount of light-scatter and thus rendered 
spectroscopic characterisation of Fe(III)PPIX in this environment difficult. Several assays for 
screening potential  βH inhibitors employ neutral detergents as lipid ‘mimics’ to induce 
crystallisation of Fe(III)PPIX though no studies into the way in which they do this have been 
reported.154,155,175 Fe(III)PPIX in amphiphilic detergent solution represents an environment 
where common spectroscopic techniques can be used to investigate the structural 
implications of this environment on the potentially complicated state of Fe(III)PPIX. Chapter 
5 focussed on illuminating the nature of Fe(III)PPIX in several detergent solutions both above 
and below their critical micellar concentration (CMC). The prevailing Fe(III)PPIX species at 
approximately the pH of the DV and cytosol in detergent solutions were characterised by 
analysis of the characteristic UV-visible absorbance spectra with qualitative comparison to 
that of known Fe(III)PPIX species. Magnetic susceptibility measurements were used to 
confirm the spin-state and anti-ferromagnetic coupling of the central Fe(III) atom in each 
solution. Contrary to previous literature reports, detergent solutions were found to induce 
varied speciation of Fe(III)PPIX in solution and not just the monomeric form as previously 
thought.377,379 The neutral and zwitterionic detergents TWEEN-20, NP-40 and CHAPS, at both 
concentrations were found to stabilise the predominant aqueous species of Fe(III)PPIX, the 
π-π dimer, at acidic pH. Contrastingly, the anionic and cationic charged detergents, SDS and 
CTAB, respectively, were observed to induce the monomer form of Fe(III)PPIX in acidic 
solution. Specifically, SDS induced the monomeric form of Fe(III)PPIX throughout the pH 
range investigated exhibiting a change in the axial ligand (from H2O to 
̶ OH)  while at the 
approximate pH of the DV, CTAB was found to stabilise a mixture of the monomer with the -
OH axial ligand and the μ-oxo dimer species. With the exception of SDS, all the other 
detergent solutions were shown to stabilise the antiferromagnetic μ-oxo dimer species at 
basic pH.224  
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A correlation was observed between the observed ability of neutral and zwitterionic 
detergents to promote the π-π dimer Fe(III)PPIX species in solution and the successful 
mediation of βH formation at 37°C and pH 4.80. Previous studies have proposed that 
detergents, long-chain alcohols and polyethylene glycols induce βH formation by solubilising 
Fe(III)PPIX in acidic solution and facilitating loss of the H2O axial ligand to form the μ-
propionato βH precursor in a non-aqueous environment.148,150 While all the detergents 
tested were able to solvate Fe(III)PPIX in acetate solution, with a measured decrease in the 
surface tension of the detergent solutions, not all the detergents were able to promote βH 
formation under these conditions. The charged detergents that favoured formation of the 
monomer or a monomer/ μ-oxo dimer mixture at the DV pH were found not to promote βH 
formation. This correlation of the prevalence of the π-π dimer species as a precursor to βH 
formation in lipophilic solution has been previously suggested and explored using MD 
simulations, from which the authors reported that conversion from the π-π dimer to the μ-
propionato dimer of βH is easily facilitated in the non-aqueous environment.57  
Using preliminary 1H NMR and fluorescence quenching of NR fluorescence in neutral 
detergent, TWEEN-20 micelles, Fe(III)PPIX was shown to partition into these micelles at 
neutral pH. These data tentatively indicate that the π-π dimer Fe(III)PPIX species is located 
inside the hydrophobic detergent micelle in solution. Whether this partitioning is essential 
for βH formation remains unclear as the surface tension measurements, UV-visible spectra 
and βH formation tests indicate that there is little difference between the detergent 
solutions at the concentrations above and below their observed CMC. This observation may 
be correlated to the existence of pre-micellar detergent aggregates in solutions that occur 
below the detergent’s measured CMC.167  
Nevertheless, while Fe(III)PPIX partitioning into detergent micelles or association with the 
hydrophobic regions of premicellar aggregates may occur, the detergent’s ability to interact 
with Fe(III)PPIX and affect its speciation appears to be weaker than that of quinoline 
antimalarial drugs. CQ has been shown to induce and strongly associate with the μ-oxo 
dimer form of Fe(III)PPIX in aqueous solution at pH 7.4.224 It was shown here that the neutral 
detergents ability to stabilise the π-π dimer species at even basic pH solution, failed to affect 
this association. The value of log 𝐾𝑜𝑏𝑠𝑝𝐻 7.5 was measured at 13.50 ± 0.02 in NP-40 (below 
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CMC) with almost no difference to the reported value of 13.3 ± 0.2 in aqueous solution. The 
stoichiometry of CQ-Fe(III)PPIX association was found to be 1:2 in both aqueous and 
detergent solution. Similarly, the association of QD and QN with monomeric Fe(III)PPIX was 
found to be unaffected by this detergent.230  
In light of these findings, in Chapter 6, the kinetics of NP-40 mediated βH formation in the 
absence and presence of drugs, CQ and QD, was investigated. Of particular relevance was 
the detergent ability to mimic the model lipid suspension in which the kinetics of βH 
formation have been measured and reported.63 The neutral detergent was found to induce 
βH formation with a half-life, t1/2 of 19 ± 1 min which was at least forty times slower than 
that reported for the NLBDs. Despite this decrease in rate constant, the kinetic profile was 
found to match the reported exponential-shape for the neutral lipid. The data was likewise 
found to fit the Avrami equation with an Avrami constant of n=1 corresponding to 
instantaneous nucleation and linear growth to form βH crystals. Both drugs were found to 
decrease the rate of NP-40 mediated βH formation in a concentration dependent manner. 
However, the observed decrease in rate constants of βH formation with both drugs was not 
found to lead to an eventual decrease in βH yield in the NP-40 detergent system. This was a 
deviation from the kinetic model outlined for the lipid system where an increase in drug 
concentration was accompanied by an eventual decrease in the yield of βH formed.63    
In the lipid system, Fe(III)PPIX was proposed to associate irreversibly with the drugs to form 
a drug-Fe(III)PPIX complex at high concentration that precipitated out of solution. 
Furthermore the quinoline antimalarials were shown to adsorb to the fastest growing 
surface of the βH crystal with rate constant, log 𝐾𝑎𝑑𝑠. While no precipitation of a drug-
Fe(III)PPIX complex was observed in the detergent system, the observed decrease in 
equilibrium constant in the presence of antimalarials was shown to arise from the 
independently measured adsorption of these drugs to the βH crystal surface. QD, with a log 
𝐾𝑎𝑑𝑠 of 4.48 ± 0.05 was found to exhibit a stronger adsorption constant than CQ with 
log 𝐾𝑎𝑑𝑠 of 3.85 ± 0.07. While kinetic experiments cannot distinguish between mechanisms 
in solution and the interaction of these drugs with Fe(III)PPIX has been established in this 
detergent solution, the results indicated that the neutral detergent prevented the proposed 
precipitation of the drug-Fe(III)PPIX complex, favouring the adsorption pathway for 
inhibition, which was thus observed to be reversible. This finding represents a key difference 
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between the NLBD system and the neutral detergent ‘mimic’, which may be sufficient as an 
initiator of crystallisation for screening inhibition potential but should be cautiously used to 
infer lipid mechanisms of action. 
In the rational design and identification of novel antimalarials, a sound understanding of the 
mechanisms by which known drugs act is essential. While no definitive mechanism of action 
for all the quinoline antimalarials has been established, a number of physicochemical factors 
affecting their interaction with Fe(III)PPIX need be considered. This work highlights the 
importance of; (1) the ability of drugs to affect Fe(III)PPIX partitioning into neutral lipids, (2) 
the dominance of drug-Fe(III)PPIX association with regards to Fe(III)PPIX speciation in 
aqueous and lipophilic environments and (3) the ability of these drugs to decrease the rate 
of  βH formation in detergent solution by adsorbing onto the surface of βH crystals in a 
manner that may be attributed to their mechanism of action. 
Finally, some important questions about the Hz formation pathway have been addressed 
here. In a review by Pisciotta and Sullivan, the authors question the state of Fe(III)PPIX prior 
to crystallisation and ponder whether drug-Fe(III)PPIX complexes can still make crystal 
dimers from solution, among other pertinent questions about the mechanism of Hz crystal 
formation and drug-Fe(III)PPIX complexation.132 While, the state of Fe(III)PPIX in neutral 
detergent solution under acidic pH conditions can only be tentatively compared to the in 
vivo Fe(III)PPIX speciation that prevails as a result of the likely association with a lipid 
environment in the parasite DV, this work shows that Fe(III)PPIX speciation is affected by a 
lipophilic association and the neutral detergents that do promote Fe(III)PPIX crystallisation, 
do so from the π-π dimer species of Fe(III)PPIX. Significant correlation between the π-π 
dimer species of Fe(III)PPIX in acidic solution from which βH was formed led to the 
conclusion that this species and not the μ-oxo dimer or monomeric forms of Fe(III)PPIX, 
serves as a precursor to the βH formation pathway. However, the question of whether this 
species is the nucleating species of βH still remains unanswered.  
While it has been shown that Fe(III)PPIX readily partitions into NLBDs and detergent 
micelles, one cannot assume that this hydrophobic environment is necessarily the location 
of Hz formation in vivo, since detergent solutions were found equally capable of stabilising 
the π-π dimer and promoting βH formation below their CMC presumably from proposed 
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non-aqueous regions comprised of pre-micellar aggregates. The kinetics experiments in this 
neutral detergent environment, also show that while quinoline antimalarial-Fe(III)PPIX 
complexes may form in solution, the drugs appear to act chiefly by slowing the rate of 
crystallisation through drug adsorption to the crystal in a mechanism that is observed to be 
reversible. This thesis contributes toward a growing understanding of the mechanism of Hz 
formation in the context of Fe(III)PPIX behaviour in lipophilic solution, several key insights to 
the role of this non-aqueous environment in the crystallisation process have been identified.   
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(7.2) Future Work 
The observed ability of Fe(III)PPIX to partition into SNLBDs raises an interesting question as 
to the precise location of Hz formation. Both free acylglycerol lipid droplets143 and DV 
membrane phospholipids131 have been shown to induce βH formation and are proposed to 
be the site of Fe(III)PPIX crystallisation.126 To explore the alternative proposal, it is suggested 
that Fe(III)PPIX quenching studies of NR labelled phospholipids be performed to (a) 
determine if the zwitterionic DV membrane phospholipids form lipid droplets with a 
hydrophobic interior which soluble Fe(III)PPIX is capable of partitioning into. And (b), to 
establish if the potential Fe(III)PPIX partitioning into phospholipids is also pH dependent in a 
manner that corresponds to βH formation. 
On the other hand, while Fe(III)PPIX has been shown to be lipophilic, this does not directly 
imply that Hz formation occurs inside a lipid but may only require the lipid-aqueous interface 
for facilitating crystallisation. Hence an investigation into the behaviour of Fe(III)PPIX at lipid-
aqueous interfaces is proposed. Several reports of βH formation and inhibition in such 
solutions have been published however, none offer the comprehensive account of 
Fe(III)PPIX speciation provided here for detergent solutions. While the qualitative 
assignment of Fe(III)PPIX speciation in these solutions is not feasible using UV-visible 
spectroscopy due to the observed light scatter associated with lipid solutions, the magnetic 
susceptibility of Fe(III)PPIX isolated from deuterated lipid-aqueous interfaces can be 
measured and used to assign the induced spin-state of Fe(III) to infer the dominant 
speciation. Similarly, the effect of addition of the quinoline antimalarials to the measured 
magnetic moment in these solutions under biomimetic conditions may provide definitive 
conclusions about their ability to shift the Fe(III)PPIX speciation equilibrium upon 
complexation.  
While neutral detergents may not provide an exact mimic of the environment of the NLBD, 
they still represent a viable lipophilic solution in which studies on drug-Fe(III)PPIX 
complexation may be conducted. To date very few reports on the association of quinoline 
drugs and other βH inhibitors with Fe(III)PPIX in aqueous solution exist. It is suggested that 
neutral detergent solution can be used as a suitable medium for measurements of drug-
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Fe(III)PPIX association constants. Furthermore, the proposed ability of these detergents to 
solubilise Fe(III)PPIX at low pH, may allow for collection of this data at the pH of the DV.  
Recent investigations of another biomineralisation process, formation of bone apatite from 
calcium phosphate solution, provided a large degree of insight into the nucleation 
mechanism (classical and non-classical) of the crystal using vitrified samples analysed by cryo 
transmission electron microscopy (cryo-TEM) and dual-axis cryo electron tomography.418,419 
Direct comparison of the morphological changes in calcium phosphate was coupled to 
measurements of the changes in polydispersity and zeta-potentials over time which enabled 
study of the aggregation state during crystallisation. While it is acknowledged that the 
Fe(III)PPIX system is not the same as the calcium phosphate system, it is proposed that the 
neutral lipid mediated transformation of amorphous Fe(III)PPIX to crystalline βH could 
possibly be monitored using these techniques. Addition of a quinoline antimalarial would be 
required to decrease the rate of crystallisation allowing for a suitable time-period of study. 
Fortuitously, the proposed adsorption of these drugs to the growing crystal surface may be 
visualised using these techniques. 
A large limitation of this work is that all experiments were performed on synthetic neutral 
lipids, lipid mimics and in vitro preparations of Fe(III)PPIX and drug solutions. In support of 
the conclusions provided, a correlation between the observed in vitro behavior with in vivo 
studies on the state of Fe(III)PPIX in the parasite DV is proposed. Advances in the application 
of existing laser resonance Raman spectroscopy techniques to resolve the signal from 
monomeric Fe(III)PPIX that would be distinguishable from Hz may potentially provide this 
validation through evaluation of in situ changes in Fe(III)PPIX speciation prior to and after Hz 
formation.420 The finding that βH forms from the π-π dimer form of Fe(III)PPIX in neutral 
detergent solution can be explored in parasite samples potentially providing a definitive 
species of Fe(III)PPIX to target for inhibition of Hz formation. Furthermore, increased 
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